SDI Reports

Study finds that patients taking cholesterol reducers were more likely to remain on prescribed therapy when they received four or more authorized refills per prescription

SDI

Clients:

Mike Passanante

[email protected]

or

Media:

Tracy Everly

[email protected]

800-982-5613

267-685-4300

www.sdihealth.com

SDI, the leader in innovative analytics for the pharmaceutical and healthcare industries, today announced the results of a new study to determine if patient adherence to therapy differed depending on the number of authorized refills per prescription.

For this study, SDI analysts looked at 4,522 high prescribers, who write 270 or more prescriptions per year in the lipid-lowering market, to determine the average number of authorized refills per prescription during a 12-month period. Then, by examining the anonymous patient-level data for each prescriber, SDI was able to understand the filling behavior of patients who received different numbers of authorized refills.

The study showed that prescribers who consistently wrote prescriptions with four or more authorized refills per prescription had patient populations that filled more scripts, on average, than those who authorized fewer refills or whose patients required a new prescription in order to obtain their medication. This suggests that prescribers may be able to influence patient adherence with something as simple as authorizing more refills when they write prescriptions.

This information has wide-ranging implications for patient adherence initiatives and pharmaceutical sales in general. As health outcomes are often linked to medication adherence over time, understanding the drivers of positive adherence is key to successful management of a host of chronic conditions. Using SDI’s anonymous patient- level data, pharmaceutical companies can now identify factors that may influence patient adherence and target prescribers in need of this relevant information.

About SDI

Since 1982, SDI has been delivering innovative healthcare data products and analytic services to the pharmaceutical, biotech, healthcare, medical device, financial services, and consumer packaged goods industries. SDI is the leading provider of de- identified patient-level data analytics and offers a broad array of solutions and insights across the continuum of care. These include custom and syndicated patient-level data studies; localized disease and treatment surveillance and projection; market research audits; healthcare profiles; comprehensive managed care offerings; clinical trial optimization; direct-to-patient pharmacy programs; marketing effectiveness; sales targeting and compensation products; data integration, warehousing, and mining; list services; and direct marketing services. Its current roster includes the top 50 pharmaceutical/biotech companies. For more information, visit www.sdihealth.com or call 610.834.0800.

(c) 2008 BUSINESS WIRE. Provided by ProQuest LLC. All rights Reserved.

TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration

HOUSTON, Sept. 10 /PRNewswire/ — A landmark study at five university-based research centers found that TOZAL(R), a patented combination of antioxidants and micronutrients, enabled patients with “dry” macular degeneration to improve their vision. Patients in the study’s placebo arm, who received the “AREDS-type” nutritional formulation (the current standard of care), continued to lose their eyesight. Results of the TOZAL study are supported by a major new study, which shows that omega-3 acids cut the risk of developing “wet” macular degeneration.

“The TOZAL study demonstrates that treatment with this supplement can help patients with age-related vision loss,” said lead investigator Francis E. Cangemi, M.D., a macular degeneration specialist affiliated with Vitreo-Retinal Associates of New Jersey.

At six months, 57 percent of those in the TOZAL treatment group improved an average of one-half eye-chart line of visual acuity, and 20 percent stayed the same. All patients in the placebo (AREDS-type nutritional supplement) arm lost visual acuity, with an average loss of 1.49 lines at the end of six months. The treatment group continued to show improvement over time, while most in the placebo group continued to lose visual acuity over time. The study was published in the February 2007 issue of BMC Ophthalmology, a peer-reviewed open-access medical journal.

Age-related macular degeneration is a progressive disorder associated with central vision loss and is the leading cause of visual impairment and blindness in people over age 60. More than 15 million Americans have macular degeneration, and an additional 50 million are at risk. Ninety percent of those with macular degeneration have the atrophic or “dry” form of the disease.

Although there is no cure for macular degeneration, the accepted standard of care since 2001 has been the use of nutritional supplements based on the federally funded Age-Related Eye Disease Study (AREDS). Further studies have suggested that the AREDS formulation is not optimal and clinical trials of a new formulation — dubbed “AREDS II” — are now underway. TOZAL’s ingredients are similar to those in AREDS II, with some additional components. TOZAL is made from taurine, omega-3 fatty acids, zinc, antioxidants and lutein.

While the TOZAL study shows how a combination of nutritional components can arrest macular degeneration, a study published in an August 8 issue of The American Journal of Clinical Nutrition demonstrates that one critical ingredient in the TOZAL formulation — omega-3 fatty acids — can significantly reduce the risk of developing the disease. In a large population-based study in seven European countries, researchers found that seniors who had higher intakes of omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) had far lower risks of developing wet macular degeneration. Those in the top 25 percent of DHA and EPA levels — 300 milligrams a day and above — reduced their risk by 70 percent. TOZAL is the only currently available eye-health formulation that contains these acids.

“While the AREDS II study will not be completed for five years, both of these studies demonstrate the value of trying this new nutritional approach right now to stave off five years of age-related vision loss,” said Dr. Cangemi.

Dr. Cangemi enrolled 75 elderly patients in the TOZAL study who had at least one of their eyes diagnosed with dry macular degeneration. Study sites included New York Eye and Ear Infirmary, Ohio State University, University of California, Irvine and University of Texas, Austin. All patients were treated with the TOZAL formulation for six months.

Study participants saw the researchers during five visits over the six months, during which they repeatedly received a battery of eye tests. Participants were instructed to take TOZAL three times a day and to maintain a log, which was checked by researchers on each visit. The primary objective of the study was to measure change in visual acuity, while a secondary objective was to find improved macular function as measured by these tests.

“We saw significant improvements in visual acuity, but did not see demonstrated improvements in function,” said Dr. Cangemi. “This is likely due to the short duration of the study.”

The study’s Institutional Review Board determined that all patients must receive the standard of care, so no true placebo arm was permitted. Instead, Dr. Cangemi used a widely accepted placebo protocol and constructed comparisons with placebo data from the “MIRA-1” study, which followed the same inclusion and exclusion criteria as TOZAL. All patients in the MIRA study — including those in the placebo arm — received AREDS supplements.

Patients in the TOZAL study were initially divided into two groups: those receiving TOZAL plus electrical microcurrent stimulation (MCS) and those receiving TOZAL and sham MCS. MCS was abandoned early in the study. Reported results are based on the arm of the study in which 37 patients received TOZAL and sham MCS.

TOZAL was developed by Edward L. Paul, O.D., Ph.D., an optometrist and nutritionist who is an authority on nutrition and vision loss. Dr. Paul has licensed the TOZAL formulation to AmeriSciences, a leading developer of science-based nutritional supplements that is based in Houston. He serves on the AmeriSciences Scientific Advisory Board.

Dr. Cangemi received funding for the study and manuscript preparation from Atlantic Medical, Inc., a company that holds patent rights to TOZAL.

Atlantic Medical, Inc.

CONTACT: Rexy Legaspi of Widmeyer Communications, +1-646-213-7245,[email protected]

Dr. Paul Korner Joins Ferring Pharmaceuticals As Vice President, Medical Affairs

PARSIPPANY, N.J., Sept. 10 /PRNewswire/ — Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the appointment of Paul Korner, M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be responsible for Medical Affairs for Ferring’s Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas as well as Product Safety.

“As a result of our continued and projected growth, we have expanded and realigned our management staff to best meet our business needs,” said Wayne Anderson, President and CEO. “Dr. Korner is exceptionally well qualified to fill this new role, as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas.”

Dr. Korner joins Ferring with a broad range of experience in medical affairs, clinical development, management and business development. Prior to joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women’s Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women’s Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women’s Health and Bone Repair for Wyeth Research.

Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring’s line of products includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R) (menotropins for injection, USP); REPRONEX(R) (menotropins for injection, USP); Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com/.

Ferring Pharmaceuticals Inc.

CONTACT: Tara Fisher of Kovak-Likly Communications, +1-203-762-8833,[email protected], for Ferring Pharmaceuticals Inc.

Web site: http://www.ferringusa.com/

Abeome Forms First Class Scientific Advisory Board

ATHENS, Ga., Sept. 10 /PRNewswire/ — Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome’s ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company.

The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of Abeome’s patented monoclonal antibody technology. The SAB will consist of:

Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations as well as for her broad scientific applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of research.

Jeff Boyd, PhD, Chief Scientific Officer and Sr. VP at Fox Chase Cancer Center in Philadelphia, has an international reputation as one of the leading scientists in the study of molecular genetics of women’s cancers. Dr. Boyd was named Distinguished Cancer Scholar by the Georgia Cancer Coalition. His long-term research focus has studied molecular genetics of ovarian cancer with emphasis on hereditary predisposition.

Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production.

“We are pleased to assemble such an incredibly talented team of scientists to serve on our SAB and to participate in target validation on our ovarian cancer therapeutic project. Their active participation provides Abeome with valuable expertise in pre-clinical and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of immunology experience specific to monoclonal antibody development,” states Abeome CEO, Mike Wanner.

“The company will deploy its monoclonal antibody technology to rapidly develop a pipeline of therapeutic candidates in a number of cancer areas and will benefit by these individual’s commitment to our mission. They join an already outstanding group of Abeome scientists, biotech-oriented Board of Directors, and scientific founder, Dr. Richard Meagher to form a team of world-class scientists to insure Abeome’s future success.”

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance. Its current focus is on developing a cancer therapeutic and diagnostic for ovarian cancer.

For more information on Abeome, visit http://www.abeomecorp.com/.

Abeome Corporation

CONTACT: Mike Wanner of Abeome Corporation, +1-706-248-6098,[email protected]

Web site: http://www.abeomecorp.com/

Florida Hospital Lab & Nursing Staffs Enhance Patient Safety With Sunquest Collection Manager

Sunquest Information Systems, Inc., a market leader in laboratory information systems, today announced that Florida Hospital, rated one of the best hospitals in the country by U.S. News & World Report, is utilizing its Sunquest Collection Manager solution to significantly reduce specimen collection errors and improve productivity for its laboratory and nursing staff. Florida Hospital’s lab and nursing staff collect over 15,000 blood specimens per month and now experience less than one patient identification error per year since implementing the system in 2004. Sunquest Collection Manager integrates with Sunquest’s award-winning Laboratory Information System (LIS) and allows organizations to save time and reduce errors by automating their processes for specimen collection, specimen labeling, and data entry.

An article describing Florida Hospital’s use of Sunquest Collection Manager and patient safety achievements were featured in the August issue of the Medical Laboratory Observer Magazine, a Peer-Reviewed Lab Management Resource since 1969.

“Sunquest’s Collection Manager enabled us to increase our collections with less staff and improved our stat laboratory test turnaround time by sixteen to twenty percent,” said Patrick O’Sullivan, MS, MT (ASCP)SBB, Florida Hospital administrative laboratory director. “But most importantly, we were able to reduce our patient identification errors to less than one per year with over one hundred and eighty thousand collections being performed.”

“Florida Hospital’s patient safety initiatives reflect what we see throughout healthcare organizations today,” said Roger Neubauer, vice president of implementation and professional services for Sunquest Information Systems, Inc. “The success achieved by Florida Hospital and many of their peers is a testament to their commitment to deliver safe, quality patient care as well as to Sunquest’s commitment to delivering solutions that play a key role in meeting safety and quality goals.”

About Sunquest Collection Manager

Sunquest Collection Manager allows real-time transmission of all lab orders including stats directly to the phlebotomists’ handheld device. This eliminates the need for the laboratory to have a person dedicated to taking calls from the Care Centers and then dispatching the phlebotomist to collect the stat specimens. This increases productivity and improves turnaround time by reducing the time it takes to collect specimens, resulting in faster delivery of the results to the doctors and a corresponding acceleration of patient treatment.

About Florida Hospital

With seven hospitals and 14 Centra Care walk-in medical centers, Florida Hospital is one of the largest hospital systems in the country, caring for almost one million patients every year. Florida Hospital specializes in a wide range of health services including many nationally and internationally recognized programs in cardiology, cancer, women’s medicine, neurology, diabetes, orthopaedics and rehabilitation. For the last five years, Florida Hospital has been recognized as one the best hospitals in the country by U.S. News & World Report. More information is available at: www.flhosp.org.

About Sunquest Information Systems, Inc.

Sunquest Information Systems, Inc., is a global market leader in clinical data management solutions with more than 1,200 hospitals and commercial laboratories using its products worldwide. The company is dedicated to providing best-of-suite solutions that enable quality patient care, clinical safety, and operational efficiencies. Its experienced sales and technical service teams deliver 24×7 assistance to customers for their procurement, implementation, and customer care needs. The Sunquest Laboratory(TM) system achieved “Best in KLAS” in the Laboratory Segment for 2007, which was its fourth consecutive year (KLAS Enterprises, LLC, www.KLASresearch.com).

Sunquest’s professional services division provides a wide array of management and technical tools, including lab redesign and optimization, outreach and lab network program development, and operational business and implementation plans. For more information, call 800-748-0692 or visit: www.sunquestinfo.com.

Sunquest is a Trademark of Sunquest Information Systems, Inc. All other product or service names are the property of their respective owners.

Ancillary Care Management Announces Name Change to NovoLogix

MINNEAPOLIS, Sept. 10 /PRNewswire/ — Ancillary Care Management (ACM), a leading healthcare technology company, today announced that it has changed its corporate name to NovoLogix(SM). The change is effective immediately.

“Building on the company’s rich history and our 13-year track record servicing healthcare clients across the country, our new name captures the essence of the technology-driven processes and fresh thinking that have been the hallmarks of our success,” said David J. McLean, NovoLogix CEO.

From Latin, Novo means ‘new, innovation’; Logix (or Logos) is taken from Greek, meaning ‘intelligent, smart, logic’.

Commenting on the reasons behind the change, McLean added, “Healthcare has evolved dramatically over the past decade, particularly in the home health/ancillary care field: changing economic demands and government mandates, the flood of biopharmaceuticals in the market, shifting sites of care, and the administration support required for many of the new drug therapies.

As a company, we have done much more than keep pace with the changes. We have helped our clients stay ahead of the curve. Now, given where we are in the industry and where we are as a business, the time is right for us to rename and rebrand the company in a way that more accurately reflects the value and benefits we provide to clients. The field has grown and needs have changed, and there is more and more demand for our services and expertise outside of the ancillary space. We feel confident that the name and brand image of NovoLogix translates our vision for the future into one clear message, while also acknowledging the core competencies and capabilities that helped us get to where we are today.”

Along with the name change, the company has adopted a new logo and branding, and has unveiled a new web site at http://www.novologix.net/. New provider and client sites are under development. And a marketing campaign via print, trade shows, and online media is planned to promote the NovoLogix brand throughout 2008.

The company also recently announced a new business development initiative focused on meeting the unique needs of federal- and state-level government programs (e.g., Medicare and Medicaid) for value-driven electronic technology services to manage and re-price pharmaceuticals paid under the medical benefit. NovoLogix remains committed to providing current customers with the latest technology and services to manage trend, maximize revenue, reduce costs, and eliminate administrative inefficiencies, and will continue to reach out to other commercial clients as well, including national health plans, pharmacy benefits management companies (PBMs), and pharmacy and device manufacturers.

“Our new name and new initiatives will drive our focus on the future and the ways that we can help our clients exploit both existing and emerging technologies to fundamentally change the economics of America’s healthcare system and keep us all moving forward,” McLean concluded.

Company History

Beginning in 1995, co-founders Dave Willcutts and Tom McNulty built an organization committed to providing an informational infrastructure for managing and integrating all the varied and distinct facets of what was then the infancy of home care. A pioneer throughout the industry’s developing years as Ancillary Care Management, the company created new technology-driven logic and protocols for processing prior authorizations and a proprietary NDC to HCPCS Crosswalk Methodology that accurately and precisely prices claims — in particular drugs, injectables, infusibles, and other pharmaceuticals paid under the medical benefit. These two state-of-the-art technology applications serve as the foundation for the new NovoLogix — a company that will drive healthcare innovation for decades to come.

NovoLogix Today

NovoLogix delivers technology applications, systems, and processes to positively impact both the economics and quality of how services and drugs are priced, paid for, and delivered to patients across the U.S. Next generation innovations include value-driven electronic technology to manage and re-price claims — in particular drugs, injectables, infusibles, and other pharmaceuticals paid under the medical benefit-decision support tools to manage prior authorizations, and nationally-recognized patient care programs. Covering millions of members for the nation’s largest health plans, pharmacy benefits management companies (PBMs), and other payers, Minneapolis-based NovoLogix is URAC-accredited and holds full accreditation by EHNAC. http://www.novologix.net/.

Ancillary Care Management

CONTACT: Wendy Capetz of Ancillary Care Management, +1-952-826-2552,[email protected]

Web site: http://www.novologix.net/

Doing Baptisms, Bars, and Bloodlust

The scene opens beneath murky swamp water, where a potentially prehistoric sea creature patiently lingers. Rising above the surface and backed by a bluesy guitar riff, the camera moves through the bayou and transitions to a dryland highway and the small town South, where the environment and buildings grow more human, but the primeval sense remains. This is a world where the conflicting ecstasies of religion, sex, and bloodlust share striking similarities. This is True Blood, where “doing bad things” has never felt — or looked — so very, very good.

The latest brainchild of writer/director Alan Ball (American Beauty, Six Feet Under), True Blood premiered on HBO last Sunday September 7, and the scenes described above are only the beginning. Conceived and created by creative studio Digital Kitchen (www.d-kitchen.com), the show’s opening title sequence shows a chaos and mixing of cultures, races and social strata, where whores and churchgoers commingle in a region with many influences and a town of many characters and mindsets.

“What I like about Digital Kitchen’s creative approach is their intuitive ability to depart from the status quo. We first worked with DK on the titles for ‘Six Feet Under’ and the opening for True Blood is equally thrilling,” said Alan Ball, creator/director, True Blood. “This vivid title sequence so effectively evokes the spirit of the show. It immediately transports the viewer into the True Blood world where the conjured thematic images of sex, death and religious fervor blend into a gripping crescendo. I’m enthralled every time I watch it.”

The True Blood project originated with a creative brief to launch the development stage; the brief asked for DK artists to contribute their ideas, with a particular focus on finding what techniques or imagery could best express the dirty, messy collisions of ideas in a contemporary northern Louisiana town.

The concept that stood out the most was the work of Digital Kitchen creatives Rama Allen and Shawn Fedorchuk. “We were super excited to be working on such an interesting project,” says Allen. “Shawn and I had several extended conversations late into the night, and we quickly discovered we were on the same page as to how we could make this opening exceptionally cool. I came up with a set of storyboards with a loose, linear progression that juxtaposed the type of images I wanted. Shawn is also the editor on the project, and he created a very complex edit, based on found footage, that communicated stylistically how we wanted things to play out on screen.”

“From the start, I loved the idea of images of Americana linked to scenes of lonely, stark places,” says Fedorchuk. “When I worked on my initial edit, I gravitated toward a point of view of a supernatural, predatory creature observing human beings from the shadows, almost stalking them. We wanted to convey a feeling of bloodlust, together with a vivid hyperreality. Stitching together these contradictory, yet strikingly similar worlds of sex, death, and transcendence was a major influence. We were after a frenzied effect, a cathartic crescendo, and an apex of emotion linked to the possibility of redemption and forgiveness.”

Based on the “Sookie Stackhouse” novels written by Charlaine Harris, True Blood stars Academy Award winner Anna Paquin (The Piano, X-Men) as a feisty waitress in a southern town populated by religious fanatics, redneck bigots, and vampires. As evidenced by a billboard announcing ‘God Hates Fangs,’ the show explores the vampires’ sense of oppression and outcast as much as it shows the humans’ fear of them.

FOUR DAYS IN LOUISIANA

In the interests of the raw mood, Digital Kitchen Creative Director Matthew Mulder deliberately steered the project away from computer- aided effects, opting instead for live action footage and striking physical transition effects involving Polaroid photographs.

“We’re particularly proud of our analog work,” explains Mulder. “The transition effects have an eerie, tactile quality because they were created with Polaroid transfers, water, and airguns. The resulting transitions feel almost like scorched skin.”

Developed by designer Ryan Gagnier, the Polaroid transfer technique uses chemicals to separate the emulsion in a Polaroid from its backing. The resulting image has the quality of thin plastic wrap, which is then placed on a wet glass plate, then is blasted with canned air and water to create a violent effect.

“For those transitions, we took the last frame of a cut and the first frame of the next cut, blew them up, and shoot a Polaroid of them together,” explains Mulder. “We then put the Polaroid in a chemical bath to separate the transition, manipulate it on another camera, shoot it, and place it back in the edit. It made for some great transitions.”

The True Blood titles themselves are rendered in an original font created by Digital Kitchen. Some of the fonts were created using an exacto knife and other hand tools; Camm Rowland developed the font for the show credits based on southern-style road signage.

This very literal “hands-on” approach also took the Digital Kitchen creative team on a four-day Winnebago odyssey through Louisiana, during which they shot footage of anything and everything they felt would be appropriate to the True Blood mood:

“We would drive along and jump out when we saw something cool,” says Allen. “I saw a wrecked schoolbus in somebody’s yard, so we knocked on the door and ended up getting approval to shoot all over his property, even inside his home. There’s a scene of a man in a rocking chair, and he was just a good guy who invited us over for beers. We met all kinds of people and shot more footage than we could possibly use, but it was an incredible experience. We threw ourselves into this project literally, artistically, and physically.”

And Mulder isn’t kidding about that last part. Several Digital Kitchen staff members make cameos in the opening scenes. A shoving match in a rough-looking bar involves Digital Kitchen Executive Producer Mark Bashore, who also volunteered for a particularly rousing dance with a female bar patron. Digital Kitchen’s office assistant and an assistant editor portray a couple of weeping religious women, while Bashore’s sons make short, messy work of some blood red berries. The climactic scene of a very wet night baptism involves a young Cajun woman flanked by a line producer and Producer Morgan Henry.

“We had a lot of fun working on this project, and we hope that shows,” says Henry. “This is the kind of work Digital Kitchen is best at. There are no tried-and-true techniques used on the True Blood opening. The way we decided to gather imagery was entirely new to us, and we wanted to celebrate that adventure. The practical shooting in unfamiliar territories is philosophically and psychologically what Digital Kitchen is all about.”

The True Blood project adds to Digital Kitchen’s portfolio of main titles work; DK’s opens created for Dexter and Six Feet Under both were recognized with Emmys. True Blood premiered September 7 on HBO.

About Digital Kitchen

Digital Kitchen (www.d-kitchen.com) is a creative agency that focuses on film production, experiential design, motion graphics, brand identity, and interactive work for marketing and entertainment. DK people make brands, spaces, spots, sites, products, and shows feel powerful, look great, and otherwise get sexy and influential. DK is high gloss and matte finish, persuasive and complete.

DK’s skills stretch from strategy and messaging to concept development and execution in just about any medium – including skywriting. The creative studio excels in the expanding media spacescape by harboring creative thinkers who are agile, inventive, and dedicated to their crafts. From its studios in New York, Chicago, Seattle, and Los Angeles, DK has created experiential campaigns for Target and Microsoft, broadcast spots for hundreds of leading brands, interactive work for AT&T, Budweiser, and Mercedes, the Emmy Award-winning main titles for “Dexter” and “Six Feet Under,” a series of manga comic books for Nike, and the live show content for The 2008 Webby Awards.

 CREDITS: Client: HBO Creator/Director: Alan Ball 

 Agency: Concept: Rama Allen, Shawn Fedorchuck Creative Director: Matthew Mulder Designers: Rama Allen, Ryan Gagnier, Matthew Mulder, Camm Rowland, Ryan Rothermel Editor: Shawn Fedorchuck Compositors: Ryan Gagnier Live Action Direction: Rama Allen, Morgan Henry, Matthew Mulder, Matt Clark, Tevor Fife Producers: Morgan Henry, Kipp Christiansen, Keir Moreno Executive Producer/Head of Creative: Mark Bashore Executive Creative Director: Paul Matthaeus 

 CONTACT: Eric Eddy double E communications 39 West 19th Street (between 5th and 6th Avenue) Suite 611 NY NY 10011 212-941-7590 (office) 646-283-6528 (mobile) 

London-Based Arab Paper Report on Possible Strike By BBC Arabic Section

Text of unattributed report headlined: “BBC Arabic section journalists demand improvement of human resources or reconsideration of extension of broadcasting hours”, published by London-based newspaper Al-Hayat on 7 September

The saga of the bumpy launch of BBC Arabic Television, which was delayed from autumn 2007 to spring 2008, does not seem to be over yet. Barely six months since the launch and before broadcasting is due to be extended from 12 to 24 hours a day by October [2008], reports have been circulating of the first move ever by BBC Arabic journalists to go on strike. The strike includes BBC Arabic television, radio and the Internet.

The journalists, most of whom are members of the British Union of Journalists, have threatened to go on strike unless the management responds to their demands by the 12th of this month [September]. The question is: would the BBC, the world’s most famous broadcasting corporation, respond to the journalists’ demands or would things develop for the worse, at a time when the BBC is planning to launch other satellite TV channels, broadcasting in languages other than English, of which BBC Arabic TV was only the beginning, to be followed by a BBC Persian [Farsi] channel?

The number of journalists, who voted for a strike as a last resort, was 145, all of whom are members of the National Union of Journalists [NUJ], out of a total of 250 that make up the editorial cadre, which includes BBC Arabic radio and the Internet.

In a communication with Nahad Abu-Zayd, head of the union branch at the BBC Arabic section, and in reply to a question about the causes of the confrontation with the BBC management, he stressed that the motivation behind strike action is purely professional and is focused on the level of performance and competition, especially as the date for extending broadcasting to 24 hours a day is approaching. He said: “Journalists are working very long shifts, especially at night, and human and financial resources are ‘meagre,’ and this doubles the pressure on journalists, the impact of which is more obvious when journalists are on leave.”

Asked for his view of the response of BBC World Service Director Nigel Chapman, who said that all BBC news-gathering centres are at the service of BBC Arabic and that the management had made concessions concerning the number of hours per shift, Abu-Zayd said: “The issue is not as simple as the management makes it appear. The reports we use have to be translated into Arabic and reconstructed with images and commentary by the editor. All this without the help of the support cadres that are available to other sectors of the BBC.” He added: “We are being asked to do double action assignments. The journalist on an assignment is expected to provide coverage for television, radio and the Internet, without any additional pay incentive. Alternatively, we have to send more than one journalist to cover an event. At the same time, we have the expected increase in broadcasting time, without human resources development courses, because there is no one to cover for them while they are on these courses.”

As for the reduction of night shifts from 11 to 9-1/2 hours, Abu- Zayd said that the reduction was made up for by increasing the day shifts to 12 hours, “which means exhausting the journalist and depriving him of interaction with his family and social environment.” Abu-Zayd considered that in doing so, “the management is making savings at the expense of human resources, or, as, NUJ official Paul McLaughlin put it to The Guardian “the BBC is trying to run the World Service on the cheap.” He added that “if they want to provide an acceptable service, they have to pay for it.”

Journalists with BBC Arabic Television believe that the demands made of them exceed those made of their colleagues in other sections of the BBC World Service, especially as the planning and news- gathering section is almost dysfunctional, a fact admitted by BBC management, which has set up a committee to investigate the reasons, headed by the deputy head of the Africa and Middle East section of the BBC World Service. But although some time has elapsed since the committee was formed, no positive steps have been taken to improve performance.

In reply to accusations of ‘meanness,’ Nigel Chapman, director of BBC World Service, said that the management was actually very generous and no one can say that a budget of 40m pounds is meagre. He criticized some of the demands that he said “would exhaust the budget,” including the demand for taxi fares for early morning or late night assignments, which would cost the taxpayer almost 650,000 pounds a year, and if added to the support cadre could reach 1.5m pounds.

To this Abu-Zayd replied by saying that the management exaggerates some issues such as the taxi fares, which they merely raise to heat things up. He believed that “the management is under pressure from the Foreign Office, the main financier of the project, that the budget should not exceed 40m pounds and that broadcasting time should be increased to 24 hours. Carrying out the project under the present conditions will be at the expense of the workers in the BBC Arabic Service.” He gave as an example that a work shift at present includes 31 journalists, which will rise to only 33 journalists when broadcasting is extended to 24 hours a day.”

But what about the generous offer which the management says it has made to the union’s representatives but it was withdrawn because it was rejected by the NUJ?

To this question, Abu-Zayd replied by saying: “The generous offer merely reiterated what already existed in the BBC World Service. The offer that the management calls generous is the same offer that was rejected by 80 per cent of the members.”

It should be noted that the Arabic section of the BBC World Service has an estimated 14 million radio listeners and Internet users in the Middle East and North Africa per week, but no statistics are available for the number of viewers of BBC Arabic TV, which was expected at its launch to compete with Al-Jazeera TV Channel, but so far has not done so.

The 12th of this month is the end of the period that the journalists union has given the management to show goodwill and understanding, in the light of which the date and form of the strike will be determined.

Summarizing the demands of the union, Abu-Zayd stated: “the decision to increase broadcasting time should be reviewed as it is disproportionate to the human and financial resources allocated at present and thus, either increase the human resources, or decrease the broadcasting time. Contrary to the accusation, we do not want to exhaust the British taxpayer; our demands are purely professional and we do not want to offer media services at a level below that of our competitors, which is bound to happen, if the management continues to overwork the journalists in this manner.”

Originally published by Al-Hayat, London, in Arabic 7 Sep 08.

(c) 2008 BBC Monitoring Middle East. Provided by ProQuest LLC. All rights Reserved.

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ — Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol achieved bronchodilation, or opening of the airways, within 15 minutes(1) and reported feeling their medication begin to work right away.(1) The studies evaluated onset of bronchodilation and patient perception of onset of effect(1) of SYMBICORT compared with placebo and its individual components, budesonide pressurized metered-dose inhaler (pMDI) and formoterol dry powder inhaler (DPI), in patients with asthma.(1) These data, which were published today in the Annals of Allergy, Asthma and Immunology, also showed patients were more satisfied with how quickly they felt their medication working compared with patients taking placebo.(1) SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(2) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(2)

“The data showed that patients receiving SYMBICORT reported they could feel their medication begin to work right away and were satisfied by how quickly their medication began to work,”(1) said lead investigator Harold Kaiser, Clinical Professor of Medicine, University of Minnesota Medical School.

Results of both studies (Study I and Study II) showed that more patients taking SYMBICORT achieved onset of clinically significant bronchodilation within 15 minutes postdose at randomization (median time, 13 minutes), compared with budesonide pMDI and placebo (P

Additionally, results showed that a significantly greater percentage of patients receiving SYMBICORT versus those receiving budesonide pMDI and placebo reported feeling their study medication begin to work right away (P less than or equal to .004; end of week 1).(1) Similar results (P

In both studies, the majority of reported adverse events were mild or moderate in intensity.(3,4) The most common adverse events reported in Study I were headache, upper respiratory tract infection and nasopharyngitis, also known as the common cold.(3) The most common adverse events reported in Study II were nasopharyngitis, headache and pharyngolaryngeal pain.(4)

About the Design of Study I and Study II

Onset of bronchodilation and patient perception of onset of effect was assessed in two 12-week randomized, double-blind, placebo-controlled studies in asthma patients who were previously treated with inhaled corticosteroids (ICS),(1) either alone or in combination with other asthma maintenance therapy. Study I involved 596 patients ages 12 years and older with moderate to severe persistent asthma; Study II involved 480 patients ages 12 years and older with mild to moderate persistent asthma.(1) Each study included a two-week run-in period during which patients discontinued use of their current asthma therapy and received single-blind budesonide pMDI 80 micrograms (mcg) two inhalations twice-daily (Study I) or placebo (Study II) and albuterol as needed for rescue.(1)

After run-in, patients within Study I were randomized to receive treatment with two inhalations twice-daily of SYMBICORT 160/4.5 mcg, two inhalations twice-daily of budesonide pMDI 160 mcg + two inhalations twice-daily of formoterol DPI 4.5 mcg, two inhalations twice-daily of budesonide pMDI 160 mcg, two inhalations twice-daily of formoterol DPI 4.5 mcg, or placebo.(1) Patients within Study II after run-in were randomized to receive treatment with two inhalations twice-daily of SYMBICORT 80/4.5 mcg, two inhalations twice-daily of budesonide pMDI 80 mcg, two inhalations twice-daily of formoterol DPI 4.5 mcg or placebo.(1)

Onset of clinically significant bronchodilation was defined as the time to achieve a 15 percent improvement in FEV1 from the predose FEV1 after study medication was administered.(1) Forced expiratory volume in one second (FEV1) quantifies how much air a person can exhale during a forced breath in the first second of exhalation.(5)

About Patient Perception of Onset of Effect

In these studies, perception of onset of effect was assessed in two ways.(1) Patients completed the Onset of Effect Questionnaire(c)(OEQ), a validated self-administered questionnaire.(1) Answers to statements were recorded in an electronic diary at the end of weeks one through 12:(1) They included: during the past week (1.) you could tell your study medication was working; (2.) you could feel your study medication begin to work right away; (3.) you felt physical sensations shortly after taking your study medication that reassured you that it was working; and (4.) you were satisfied with how quickly you felt your study medication begin to work.(1) Each question in the OEQ was rated by patients using a five-point scale: “strongly disagree,””somewhat disagree,””neither agree nor disagree,””somewhat agree,” or “strongly agree.”(1)

In addition, patients were asked a single perception of onset of effect question — “Can you feel your study medication working?” — four times during the first hour post-dose at the clinic on the day of randomization, at the end of week 2, and at the last study visit at the end of week 12.(1)

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(2) Administered twice daily, SYMBICORT is a combination of two proven asthma medications — budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA).(2) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(2)

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in > 5 percent of patients, regardless of relationship to treatment, including nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

   Please see full Prescribing Information and visit http://www.mysymbicort.com/.    About AstraZeneca  

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world’s leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people’s lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit http://www.astrazeneca-us.com/.

Onset of Effect Questionnaire is a copyright of the AstraZeneca group of companies. (c) 2007 AstraZeneca Pharmaceuticals LP. All rights reserved.

References

(1) Kaiser, H., et al. Onset of Effect of Budesonide and Formoterol Administered Via One Pressurized Metered-Dose Inhaler in Adults and Adolescents with Asthma Previously Treated with Inhaled Corticosteroids. Annals of Allergy, Asthma and Immunology. 2008; 101(3):295-303. Published 09 September 2008. Available at: http://lysander.annallergy.org/vl=4825828/cl=18/nw=1/rpsv/cw/acaai/10811206/v1 01n3/s12/p295.

(2) SYMBICORT Prescribing Information.

(3) Noonan M., Rosenwasser, L., Martin, P., O’Brien, C., O’Dowd, L. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of SYMBICORT(R) (160/4.5 micrograms) versus its Mono-Products (budesonide and formoterol) in Adolescents (greater than or equal to 12 Years of Age) and Adults with Asthma. Drugs. 2006; 66(17):2235-2254. Accessed 05 August 2008. Available at: http://www.astrazenecaclinicaltrials.com/.

(4) Corren, J., Korenblatt, P.E., Miller, C.J., O’Brien, C.D., Mezzanotte, W.S. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of SYMBICORT(R) pMDI (80/4.5 micrograms) versus its Monoproducts (budesonide and formoterol) in Children (greater than or equal to 6 Years of Age) and Adults with Asthma – SPRUCE 80/4.5. Clin Therapeutics. 2007; 29:823-843. Accessed 05 August 2008. Available at: http://www.astrazenecaclinicaltrials.com/.

(5) What Are Lung Function Tests? National Heart, Lung and Blood Institute. Accessed 07 August 2008. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/lft/lft_all.html.

AstraZeneca

CONTACT: Michele Meeker, +1-302-885-6351,[email protected], or Katie Neff, +1-302-885-9960,[email protected], both of AstraZeneca

Web site: http://www.astrazeneca-us.com/http://www.mysymbicort.com/

Company News On-Call: http://www.prnewswire.com/comp/985887.html

Altor BioScience Licenses T-Cell Receptors Targeting HIV and Hepatitis C From Massachusetts General Hospital

Altor BioScience Corporation (Altor) today announced that it has entered into an agreement with Massachusetts General Hospital (MGH) for exclusive, worldwide rights to develop and commercialize T-cell receptors (TCRs) specific for cells infected by HIV and Hepatitis C Virus (HCV). The license has resulted from the success of Altor’s collaboration established in 2004 with Howard Hughes Medical Institute and the Partners AIDS Research Center at MGH. Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor (STAR(TM)) technology.

Hing Wong, Ph.D., President & CEO of Altor, commented, “The receptors we have licensed were discovered and characterized by Dr. Bruce Walker, one of the foremost authorities on viral antigen expression and T-cell immune responses in HIV and HCV patients. We are excited to have the opportunity to add these targeting molecules to our STAR(TM) program and look forward to taking an anti-HIV and anti-HCV drug candidate into the clinic.” Dr. Wong added, “The specific targeting to HIV-infected cells makes it possible for the first time to eliminate latent viral reservoirs, which cannot be achieved with currently available treatments.”

There are over 2 million people living with HIV in North America and Western Europe, and over 40,000 new infections occur in the U.S. each year. The availability of more than 40 approved antiretroviral drugs has dramatically lowered deaths from AIDS and reduced progression from HIV to AIDS. AIDS patients, however, continue to develop drug resistance requiring a change in antiviral therapy and also endure toxic side effects from these drugs, none of which provide a cure for the disease.

HCV is the most common cause of chronic blood-borne infection in the U.S. It causes inflammation of the liver, which can lead to fibrosis, cirrhosis, liver cancer and liver failure. The CDC estimates that nearly 4 million Americans are infected with HCV today and has projected a four-fold increase in the diagnosis of chronic infections between 1990 and 2015. Chronic liver disease accounts for roughly 25,000 deaths annually, with 40% of these HCV-related.

Altor BioScience Corporation is a privately-held biotechnology company developing targeted therapeutics for treating cancer, viral infection, and inflammatory disease, based on its proprietary STAR(TM) technology. The Company currently has several drug candidates at various stages of clinical development. For more information, visit www.altorbioscience.com.

Health Integrated Receives NCQA Certification for Health Utilization Management

TAMPA, Fla., Sept. 10 /PRNewswire/ — Health Integrated announced today that it has received Organization Certification for Utilization Management from NCQA, an independent, not-for-profit organization dedicated to measuring the quality of America’s health care.

NCQA’s Organization Certification (OC) program is available to organizations that perform Utilization Management (UM) for health plans and other types of organizations eligible for NCQA accreditation or certification. NCQA Certification provides these organizations the opportunity to demonstrate the quality of their UM programs.

NCQA’s certification review includes a rigorous on- and off-site evaluation conducted by a team of physicians and managed care experts. A review oversight committee of physicians analyzes the team’s findings and assigns a certification status based on the organization’s performance against standards within applicable certification options.

“Health Integrated is honored to be certified in Utilization Management by NCQA,” said Sam Toney, MD, Chief Medical Officer of Health Integrated. “We are pleased to be recognized in the industry for our focus on quality. The NCQA distinction underscores the quality of our work with customers, patients, clients, payors, and practitioners by demonstrating compliance with national standards for Utilization Management services.”

Health Integrated’s Utilization Management program is part of the company’s Synthesis Health Management Services offering. Synthesis includes a complete suite of medical and behavioral health management programs that can stand alone or be integrated to meet customer needs and best serve patients. In addition to Utilization Management, Synthesis includes Case Management, Physician Review Services, Nurse Advice/Triage and Behavioral Health Integration, a ground-breaking carve-in service to assist health plans in integrating behavioral health management with medical management.

“Achieving Organization Certification from NCQA demonstrates that Health Integrated has the systems, process and personnel in place to conduct utilization management in accordance with the strictest quality standards,” said Margaret E. O’Kane, President, NCQA.

Additionally, Health Integrated offers industry-leading Synergy Targeted Population Management(TM), a health management program for the chronically ill that improves clinical outcomes and lowers avoidable utilization by addressing the critical interplay between psychological, social and physical health.

About Health Integrated

Health Integrated is a Targeted Population Health Management company dedicated to integrating health with life. Driven by a strong entrepreneurial culture, Health Integrated addresses the critical interplay between physical, psychological and social health. Working with health plans and their members, Health Integrated drives improvements in health status, quality of life and clinical outcomes while reducing unnecessary utilization and healthcare costs. For more information, visit http://www.healthintegrated.com/.

   CONTACT:   Mike Miniati, Health Integrated   813.388.4030   [email protected]   

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

Health Integrated

CONTACT: Mike Miniati, Health Integrated, +1-813-388-4030,[email protected]

Web site: http://www.healthintegrated.com/

Big Pharma Looks for Strategies to Fight the Decline

In an effort to survive declining profits and drug failures, the pharmaceutical industry is turning to layoffs and outsourcing. While many consider these trends a knee-jerk reaction, people who pull the strings in these companies have a different view of the situation.

Rising healthcare expenditures have become a major concern to European governments. While price regulations and generic manufacturers are doing a great job in reducing costs for governments, the companies developing drugs have not helped themselves.

“One accusation directed towards these companies is that they have been focusing on developing drugs for the so called ‘costly’ diseases, which have a very low patient population to cater to,” says Frost & Sullivan (http://www.healthcare.frost.com) Research Analyst John Paul. “While acquiring an orphan drug status has its own advantages, the cost of developing and marketing such a drug outweighs the revenue it would generate.”

In addition, the drug approval process for ‘small molecule’ drugs is not getting any better, the cost has increased and the possibility of lawsuits and withdrawal is much higher. Together with the impending patent expiries of several top drugs, pharmaceutical companies are being forced to look for efficiency in operation.

Pharmaceutical companies have realised that their strength lies in the later stages of product development and are cutting their costs by outsourcing both their manufacturing and R&D activities, particularly to Asia. Frost & Sullivan estimates that the cost of employing an experienced R&D person in China or India is 10 times cheaper than in the Europe or the US.

“For instance, AstraZeneca has turned to China and announced investments of $100 million in R&D,” says Paul. “GSK is building a fully integrated, end-to-end R&D center in China that will employ more than 1,000 staff by 2010.”

Layoffs in pharmaceutical companies are performed with the intention of redirecting the costs into R&D. However, the management of drug development and other late-stage processes in several therapeutic areas is not an attractive option. Considering that European governments are giving significant support to biotech start-ups, pharma giants are seeing the acquisition of these companies as a better proposition than developing their own pipelines.

“Pharma giants, in an effort to acquire the most promising drugs in the market, are paying over and above the value of these companies,” says Paul. “Merck’s acquisition of Sirna Therapeutics for $1 billion is just one example.”

Many promising biotech start-ups are also doing their best to attract big pharma companies to acquire their technology, pipeline or the company itself, thereby sidestepping the costs of marketing. Biotech IPOs are not attracting much attention and they are under constant pressure to find a return on investment for their stakeholders.

“Be it layoffs or outsourcing, the pharmaceutical industry is geared up to fight the decline,” says Paul. “Governments should however step up efforts and encourage companies, by means other than just tax incentives, to produce quality R&D. For the moment, the pharmaceutical industry has to be in fighting trim until the investments in R&D start producing results.”

If you are interested in Frost & Sullivan’s analysis of the pharmaceutical industry and its services to help companies meet market challenges, then send an e-mail to Patrick Cairns, Corporate Communications, at [email protected], with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company’s TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnerships, visit http://www.frost.com.

Europe Can’t Rely on Russia for Gas Supply, Turns to Iran – Paper

Text of unattributed report headlined “Europe’s efforts to buy Iran’s gas: Many high ranking financial and political delegations are on their way to Tehran for talks ” published by Iranian news paper Jam-e Jam website on 8 September

It appears that the confrontation in Abkhazia and South Ossetia between the West and Russia is providing a timely economic opportunity for Iran’s economic, energy and gas exports. According to our reporter, following the relatively widespread political disagreements which have occurred between the West and Russia over Georgia, and the ensuing consequences, the West is now worried that Russia will take retributive measures in the field of energy and gas exports, an area which is the Achilles’ heel of a large number of western European states.

This is particularly pertinent as winter comes close. The end of September is the time of review of the costs and conditions for gas sales to needy customers. Europe’s important countries such as France, Hungary, Austria, Slovakia, Germany and Poland, have, over the past two and a half years, become all too familiar with the short history of Russia’s behaviour and this country’s inclination to play the powerful oil and gas card. They have tasted its bitter reality and so take the issue of diversifying oil and gas sources much more seriously.

Europe has a number of options to choose from in its quest to diversify its energy sources. Considering the relatively rich supplies of oil and gas they have, Turkmenistan, the countries surrounding the Caspian Sea and the countries in the North African continent are suitable options. However, it can be said that the most important country for Europe when it comes to diversifying its oil and gas sources, one which is its first choice and dependable in all aspects, is Iran. After Russia, Iran has the second-largest natural gas reserves in the world, and in this respect it stands head and shoulders above its rivals. Consequently, over the last few days, the European Union has begun noticeable political efforts to establish political and diplomatic contacts with Tehran. It hopes that through two methods of negotiating over new projects for the construction of a pipeline and activating the potentials of previous agreements, it can confront the challenge of a possible shortage of gas supplies caused by Russia, even though this is a long-term prospect. According to diplomatic sources in Tehran, the European Union’s main priority is to use the potentials of the previous agreements which, due to political reasons, were put on the back burner such that the agreements were signed but they never reached the implementation stage.

Europe’s cold memories of Russia

Over the past year, and until the final weeks of 2007, the inhabitants of Western Europe were concerned about their supply of gas from Russia. They have cold memories in this regard. The most famous of these memories is the speech given by Vladimir Putin, the former Russian president, on 31st December 2005 in which he gave [asked] Ukraine, which is seen as one of the closest allies of the West in the territory of the former Soviet Union, until the 1st January 2006 to either accept the new price announced by this country for gas or face its gas supply being cut off.

In his orders to Medvedev, the current president of Russia, who at that time was the chairman of Gazprom, the price of gas for Ukraine rose from 50 dollars per thousand cubic metres to 230 dollars. Under such conditions, the pro-western president of Ukraine refused to agree to the proposal, so the Russians cut off the supply of gas to this country. As a natural consequence of this, gas supplies for Europe which transited Ukrainian soil were also reduced by 50 per cent, and a large part of Europe in extremely cold temperatures faced either reduced gas supplies or none at all. And this is not the only bad memory the Europeans have of Russian gas [supplies]. In 2006 too, only a few hours after Medvedev’s victory, Gazprom called on Ukraine to pay the 1.5 bn dollars it owed it for gas supplies. This created another challenge to the supply of gas to Europe, though it was not as serious as the previous one.

In addition to Ukraine, Russia has also exerted pressure on other countries which transit gas and oil to Western Europe, amongst these are Georgia and Armenia. For example, in the month of Aban 1385 [November 2006], it increased the price of gas exported to Armenia from 110 dollars per 1000 cubic metres to 230 dollars, more than doubling the cost.

The culmination of these events has brought Europe to the conclusion that over-dependence on the supply of energy from Russia will create a serious challenge for this continent, one which has to be resolved, and energy must be obtained from a variety of sources not through reliance on one source alone. The recent military conflict in the separatist regions of Abkhazia and South Ossetia and the worry about a delayed reaction from Russia as winter approaches have once again proved the correctness of this view. Therefore the situation is that the diplomats are packing their suitcases and heading off for Tehran.

Delegations on way to Tehran

Our reporter has obtained information that a number of high- ranking political and economic delegations are on their way to Tehran to hold talks on activating previous projects for the export of Iran’s gas to Europe. The first and largest of these teams, headed by the European Union energy commissioner, will arrive in Tehran within next two weeks. This trip has two aims, the first is to revive the agreement signed between Iran and Turkey in Tir 86 [July 2007] for the export of Iranian gas to Europe across this country’s land, and the second is to hold talks over the planning and inauguration of new pipeline projects with Iran.

Kazem Vaziri Hamaneh, Iran’s former oil minister, and Hilmi Guller, Turkey’s energy minister, signed an agreement on 23 Tir 86 [13 July 2007] according to which Turkey would allow the construction of a pipeline and the transit of Iran’s gas to Europe across its land, in exchange for its participation in the development of the South Pars gas field. Up to now, however, this matter has remained at the stage of agreement [as received].

Originally published by Jam-e Jam website, Tehran, in Persian 08 Sep 08.

(c) 2008 BBC Monitoring Middle East. Provided by ProQuest LLC. All rights Reserved.

Gundersen Opens New Ramp, Lobby Monday

By Rindfleisch, Terry

Gundersen Lutheran’s new underground patient parking and lobby addition will open Monday. The $10 million structure was dedicated Friday with an afternoon ceremony. The ramp adds 230 more parking spaces to the medical center’s grounds, with 549 parking stalls on two underground levels and one above-ground level, and direct access to the floors and elevators of the clinic.

Elevators are connected to the reception desks at all floors except the second floor, which is part of a two-story atrium. Patients will have 24-hour access to the ramp.

Complimentary valet parking will continue to be offered on the surface level of the ramp, and the valet shuttle will be reassigned to the ramp to help patients get to the elevators.

Also on Monday, the main entrance of the clinic will close for remodeling, which is expected to take six months. The temporary entrance will be next to the ramp.

Gundersen Lutheran will start construction on a second parking structure near the hospital this fall. The structure for 500 patient vehicles west of the hospital should be completed by the end of next summer and eventually will be connected to a new critical-care hospital.

Copyright La Crosse Tribune Aug 16, 2008

(c) 2008 La Crosse Tribune. Provided by ProQuest LLC. All rights Reserved.

A Savage Crime – but Don’t Rush to Blame the Attacker

By Deborah Orr

IT WILL not be of great consolation to the 14-year-old girl who was raped twice at knifepoint by Darren Harkin last February, or to her angry family – and nor should it be.

But Harkin’s is likely to be a landmark case, one that will reveal worrying failures of “joined-up thinking” in the Government’s reorganisation of the criminal justice system, particularly when it is dealing with the criminal behaviour of the mentally ill.

The 21-year-old, who savagely killed his baby stepbrother in 2000, when he was 12, was this week detained indefinitely at the maximum security Broadmoor Hospital, from which this young man is unlikely to escape. Harkin cannot be blamed for his crimes, or punished for them. He has been diagnosed as both autistic and schizophrenic, and one tragic aspect of this case is that it will not help to soften attitudes in general towards people struggling with these little-understood disorders. But quite clearly Harkin is a danger to others, and needs to be contained.

Yet for a year, until he walked out and abducted his victim, Harkin had been under the care of staff at Hayes hospital, in Pilning, a village near Bristol. The hospital is run by the National Autistic Society, houses 12 patients, and runs a regime aimed at rehabilitating people with Asperger’s syndrome, who are “detainable” under the Mental Health Act 1983, in the hope that they can be returned to the community. The hospital is staffed with autism not schizophrenia specialists.

We are told that an independent inquiry has been investigating, among other matters, how Harkin managed to abscond from Hayes hospital early this year and perpetrate the attack. Yet there is no real mystery about this. Hayes hospital is a low-secure unit. As such, it is defined as a place where “security arrangements are provided to impede rather than completely prevent those who wish to either escape or abscond. Low secure provision will have a greater reliance on staff observation and support rather than physical security arrangements.”

Staff observation had confirmed that Harkin had asked a member of staff to have sex with him, which had prompted a decision not to allow him to be alone with a female staff member. He had also been put on 24-hour watch after punching walls and lunging at carers. These incidents should have alerted staff to the fact that Harkin was not a suitable patient for a low-secure unit. Instead they appear to have stepped up security in an ad hoc fashion.

Professor Louis Appleby, who is the Government’s “mental health tsar”, told the Today programme yesterday that he is worried about the number of escapes from mental health units, which he says are running at 20 times the rate of escapes by offenders held in prison. However, since he, alongside Richard Bradshaw, who directs prison health at the prison service, signed off the document that contains the above description of security attitudes at such units, the reasons behind the statistics cannot be so very elusive to him.

The real question, certainly, is why Darren Harkin found himself in such a place at all. The crime Harkin committed while he was under the hospital’s care, along with some of the evidence submitted at his trial, makes it clear, in sad retrospect, that he was placed at Hayes in error. Again, we must wait for the results of the inquiry. But we are told that Harkin fulfilled government criteria for transfer to a low-secure unit.

Yet it is clear from the procedure for the transfer of prisoners to and from hospital under sections 47 and 48 of the Mental Health Act, that such criteria need not be in the least exacting, or actually comprehensible, even when a transfer from prison is under consideration.

In fact, the document says, a detainee can be considered for transfer to a low-secure unit if they fulfil any – not “all” but “any” – of the following criteria: acute illness; mix of offending and non-offending behaviours such as challenging behaviour; self- neglect and deliberate self-harm; history of non-violent offending; risk predominantly to others; and low risk of abscond.

The list is hazy, because it assumes that assessments are being made by people who know and understand their patients. How Harkin’s case was handled, from his arrest as a child, through the juvenile system, and into the adult system, is likely to offer a telling illustration of how far from its fine ambition – of appointing under the National Offender Management Service a single person who oversees a detainee’s journey through an ever more complex system – the Government has drifted.

[email protected]

(c) 2008 Independent, The; London (UK). Provided by ProQuest LLC. All rights Reserved.

A System That Does Neither Students nor Lecturers Any Good

By J.M.L.

I REFER to the letter “Lecturers just not up to par” (NST, Sept 4) from I.T. of Kuala Lumpur.

I was a lecturer in a local private university for a few years, and would like to shed some light on how things worked at my former workplace.

During my tenure, not once was I given any formal training on how to teach. There were workshops on critical thinking skills and statistical tools, but I never attended one on teaching skills.

Lecturers were given a course title and expected to come up with the entire syllabus. There was no one to vet the course content and many of us had to burn the midnight oil to come up with our own content within a short time frame.

Also, to maximise the use of human resources, we were dumped with courses that we were not even eligible to teach. And we had no say in this.

If we even dared to complain, we were given threats such as “you can work someplace else” by the university’s president.

Lecturers were also made to teach classes that went on till 10pm. This is because the university wanted to offer as many courses as possible every semester to maximise profit.

The lecturers became the victims. Students, too, were tired of this schedule but they had no choice, or else they would not be able to graduate on time.

Lecturers were also given absurd deadlines when it came to marking examination scripts. Some of us had to mark 350 or even more exam scripts within two weeks or less. How do we ensure quality in marking exam scripts this way?

The university boasts of having an ISO (an international standard) and Sirim accreditation. But we lecturers know what it is like.

Having a proper filing system for procedures does not guarantee the quality of education. It merely shows that I have done A, B or C. How well I have carried out the three tasks is never known.

One of the requirements by Sirim is that lecturers must have a teaching permit.

It was amusing when my teaching permit finally arrived on my desk in a frame, a day before the Sirim audit, after years of having taught students without a permit.

ISO and Sirim also do not vet the accuracy of marking scripts, which is questionable as only a limited time is given for lecturers to correct them.

In short, I believe that the Higher Education Ministry should look into these issues.

Lecturers’ feedback is especially important, but no one seems to bother about what we have to say as long as those from the higher management are friendly with the ministry’s people.

Many lecturers are disgruntled from being overworked and this is passed down to the students. It is an unhealthy trend which causes students to lose out in the end.

J.M.L.

Petaling Jaya

(c) 2008 New Straits Times. Provided by ProQuest LLC. All rights Reserved.

Sri Lanka’s Jungle Adventures

Sri Lanka’s jungle adventures

Adventure tourism a growing global phenomenon

Lazy summer days at the beach getting a tan are pass as Sri Lanka Tourism Promotion Board (SLTPB) is marketing the country as an adventure destination with adventure seekers being identified as a potential growth market.

“Adventurous holidays are a rapidly growing trend in global tourism and an increasing number of travellers are seeking out new adventures like Sri Lanka having done the usual African Safaris,” said SLTPB Managing Director, Dileep Mudadeniya.

“The adventure tag fits in very well to Sri Lanka given the number of fantastic adventure and wildlife activities we have on offer,” he said.

Sri Lanka is a land where you can glimpse a wild elephant, gaze at the pristine grace of a leopard, see a nesting turtle lay its eggs on the beach or witness the dazzling display of peacock feathers. The country is blessed with an abundance of natural diversity despite its small size. This astounding diversity is largely due to its dramatically different terrains ranging from coastal plains to hill country and lush rainforests to arid dry zones.

Large areas rich in flora and fauna are conserved in 13 national parks across the country and over 100 other protected areas. This is not surprising given the country’s 2000-year old history of conservation. What was probably the world’s first wildlife sanctuary was created here in 3rd Century BC.

A trip to Sri Lanka’s wildlife parks is memorable as one is greeted by the sounds of numerous birdcalls. As you enter a park with an expert tracker in a four-wheel drive vehicle, the jungle comes alive with a myriad sights, sounds and motions.

As the vehicle bumps along rutty jungle tracks, the scenery is constantly changing. Monkeys scamper across the path casting anxious glances at the vehicle. A peacock slowly opens its plumage and strikes up a regal pose for the cameras. A cuddly white rabbit hops into view, stops and looks enquiringly and disappears among the foliage just as quickly.

Wildlife and nature conservation in Sri Lanka has a long history. The country’s traditional law has reference to forests where the felling of timber is prohibited. Ancient Sri Lanka also had reservoirs built in the forests so that wild animals would not need to enter human settlements in search of water.

There are many tanks and waterways in and around the wildlife parks of Sri Lanka and there are plenty of crocodiles in the water. Water Monitors, Iguanas and a variety of lizards also inhabit the jungles of Sri Lanka.

Sri Lanka has more than 950,000 hectares of national parks, sanctuaries and nature reserves. Popular among them are the Bundala National Park, Horton Plains, Kumana Bird Park, Sinharaja Forest, Wasgomuwa National Park, Wilpattu National Park and Yala National Park and the Habarana Safari Park.

Large and small herds of elephants are a common sight at the Yala National Park. It also has the largest leopard population in Sri Lanka. Common also are large herds of Spotted Deer and Sambhar, Wild Buffalo, bears and different species of monkey are also in plenty.

Among the primates are several species of monkeys including the macaque and the large-eyed loris. The scaly pangolin can also be spotted along with wild buffalo, giant squirrel, wild boar, jungle cat and the cat-like palm quivet.

The wildlife parks are also home to a variety of birds. Peacocks, painted storks, herons, parrots, spoonbills, bee-eaters, hornbills, woodpeckers and many more of over 450 species of birds can be observed. Some of them are migrant and seasonal. The Siberian duck for instance fly away from the winter to the moderate climate in Sri Lanka. Twenty-six species of birds are endemic to Sri Lanka.

Apart from birds, the other brilliantly coloured creatures seen flying in the island’s skies are over 250 species of butterfly, most of them found in the foothills up to about 900 metres.

Sri Lanka also has an intriguing number of creatures that slither, swim or jump, with 54 species of freshwater fish, and a variety of frogs and reptiles.

In addition, there are 3,350 species of flowering plans, lush tropical fruits, majestic tall trees, lush undergrowth, and rare orchids and medicinal plants.

Wildlife trips offering tourists up-close views of nature’s beauty and beasts in their natural habitat are a fast-growing niche and form part of Sri Lanka’s eco-tourism industry. The animals, despite being wild, aren’t prone to attack and even though game- hunting draws tourists to certain countries, in Sri Lanka, guests shoot with their cameras and not their rifles. 2008 Al Bawaba (www.albawaba.com)

Originally published by By Al-Bawaba Reporters.

(c) 2008 Al Bawaba. Provided by ProQuest LLC. All rights Reserved.

Fresenius Medical Care Gears Up for Third Storm

As Hurricane Ike threatens the Gulf Coast this week, Fresenius Medical Care North America, operator of the nation’s leading network of dialysis facilities, is preparing its patients and clinics for the third storm in two weeks. Dialysis patients are especially at risk during hurricanes because they need treatment every other day to survive.

“Our employees have worked tirelessly to care for patients through these devastating storms,” said Mats Wahlstrom, co-CEO of Fresenius Medical Care North America. “They have done an outstanding job under very difficult circumstances. The entire Fresenius team has demonstrated that we are the true leaders of our industry and that we care deeply about our patients. This has been a tremendous demonstration of teamwork, and that is what our mission at Fresenius is all about.”

About 110 Fresenius Medical Care facilities were impacted by Hurricane Gustav, causing an estimated 7,000 dialysis patients to change their scheduled treatment sessions in order to get dialysis before the storm.

Because of Gustav, Fresenius temporarily closed 93 dialysis clinics in Louisiana, Texas, Mississippi and Alabama. However, 87 of those reopened within three days, largely because of the company’s comprehensive disaster plan. As of Tuesday, only three clinics in coastal Louisiana remained closed because of the storm.

Before Gustav hit the Gulf Coast, Fresenius instituted a 24-hour Patient Disaster Hotline, 1 (800) 626-1297, which anyone on dialysis – whether or not they are Fresenius patients – can call to find the closest dialysis clinic if they need to evacuate or their usual clinic is closed. Since Sept. 29, Fresenius has received more than 1,240 calls – the majority of them from Louisiana residents who were evacuating and needed to find a dialysis clinic in another area.

“The past few weeks, Fresenius employees have taken extraordinary measures to care for patients through Hurricane Gustav, Tropical Storm Hanna, and now Hurricane Ike,” Wahlstrom said. “Our staff have worked around the clock to provide life-sustaining dialysis even in areas where there is no electricity, thanks to backup generators in many of our clinics.”

In addition, Fresenius Medical Care:

— Took in more than 500 patients from other dialysis providers throughout the South, while taking care of its own patients

— Sent backup generators, water, fuel and mobile homes to the Gulf in preparation for Gustav

— Delivered personal generators and food supplies to many employees whose homes are still without electricity in Louisiana

— Gave patients disaster plans, dietary guidelines and wristbands with their medical information, in case they needed to transfer to another clinic

— Purchased an ice machine for clinics in Louisiana because ice was not available

— Sought out patients at emergency shelters who had missed dialysis appointments, and assisted in organizing their treatments

— Provided gasoline for employees so they could get to work to provide patient care, since no gasoline was available at local stations

In parts of Louisiana, the stocks of grocery stores had been depleted. Fresenius staff who chose to stay and provide critical treatment for patients could not get food. So Fresenius Medical Care sent employees to unaffected grocery stores in Lafayette, La. to shop for 19 clinics in Baton Rouge and New Orleans. At some clinics, outdoor grills were set up so employees could cook food from home before it spoiled due to lack of refrigeration.

“We’re so grateful that the Fresenius team truly came together to help both our employees and patients,” said Bernadette Vincent, vice president of operations for Fresenius Medical Care’s South Business Unit. “It’s much easier for our staff who evacuated to return home and care for our patients if they have some of their own needs met.”

About Fresenius Medical Care North America

Fresenius Medical Care North America is a subsidiary of Fresenius Medical Care AG & Co. KGaA, the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,600,000 individuals worldwide. Through its network of 2,297 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 177,059 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS-p).

For more information about Fresenius Medical Care’s U.S. network of more than 1,650 dialysis facilities, visit the Company’s website at www.ultracare-dialysis.com. For more information about Fresenius Medical Care, visit the Company’s websites: www.fmcna.com or www.fmc-ag.com.

TomoTherapy and Vision RT Partner to Expand Hi-Art(R) System Imaging Options

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has partnered with Vision RT to expand imaging options for Hi-Art(R) treatment system users. The companies will jointly introduce AlignRT(R) 3D imaging technology for the Hi-Art platform at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, Mass., Sept. 21-25, 2008. TomoTherapy will distribute AlignRT(R) for use with both its TomoHelical(TM) and new TomoDirect(TM) delivery modes.

“We are excited about our strategic alliance with Vision RT, a company that is as focused on best-in-class clinical workflow and high-quality patient treatments as we are,” said Fred Robertson, CEO of TomoTherapy. “AlignRT(R) does for Hi-Art system imaging what TomoDirect does for Hi-Art treatment delivery: both provide a new option for our users that can significantly improve patient throughput across a broad range of cancer cases.”

AlignRT(R) for the Hi-Art platform will consist of two ceiling-mounted 3D camera units, each focused toward the external isocenter of the radiotherapy device. Immediately prior to treatment, the patient will lie on the treatment couch for initial set-up. The cameras will then quickly acquire a surface scan of the body in treatment position, and state-of-the-art software will be used to register real-time image data to the reference surface scan, and–within seconds–provide new couch coordinates for optimal patient positioning.

According to Corey Lawson, director of product strategy for TomoTherapy, the AlignRT(R) offering complements the Hi-Art system’s integrated CTrue(TM) imaging technology: “CTrue will continue to be used extensively when the tumor is deep-seated, or can move internally without external evidence. However, we believe AlignRT(R) will prove useful in approximately 40 percent of cases, based on a standardized mix. Where this technology is best suited, we estimate a 50 percent reduction in setup and registration time.”

“The Hi-Art treatment system offers an innovative approach to radiation therapy,” said Dr. Norman Smith, CEO of Vision RT. “We are delighted to partner with TomoTherapy to expand imaging options while boosting patient throughput for this next-generation platform. In addition, through this partnership, we look forward to developing advanced features that will further enhance the accuracy and precision of TomoTherapy treatments for a broad patient population.”

For more information and a product demonstration of AlignRT(R) for the TomoTherapy Hi-Art treatment system, please join TomoTherapy and Vision RT in booth #1533 at ASTRO 2008.

About Vision RT

Vision RT Limited is a UK based company that has developed a novel approach to enhance the crucial process of patient setup, surveillance and respiratory gating during radiation therapy for the treatment of cancer. Vision RT’s revolutionary products, AlignRT(R), GateCT(R) and GateRT(R) utilise a proprietary real-time 3D surface imaging technology to provide exceptional speed and accuracy designed to improve the efficacy and precision of radiation treatments. Further information on Vision RT and its products may be found on www.visionrt.com.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “will”, “can”, “believe”, “is expected to”, or “should” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

(C)2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, TomoDirect, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated. AlignRT is a registered trademark of Vision RT, Ltd.

CDC: Alternative Trauma Therapies Ineffective

In a recent review of a dozen different studies, researchers found that many doctors are using unproven methods to help children suffering from trauma.

Researchers of the U.S. Centers for Disease Control and Prevention found no evidence to prove that alternative therapies, such as drugs, art or play therapy helped children traumatized by violence or abuse, even though more than 75 percent of U.S. mental health professionals who treat children and teens with post traumatic stress disorder may use them.

What’s more, they noted that cognitive therapy, or talk therapy, is the most effective treatment.

“The good news is there is substantial research showing the effectiveness of group or individual cognitive behavioral therapy in treating children and teens experiencing the psychological effects of trauma,” the CDC’s Robert Hahn, who led the study, said in a statement.

“We hope these findings will encourage clinicians to use the therapies that are shown to be effective.”

Hahn added that childhood trauma, whether caused by physical or sexual abuse, domestic violence or natural disasters, “is a widespread problem with both short- and long-term consequences.”

He said better screening is needed, and urged therapists to use methods that have been proven effective.

“Many kids with symptoms of trauma go undiagnosed, which can lead to unhealthy behaviors in adulthood such as smoking and alcohol or drug abuse.”
Cognitive therapy uses a variety of techniques, but always involves a trained counselor and several sessions, to change a person’s thoughts and beliefs.

Hahn’s task force reviewed studies evaluating play therapy, art therapy, the use of drugs and psychological debriefing.

“Proponents of art therapy argue that trauma is stored in the memory as an image; therefore, expressive art techniques are an effective method for processing and resolving traumatic issues,” the study reads.

None has been shown to work for children with post traumatic stress disorder, the CDC team reported in the American Journal of Preventive Medicine.

On the Net:

Governor Rendell Announces Resignation of Health Secretary Dr. Calvin Johnson

HARRISBURG, Pa., Sept. 9 /PRNewswire-USNewswire/ — Governor Edward G. Rendell today announced the resignation of Dr. Calvin B. Johnson, who has served as Secretary of the Pennsylvania Department of Health since April 2003.

“Dr. Johnson has been a passionate voice for protecting and improving the health of all Pennsylvanians,” said Governor Rendell. “Calvin has distinguished himself as an effective leader, addressing a variety of issues from preventive health and health disparities to patient safety and preparedness for pandemic influenza. I know that he will take the same energy and commitment he has given here into his future endeavors, and I wish him well.”

As Secretary of Health, Dr. Johnson served as an advisor to the Governor and directed nearly 1,800 employees in carrying out the department’s mission to promote healthy lifestyles, prevent injury and disease, and assure the safe delivery of quality health care. During his tenure, Dr. Johnson led the Department of Health in successfully addressing significant, public health issues, which include:

— Managing the largest single-source Hepatitis A outbreak in U.S. history in 2003, which garnered the department national recognition.

— Responding to Governor Rendell’s call to improve the quality of life for all Pennsylvanians by creating the Office of Health Equity, which takes a coordinated approach to eliminating health disparities through continued collaboration with community-based organizations, other state agencies and the public.

— Implementing several pieces of Governor Rendell’s health care reform initiative, including decreasing the rate of health care-associated infections that have been shown to significantly increase both hospital in-patient stays and related costs.

— Promoting and championing the need to protect Pennsylvanians from the deadly health effects of secondhand smoke culminating in the enactment of the Clean Indoor Air Act, which prohibits smoking in most public places.

— Creating an innovative and comprehensive intervention and surveillance initiative, entitled Pennsylvania Injury Reporting and Intervention System, to address gun violence.

— Increasing primary health care services to underserved areas, which allow more Pennsylvanians to receive quality health care.

— Implementing a department-wide performance-based management initiative to ensure public health programs are effectively meeting the needs of Pennsylvanians.

— Using $505 million in Tobacco Master Settlement Agreement funds to focus on biomedical and clinical investigations and health services research.

“Improving and protecting the public’s health is critically important,” said Dr. Johnson. “It has been my privilege to serve Governor Rendell and the people of Pennsylvania, and I appreciate having been entrusted with this significant responsibility.”

A board-certified pediatrician, Dr. Johnson attended Morehouse College in Atlanta, Georgia, graduating with a degree in chemistry. He earned his medical degree from the Johns Hopkins University School of Medicine and a master’s degree in public health from the Johns Hopkins University Bloomberg School of Public Health.

Governor Rendell is expected to announce Dr. Johnson’s successor in the near future.

The Rendell administration is committed to creating a first-rate public education system, protecting our most vulnerable citizens and continuing economic investment to support our communities and businesses. To find out more about Governor Rendell’s initiatives and to sign up for his weekly newsletter, visit: http://www.governor.state.pa.us/.

   CONTACT:   Chuck Ardo   717-783-1116  

Pennsylvania Office of the Governor

CONTACT: Chuck Ardo of the Pennsylvania Office of the Governor,+1-717-783-1116

Web Site: http://www.governor.state.pa.us/

Women’s Focus III, Breast Cancer Awareness Month Releases

The following releases focuses on the topic Women’s Focus III, Breast Cancer Awareness Month:

ALL TIME-OFFS ARE IN EASTERN TIME, UNLESS NOTED STORIES MOVED AT 4:35 AM ET ON SEPTEMBER 9, 2008.

When Hot Flashes Require Medical Attention Source: BioSante Pharmaceuticals, Inc.

New Project Captures Underrepresented Voices of Young Breast Cancer Patients

Source: Iris BioTechnologies

The following knowledgeable industry leaders and scholars from Business Wire’s ExpertSource database are available to discuss topics relating to Women’s Focus III, Breast Cancer Awareness Month

Paul R. Gliedman, M.D. is the Medical Director of Brooklyn Radiation Oncology — Vantage Oncology. He is an Associate Director of Continuum Cancer Centers of New York and the Director of Radiation Oncology at Beth Israel Medical Center, Brooklyn Division. He also serves as an attending physician in the Department of Radiation Oncology at Beth Israel Medical Center and St. Luke’s Roosevelt Hospital. Prior to his position as Medical Director at Brooklyn Radiation Oncology, he also served as Director of Radiation Oncology at St. Luke’s-Roosevelt Hospital. Before joining Continuum Cancer Center, Dr. Gliedman was a Director of Radiation Oncology at Hackensack University Medical Center. Dr. Gliedman has extensive experience in managing cancer of the prostate, breast, lung, central nervous system, and gastrointestinal tract, as well as gynecologic cancers. He has developed active cancer programs in prostate radioactive seed implantation (Brachytherapy) and stereotactic radiosurgery. Dr. Gliedman has received numerous awards and recognitions including Castle Connolly’s New York Top Doctors and the Ladies Home Journal Top Doctors for Women. Dr. Gliedman received his medical degree from Columbia University College of Physicians and Surgeons in New York and his residency in Radiation Oncology at New York University Medical Center also in New York.

PR Contact: Trace Longo, 949-364-2821, [email protected]

Sona Mehring is founder and executive director of CaringBridge.org. Based upon the idea of keeping friends and family informed during times of medical crisis, Mehring’s vision was to create a free service that would not only ease the stress of communication, but also provide a means for people to express cheerful words of encouragement to ones they love. This function would alleviate the burden of making several emotional phone calls without disturbing the patients need for rest. In addition, each Web site would include pictures and daily updates, as well as an online guestbook allowing all parties to stay informed without placing extra demands on hospital staff. Mehring and CaringBridge have become widely known for their creation of Compassion Technology. In 2006, she was recognized by MSN.com as one of the nation’s leading women working for change. She has also been awarded CBS affiliate-WCCO’s Good Neighbor Award, the Angel Foundation Star Award and was a finalist for the Minnesota High Tech Association’s TEKNE Award in 2004. Mehring is also a member of the Minnesota Council of Nonprofits and National Health Council. Today more than 150,000 families have created free, personalized CaringBridge Web sites. These CaringBridge sites have received over a half a billion visits and leaving over 20 million guestbook messages of hope and encouragement by families and friends. All 50 United States are represented, including over 190 countries around the world. Every 10 minutes a new CaringBridge Web site is created. CaringBridge sites connect over 20 million families a year, making it the leading force and most widely used online service of its kind. For additional information, please visit www.caringbridge.org.

PR Contact: Melissa Bohlig, 612-677-1717, [email protected]

Registered journalists can submit queries to the ExpertSource staff and/or search for more experts in this and various other topics by going to www.businesswire.com and logging in with your email address and PressPass password. If you are not registered, you may do so at www.businesswire.com. For more information or assistance with ExpertSource, please contact Stacey Frank, ExpertSource Coordinator/Business Wire at 312/223-1037, [email protected].

The following are upcoming Features Package release dates:

September 11 – Real Estate II

September 15 – Fitness & Health IV

September 16 – Fashion & Beauty III, Bridal

Questions? Contact Business Wire’s Media Relations team at [email protected] or [email protected].

SOURCE: Business Wire

Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. As Vice President, Clinical Research

HAYWARD, Calif., Sept. 9 /PRNewswire/ — Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company’s CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia’s proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Dr. Luskey has extensive experience in endocrinology and metabolism research, as well as in drug development. He spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes. Dr. Luskey began his career at the National Institutes of Health before completing a fellowship and receiving a faculty appointment at the University of Texas Southwestern Medical School. While in Dallas, he worked extensively with Drs. Joseph L. Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985 for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios, Inc. (now a member of the Johnson & Johnson family of companies) where he led research efforts to develop new treatments for diabetes and obesity. Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and drug development programs focused on diabetes and impaired glucose tolerance as Vice President, Clinical Development. Dr. Luskey also was head of experimental medicine for Tularik Inc. (subsequently acquired by Amgen Inc.), and was most recently head of preclinical and translational medicine for Nuvelo, Inc. Dr. Luskey received his medical education at the University of Texas Southwestern Medical School in Dallas. He trained in internal medicine with a subspecialty in endocrinology and metabolism.

“We are very pleased to have Ken join Intarcia Therapeutics to lead our hepatitis C and diabetes clinical development efforts,” said Alice Leung. “Ken’s drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the Company’s pipeline in the metabolic diseases area.”

Intarcia is currently conducting a phase 1 study of Omega DUROS therapy in combination with ribavirin for the treatment of patients with HCV genotype-1 who have failed prior standard of care treatment. In addition, Intarcia is preparing to initiate a phase 1 clinical trial of ITCA 650 in the first quarter of 2009 for the treatment of type 2 diabetes. Both of these programs use Intarcia’s proprietary subcutaneous DUROS drug delivery technology that provides continuous and consistent administration of drug therapy.

Dr. Luskey said, “Intarcia represents a very unique opportunity. I believe the proven advantages of the DUROS delivery technology hold great potential in developing more effective treatments for many chronic diseases, including hepatitis C and type 2 diabetes. I am very excited to join Intarcia at this stage of the Company’s development and look forward to directing clinical programs to fulfill the potential of DUROS delivery in these two disease areas.”

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia’s drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

Intarcia Therapeutics, Inc.

CONTACT: David Franklin of Intarcia Therapeutics, Inc., +1-510-723-3438

Web site: http://www.intarcia.com/

Rutgers to See If N.J. Lifestyle Causes Cancer

By BOB GROVES, STAFF WRITER

New Jersey could be harmful to your hormones, say scientists launching a program to study social and environmental links to glandular disease.

The new Center for Endocrine Research at Rutgers University will examine whether stress, toxins and bad habits are the reason rates of cancer, diabetes, osteoporosis and hyperthyroidism in New Jersey are among the highest in the nation.

Bad air, water, food and lifestyles, as well as genetics, can adversely affect hormone glands, which are also tied in with metabolism and the immune system.

Everything from tough jobs to heavy traffic makes New Jersey one of the most stressful states in the country, said Dipak Sarkar, a professor of animal sciences at Rutgers and director of the center.

“I think it’s the lifestyle here,” Sarkar said. “You leave the house and drive and you always have to watch out for the rest of the drivers. You really have to work hard to survive. You need a high income, which means more work, which means more stress.”

The $4.5 million center, operated jointly with the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, opens Monday on Rutgers’ Cook College agricultural campus in East Brunswick. The center will be funded by state and federal grants.

About 40 research scientists in different fields at Rutgers and UMDNJ will collaborate and work with locally-based pharmaceutical companies to find causes, treatments and cures for environmentally- related diseases.

The center will take a multi-disciplinary approach, Sarkar said. “It’s much different from a health specialty,” he said. “If you see a lot of toxic material leaking into water from a chemical plant, you need more than toxicology” to deal with the resultant health problems, he said.

Sarkar is focusing on the connection between stress and cancer, and the role played by endorphins, the protein chemicals in the brain that reduce pain. Studies have shown that cancer patients who can’t control stress progressed slower in treatment, he said. Cancer rates were also found to be higher in people with schizophrenia, depression and fetal alcoholism syndrome, he said.

“Endorphins make you feel good, and when they are not functioning it makes you feel depressed,” Sarkar said. “So we hypothesized whether people with higher cancer rates have abnormal endorphin function.”

Sarkar found that injecting rats with endorphins reduced the rate of prostate cancer in the rats by more than 95 percent.

“What we are trying to figure out is, do stem cells make endorphins that prevent cancer by activating immune cells, the natural killer cells that kill all foreign and tumor cells inside the body?” he said.

Stress causes neurotransmitters in the brain to produce large amounts of adrenaline, a hormone that prevents the death of cancer cells, he said. The brain’s control of stress may also impact other diseases, such as diabetes, Sarkar said.

“I really want to control these stress problems so that we have better health,” Sarkar said.

Behavior and nutrition also influence health, said Nicola Partridge of UMDNJ.

“The environment is a lot bigger than just bad air,” said Partridge, chair of physiology and biophysics at Robert Wood Johnson Medical School. “It can also be whether you don’t get out and exercise or don’t consume enough calcium.”

Partridge has her own lab at UMDNJ, but said the new center at Rutgers will be a partnership for sharing ideas, training graduate students and interacting with the pharmaceutical industry.

***

E-mail: [email protected]

(c) 2008 Record, The; Bergen County, N.J.. Provided by ProQuest LLC. All rights Reserved.

Cutting Edge

By Damayanti Datta

The operation taking place in the green tiled operating room at the All India Institute of Medical Sciences (AIIMS) is almost eerie. The patient, anaesthetised and swathed in blue drapes, is lying face up on a narrow table. But no one is touching her. Instead, the lead surgeon, Dr Arvind Kumar, sits some distance away, bowed over what looks like a video-game console. Yet action is taking place. As Kumar’s thumbs and forefingers hit the controls, a four-armed robot springs to life. Nurses, technicians, doctors stand motionless, staring at a sea of monitors, while tiny metal fingers inserted through pencil-sized holes in the patient’s chest carry out Kumar’s commands: clamping, cutting, sewing.The AIIMS robot may not intone, This won’t hurt a bit , like C3P0 of Star Trek, but surgery in the new millennium has gone through a galactic change. Technology is now the driving force, minimally-invasive the gold-standard and precision the mantra. Doctors mindmeld with machines, target drugs and instruments, don’t use hands to make a cut and with radical improvements in medical imaging, access parts of the body as never before. Surgery may not yet feature Star Trek-ian techniques, but in some regards they are on the way, says Dr Naresh Trehan, the cardiologist who pioneered robotic surgery of the heart in the country in 2002. Check out the surge of first-ever surgeries all across the country: in August, nerve electrodes enabled a ventilator patient to breath normally at AIIMS; in July, doctors at Jaslok Hospital in Mumbai performed a dual pacemaker surgery; in June, AIIMS achieved a landmark in robotic chest surgery. In March, at Bangalore’s Narayana Hrudayalaya, Asia’s first artificial heart was implanted. In January, tissue glue was used to fix up an intraocular lens in Chennai. Last year, orthopaedics replaced a patient’s kneecap totally in Delhi, while artificial spinal discs were put in Mumbai and Bangalore. In 2006, Asia’s first Brain Suite the most advanced technology to treat brain tumours was launched at the Institute of Neuroscience, Max Hospitals, in Delhi.

What has changed for the surgeon & for youLooking down at a patient during surgery is passe. Monitoring on TV or via consoles is in. Surgery is more precise. Less trauma for patient.Life gets simpler for both surgeon and patient as simple tools get camera-tipped and versatile robotic hands enter the OT.Minimally invasive is the mantra, as big incisions give way to keyhole surgery. Recovery is fast and easy. Bleeding was controlled by electricity or ultrasound once.Today electrothermal systems ensure minimum loss.Sutures and staplers are now giving way to tissue adhesives and soldering. Less scar, less pain for patient.Thanks to new generation CT, MRI and PET scans, doctors can explore every nook and cranny. Diagnosis much more accurate.

In 2003, almost like science fiction, Drs G.V. Rao and Nageshwar Reddy at the Asian Institute of Gastroenterology, Hyderabad, removed an appendix through the mouth the first in the world.

Driven by the rising health-care demands and spending power of India’s affluent generation, medical technology looks set to enter a golden age. A new Ernst & Young study predicts 15-20 per cent growth for the Indian medical equipment market, slated to reach to $5 billion by 2012, from $2 billion now. That doesn’t necessarily mean treatment will be cheaper, says Kumar, professor of surgery at AIIMS. But it promises to deliver more for the money. Almost certainly, it will be less dangerous and painful for patients.

From February this year, Ela Srivastava, 21, of Kanpur started getting periods of extreme weakness, when doors were too weighty to open, stairs too difficult to climb, food too hard to chew, eyes too droopy to focus. She suffered the ultimate onslaught respiratory failure and paralysis in May. It was a rare neuromuscular disorder and demanded a fierce chest surgery with large incisions sawed straight through the breastbone. But in June, when Kumar operated on Srivastava at AIIMS one of the five robotic surgery centres in India no rib or muscle was torn asunder, no nerve crushed and the patient could walk on her own within 48 hours. Forty years ago, when Trehan was a student, most devices in the operating room (OR) were rigid, allowing a few relatively simple procedures to be carried out with safety.

Even in the ’80s, gadgets were cumbersome and bulky, the operating table had to be cranked up or down with a jack and the overhead light fixed manually. Today, the OR looks more like a space capsule. Press a button and the table moves, in any angle and on any plane. Overhead lights are now aerodynamically controlled, with satellites lighting up hidden recesses of a patient’s body.

The crude electrocautery machine has given way to electrothermal Vessel Sealing Systems to control bleeding. From suturing, surgeons have moved on to staplers, while waterproof, biodegradable tissue adhesives and laser-assisted soldering are entering the OR.

The old anaesthesia unit is now a workstation , with sophisticated ventilators and automated recordkeeping. Twenty years ago, you had to go to the X-ray department, check out the angiograms, the blood report and all that. Today all is available on screen, allowing one to monitor those constantly, says Trehan. Not just that, the brick-and-mortar rooms are giving way to modular chambers, with fewer sharp edges to deter germ accumulation. Equipment often hang from the ceiling for utmost hygiene. Today’s ors are 20-25 per cent bigger, says neurosurgeon, Dr Sharad S. Kale of AIIMS. The state-of-the-art or under construction at AIIMS will not only be enormous, it will have four satellite rooms to house all the new technology. The glut of new technology corresponds to the third revolution in modern surgery (the first two came with antiseptics and anaesthesia). At one time, the saying was, ‘Big surgeon, big incision’, says Kumar, now it’s ‘Big surgeon, small incision.

Traditional surgery involved incisions large enough for the surgeon to put both his hands inside the patient’s body. Since the ’90s minimally invasive surgery (MAS) allowed surgeons to work through small punctures (or keyholes ) using chopstick-like tools teamed with a tiny camera. Instead of looking down at the patient, the surgeon looks up at enhanced images thrown up on a TV monitor.

In the pipelineWater jet: High pressure stream of water, used as a cutting tool in industry, is ready to be used for cutting tissuesTelesurgery: Surgeons have started using remote-controlled robots to operate on patients across continents Go virtual: Soon research will enable surgeons to scan patients, create 3-D images and practice before the real surgeryRobot brain: Let a robot use its brains to operate on a virtual patient and use it as a blueprint

But keyhole surgery is counterintuitive: to move an instrument’s tip to the left, surgeons have to push the handle to the right and vice versa. The 2-D monitor compromises depth, and the tools take away a lot of the touch sensation.

Robotics, the next stage in surgery, takes the tools out of a surgeon’s hands, performs precise movements in tiny spaces without trembling like a tired surgeon’s might and gives him 3D vision. None of this would be possible without a vital adjunct molecular imaging technology, says surgeon and cancer specialist Dr Harit Chaturvedi of the Rajiv Gandhi Cancer Institute and Research in Delhi. Later versions of Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography scanners have ensured that there’s no nook or cranny in the human body where a tumour or a disease can hide. Track the change in neurosurgery. In the past, the difficulty in distinguishing between diseased and healthy brain tissue needed a follow-up MRI a day or so following surgery, says Kale.

New breakthroughs in surgery from across the country When: 2008What: Implanting dual pacemakers for the first time in India.Where: Jaslok Hospital and Research Centre, Mumbai.When: 2008What:Robotic chest surgery on thymus gland.Where: All India Institute of Medical Sciences, Delhi. When: 2008What: Asia’s first artificial heart implant.Where: The Narayana Hrudayalaya hospital in Bangalore.When: 2008What: Tissue glue used to fix up intraocular lens.Where: The Aggarwal Hospital, Chennai. When: 2007What: Kneecap replacement; artificial discs in spine.Where: AIIMS, Bombay Hospital, Hosmat Institute, Bangalore.When: 2006What: Asia’s first Brain Suite to treat brain tumoursWhere: Institute of Neuroscience, Max Hospital, Delhi

That delay will be eliminated soon at AIIMS with high field- strength intraoperative MRI literally bringing imaging to the patient in the surgical suite. On the horizon are the newer, even less-invasive approaches of surgery through natural orifices (Natural Orifice Transluminal Endoscopic Surgery). The mouth, anus or vagina are used to pass fibre-optic instruments inside the body, says Rao. The fallout is minimum scar, pain and trauma. At the root of all this lies modern India’s interplay with the West. State-of- the-art technology was often brought in by Indian doctors who learnt their craft in the West.

On some fronts, such doctors far outstripped the West. Most American cardiac surgeons still hesitate to perform beating heart surgery, which does not require stopping the heart or using a heart- lung machine. In India, it is increasingly commonplace. Globalisation added the rest of the fillip. Sandeep Sinha, senior healthcare analyst with market intelligence, Frost & Sullivans (F & S), holds that the entry of cash-rich corporates into the healthcare fray changed the scenario: They have the wherewithal to mobilise huge resources globally. Most new technology is being adopted fast by them. Being on the cutting edge makes a sensible business proposition. New technology has also meant spiralling costs, says a F & S report, Cost of Healthcare in India, 2007. Consider: if the cost of a standard cataract operation in 2004 was Rs 35,000, with newer lenses coming into the market, it went up to Rs 42,110 in 2006 a 20 per cent hike in two years. If simple X-rays cost Rs 50 in the ’60s, ultrasound images in late-’70s cost around Rs 300, CT scans in mid-’80s Rs 2,500, MRI by mid-’90s to Rs 5,000 and now the pet scans cost Rs 25,000. But despite the price war, doctors hold, it matters when someone can walk back home after a gall bladder operation the same day instead of spending a week. After battling a long-drawn surgery, Kumar enjoys his personal ritual: reloading the hours spent in the or in his mind over a cup of steaming coffee. Today his mind wanders to the last nine months of lobbying for a robot, spending a lakh out of pocket for getting trained abroad, not to mention tackling the logistical nightmare of a public institution. They say, new technology will end the era of the ‘great man’ in surgery. If only, he smiles to himself. The robot has proved once again that the machine is the slave and the surgeon the master. Technology will move ahead so long we stick to our mandate of staying at the cutting edge.

(c) 2008 India Today. Provided by ProQuest LLC. All rights Reserved.

10th SoCalBio Investor Conference to Showcase 22 Medical Device and Biotech Companies

The Southern California Biomedical Council (SoCalBio) – a member-supported trade association that serves biotech and medical device firms, research organizations and academic institutions throughout the Greater Los Angeles region – has announced that 22 early- to late-stage companies are confirmed to present at the 10th Annual SoCalBio Investor Conference, which will be held September 19th at the Wilshire Grand Hotel in downtown Los Angeles.

The SoCalBio Investor Conference is the only annual conference of its kind in the Los Angeles region. Companies selected to present focus on a wide range of technologies and market segments including regenerative medicine, therapeutic devices targeting neurodegenerative disorders, cardiovascular devices, cancer therapeutics, teleradiology, biosensors, and personalized medicine.

The list of confirmed companies (along with their lead product/R&D focus) includes:

 Active Life Technologies (Santa Barbara, CA): Devices for measuring the mechanical properties of bones and other hard tissues in vivo.  Adventrx (San Diego, CA): Biopharmaceutical R&D focused on proprietary therapeutic candidates for treating cancer and infectious diseases.  Allvivo Vascular (Lake Forest, CA): Focused on developing a biomimetic coronary stent coating called ProteoGuard(TM) that prevents restenosis without the need for extended courses of dual antiplatelet therapy.  Anergix (Los Angeles, CA): Cell therapy for neurodegenerative disorders.  Bone-Rad (Irvine, CA): Radioactive bone cement for use as a cost-effective treatment paradigm for managing cancer tumors in bone.  California Stem Cell (Irvine, CA): Focused on manufacturing high-purity human cells for therapeutic development and clinical applications.  Capricor (Los Angeles, CA): Biotherapeutics for the treatment of heart disease.  DermTech (San Diego, CA): Development and validation of molecular tests using specimens derived from skin.  DxTerity Diagnostics (Rancho Dominguez, CA): DNA testing platforms that allow physicians to routinely and inexpensively test a patient's genetic make-up without requiring cumbersome and expensive enzymatic testing protocols.  EOS Neuroscience (Los Angeles, CA): Optical prostheses for the treatment of neurological diseases.  Histogen (San Diego, CA): Focused on regenerative medicine based on products manufactured by newborn human fibroblasts.  Inscent (Irvine, CA): R&D for using insect sensory machinery to construct biosensor devices for various applications.  Integrated Endoscopy (Rancho Santa Margarita, CA): New endoscope design  MiCardia (Irvine, CA): Minimally invasive methods to treat heart valve disease.  NeoMatrix (Irvine, CA): Devices that promote optimal breast health.  Nidus Laboratories (Los Angeles, CA): Small cyclic peptides to treat immune disorders, inflammation and cancer.  Organovo: Platform technology for "organ printing" that allows precise placement of cell types into structures (e.g., blood vessels and complex organs) to aid transplantation.  Radlink (Torrance, CA): An innovative manufacturer of digital medical imaging for diagnostic use.  Spectrum Pharmaceuticals (Irvine, CA): Acquisition, development and commercialization of a diverse portfolio of oncology drug candidates.  TerraPharm: Specialized pharmaceuticals focused on prescription botanical drugs and medical foods to treat major chronic diseases.  Tissue Genetics Inc. (Boulder, CO) Molecular diagnostics for breast and ovarian cancers.  Wavestate (Marina del Rey, CA): Medical device technology to improve neurointensive care. 

In addition to presentations by the above companies, the 10th SoCalBio Investor Conference will feature keynote presentations and breakouts that engage technologists, investors and entrepreneurs in a discussion about strategies to expedite the commercialization of life-saving medical technologies.

For a detailed agenda, please visit the Southern California Biomedical Council’s Web site at www.socalbio.org.

Conference Sponsors:

The 10th SoCalBio Investor Conference is sponsored by organizations dedicated to the growth of life-science industry in Greater Los Angeles. The list of generous supporters includes the following:

 Platinum: ---------------------------------------------------------------------- Perkins Coie LLP http://www.perkinscoie.com  Gold: ---------------------------------------------------------------------- Alfred Mann Institute at USC http://ami.usc.edu Ernst & Young LLP http://www.ey.com Oracle Corp. / LST http://www.oracle.com / http://www.lstechnologies.com Prism VentureWorks http://www.prismventure.com Reed Smith LLP http://www.reedsmith.com  Silver: ---------------------------------------------------------------------- Bench International http://www.benchinternational.com Bingham McCutchen LLP http://www.bingham.com Bolton & Company http://www.boltonco.com Los Angeles Biomedical Research Institute http://www.labiomed.org  Bronze: ---------------------------------------------------------------------- California Technology Ventures / Jacobs Capital Group http://www.ctventures.com Davis Wright Tremaine LLP http://www.dwt.com Irvine Pharmaceutical Services http://www.irvinepharma.com Los Angeles/Orange County Biotechnology Center http://www.paccd.cc.ca.us/instadmn/lifesci/biotech/ednet.htm Macadamian, Inc. http://www.macadamian.com One Lambda http://www.onelambda.com USI http://www.usi.biz 

About the Southern California Biomedical Council (SoCalBio):

The Southern California Biomedical Council is a nonprofit, member-supported trade association that represents the biotech and medical device industries in the Greater Los Angeles region.

SoCalBio’s programs help local firms gain access to capital, potential partners and business support services. The annual SoCalBio Investor Conference has grown to become the region’s premier showcase for emerging life-science companies and technologies. SoCalBio also promotes technology transfer and workforce training while educating policy makers and the public at-large about the benefits of the life-science industry.

SoCalBio is open to membership by firms and organizations engaged in biotech, medical device technology development and commercialization throughout Los Angeles/Orange Counties, the Gold Coast, and Inland Empire. More information is available at www.socalbio.org.

NewsRx Adds Pediatrics and Psychiatry Titles

ATLANTA, Sept. 9 /PRNewswire/ — NewsRx, a 25-year-old publisher and international news organization headquartered in Atlanta, has launched two new newsletters on pediatrics and psychiatry/psychology.

These new titles will cover clinical and bench research, drug development, clinical trials, business news and developments in pediatric and psychiatric medicine. The new titles are weekly newsletters, and are available in print or online at http://www.newsrx.com/ . Sample issues are also available there.

Pediatrics Week and Psychology & Psychiatry Journal each offers readers comprehensive coverage of the news that matters, ensuring that readers stay on top of the news, research and business trends that are important to them.

Pediatrics Week provides reports on children’s vaccines, new drugs approved for use in children, children’s clinical trials, and childhood diseases and conditions, including cancers, autism, ADHD, and auto-immune disorders.

Psychology & Psychiatry Journal provides coverage on mental health issues, diseases and conditions, including depression, bi-polar disorders, schizophrenias, Alzheimer’s and aging dementias, personality disorders, pharmacology, diagnostics and treatments.

Readers familiar with NewsRx’s 102 titles that currently serve the health and medical fields will recognize the quality and thoroughness of the coverage typical of NewsRx newsletters.

Now with a portfolio of 194 titles, NewsRx is one of the largest content companies in the world. Popular brands and successful franchises extend to internet and online services, streaming video, mobile devices, and branded products.

Each month, over a million readers globally view and download NewsRx articles and publications online. Although the company has focused on its digital platforms, quality print content still matters, with subscribers in 25 countries.

NewsRx has won six eHealthcare Leadership Awards in the past three years, and NewsRx.com was ranked as the #2 News and Media Site for the Pharmaceutical Industry by Amazon’s Alexa in 2007.

Moving out of its history as a publisher for the life sciences, NewsRx has recently launched 86 new scientific, technical and general interest newsletters under its new division, VerticalNews. VerticalNews has titles in almost every content area, including technology, business, finance, energy, ecology, computers, communications, physics, chemicals, electronics, real estate, investment, conservation, engineering, telecommunications, leisure, travel, nanotechnology, insurance, robotics, machine learning, farming, economics, information technology, politics, government, mathematics, mining, minerals, transportation, veterinary research, agriculture, defense, aerospace, food, entertainment, education, and marketing.

New geographic-oriented titles at VerticalNews focus on news from Asia, China, and India.

The New York Times news service called the company “the world’s largest producer of weekly health information.” NewsRx and VerticalNews publish over 10,000 issues annually consisting of over 90,000 pages with well over 500,000 articles per year.

   Press Release Contact Information:   Susan Hasty   Publisher   NewsRx   770-507-7777   [email protected]   

This release was issued through WebWire(R). For more information visit http://www.webwire.com/.

NewsRx

CONTACT: Susan Hasty, Publisher, NewsRx, +1-770-507-7777,[email protected]

Web site: http://newsrx.com/

Proposed OSU Residency Plan Raises Concern on Indigent Care

By KIM ARCHER

Oklahoma State University’s College of Osteopathic Medicine is trying to get St. Francis Hospital to take on its residency program, a deal that could mean the end of the city’s de facto public hospital for the indigent, the OSU hospital’s former chief of staff said Thursday.

“I am concerned about the impact this will have on our community, our state and the osteopathic profession,” said Dr. Ken Calabrese, whose private nephrology practice is affiliated with OSU Medical Center.

“What I know is if this deal goes through, the hospital will close,” he said.

For years, the aging facility has struggled through ownership changes and financial problems, bringing a great deal of uncertainty to OSU medical students.

The negotiations come just five months after Ardent Health Services, which owns OSU Medical Center, agreed to sell the hospital for a nominal $5 million to a public trust to be set up by Oklahoma State University by June 30, 2009. The hospital, along with equipment and facilities, is valued between $140 million and $160 million, officials said.

The deal was expected to ensure the long-term stability of the primary teaching hospital for OSU’s residency program. Under the agreement, OSU was charged with finding a partner firm to manage the hospital. But the school has been unable to do so, Calabrese said.

He said Integris was interested for a while, but that deal fell through two months ago.

“We’re pursuing every viable option to secure the future of our residency programs,” said OSU medical school spokeswoman Ellen Averill.

State Sen. Tom Adelson, D-Tulsa, said OSU needs to have a firm residency arrangement by Sept. 15 to meet accreditation requirements and so residents will know they have a place to go next summer.

“It may provide OSU the stability it needs, but at a very high price,” he said. The hospital may have to close if OSU moves its program because residents are the ones who provide the bulk of uncompensated care there, Adelson said.

In that case, the burden of an additional 34,000 emergency room visits and $50 million in uncompensated care each year will fall to the nearest hospitals, St. John Medical Center and Hillcrest Medical Center, he said.

“I think Ardent will do what it can to make sure the hospital stays open, but I’m not sure they can,” Adelson said.

There is a possibility that OU-Tulsa residents could step in to prevent the hospital from closing, he said. “If that materializes, I’m a strong proponent,” Adelson said.

Tulsa is the only metropolitan city in the country without a publicly supported hospital, he said.

“Whatever the result, without a publicly supported teaching hospital, we won’t solve both the need for a stable medical education and the challenge of indigent care,” he said.

In OSU’s defense, Adelson said officials there never received the support they needed from the state Legislature to keep the hospital open.

Earl Denning, president and chief executive officer of Hillcrest HealthCare Systems and interim CEO of OSU Medical Center, wrote in an internal memo to employees that he had not been informed of any potential residency program move.

“I will note that OSU Medical School leadership has chosen not to address these issues directly with me or other members of your hospital leadership team,” he wrote in the memo to address numerous rumors circulating among the hospital’s 1,400 employees.

Denning noted that Ardent and OSU have a signed agreement through June 30, 2009, and that it provides for the residency program to remain at the OSU hospital through the end of the academic school year.

“However, it is my understanding that leadership from the medical school shared with St. Francis physicians that we are turning the hospital into a psychiatric and long-term acute care hospital,” he wrote.

“This is false,” Denning said in the memo. “OSU medical school leadership never asked us about this erroneous conclusion before they voiced this rumor.”

Calabrese said he learned of OSU Medical Center’s plans two weeks ago during a meeting of the hospital’s medical executive committee. He said Dr. John Fernandes, president and dean of the OSU College of Osteopathic Medicine, said negotiations were under way and that the 132 residents would be placed at St. Francis Hospital on Yale Avenue and St. Francis Hospital South near 91st Street and U.S. 169.

“When I expressed my concern to him that this will close this hospital, he said, ‘My responsibility is for the college,’ 200a(unknown)” Calabrese said.

“This hospital has been in business 64 years. It has served the community well and trained almost 2,000 physicians through its post- graduate residency program, the majority of whom have stayed in the state of Oklahoma,” he said.

St. Francis officials had not returned calls for comment by press time.

Kim Archer 581-8315

[email protected]

Originally published by KIM ARCHER World Staff Writer.

(c) 2008 Tulsa World. Provided by ProQuest LLC. All rights Reserved.

PA Agriculture Secretary Announces Appointment of New State Veterinarian

HARRISBURG, Pa., Sept. 9 /PRNewswire-USNewswire/ — Agriculture Secretary Dennis Wolff today welcomed Dr. Craig Shultz, a Pennsylvania native and experienced large animal veterinarian, as state veterinarian and director of the Bureau of Animal Health and Diagnostic Services.

Dr. Shultz will assume his new duties on Sept. 29. In his position as bureau director, he will also serve as executive director of the Pennsylvania Animal Health and Diagnostic Commission.

“Dr. Shultz brings with him an unrivaled knowledge of the state’s regulatory veterinary medicine industry and a keen understanding of the role veterinary medicine plays in the production and processing of food,” said Wolff. “I am pleased to welcome Dr. Shultz to the Department of Agriculture and look forward to working with him to protect and promote Pennsylvania’s animal industry.”

Dr. Shultz brings more than 30 years of diverse veterinary experience to his new role, working previously as a private practice veterinarian, relief veterinarian for the Pennsylvania Harness Racing Commission and, more recently, with the U.S. Department of Agriculture’s Food Safety and Inspection Services. Since 1994, Dr. Shultz has been the Food Safety and Inspection Services’ veterinarian-in-charge at a large meat processing plant.

Shultz has worked extensively with multiple species, including equine, dairy and beef cattle, and poultry. Through his past work experience Shultz has developed extensive leadership and management skills.

Shultz was raised on a dairy farm in Berwick. He holds a Bachelor of Science in animal science and a Doctor of Veterinary Medicine from Cornell University. He has been recognized for excellence throughout his career, earning numerous awards including the 2000 Veterinarian of the Year award from the American Association of Food Hygiene Veterinarians, a 2003 Public Health Veterinarian mentor award, and the 2006 Outstanding Public Health Veterinarian Mentor award.

“Dr. Shultz’s strong and substantive background in veterinary medicine, particularly in the area of public health, is a perfect fit to oversee the department’s animal health activities,” said Wolff. “His extensive work in Pennsylvania has provided him an exceptional familiarity with local, state and federal aspects of regulatory veterinary medicine.”

The Bureau of Animal Health and Diagnostic Services is responsible for the control and eradication of diseases in livestock and poultry that affect human health or cause significant economic loss to the agriculture industry. The bureau administers regulatory programs for animal health certification, containment of diseased animals and elimination of disease agents.

For more information about the Bureau of Animal Health and Diagnostic Services, the Animal Health and Diagnostic Commission, or any of the Department of Agriculture’s regulatory animal health programs, visit http://www.agriculture.state.pa.us/ and click on “Bureaus.”

CONTACT: Chris L. Ryder

717-787-5085

Pennsylvania Department of Agriculture

CONTACT: Chris L. Ryder of the Pennsylvania Department of Agriculture,+1–717-787-5085

Web Site: http://www.agriculture.state.pa.us/

Charles Drew University Opens New Urgent Care Clinic Friday to Serve South Los Angeles Community

LOS ANGELES, Sept. 9, 2008 (GLOBE NEWSWIRE) — Helping fill the health care void created by the closure of Martin Luther King, Jr.-Harbor Medical Center last year, Charles Drew University of Medicine and Science (CDU) will open a new Urgent Care Clinic in South Los Angeles on Friday, September 12th, the first in what will be a substantial network of clinics developed for the community and operated by the University.

The new Charles Drew University Urgent Care Clinic will provide high quality, affordable health care for South Los Angeles residents and is located in the Kenneth Hahn Plaza at 11722 South Wilmington Avenue at 118th Street in South Los Angeles. The facility has been designed for patients requiring immediate care short of emergency treatment.

“This is truly a momentous occasion for both South Los Angeles residents and the University,” said Dr. Susan Kelly, President and CEO of CDU. “Our first clinic is very tangible evidence of this University’s mission and commitment to helping the medically underserved in our community, and this new facility is quite literally in our own back yard, blocks away from our campus. This type of clinic is a true ‘safety net’ for communities suffering from abysmal health inequities and few care options — and sadly, South Los Angeles certainly fits that description. We are stepping forward with our new model of health care for this community, filling a huge void in the most medically underserved urban area in the entire country.”

Dr. Hector Flores, Medical Director of the Family Care Specialists Medical Group and a member of CDU’s Board of Trustees, stated, “The Charles Drew University Urgent Care Clinic will meet a critical need in the South Los Angeles area. It is especially meaningful because it is operated under the auspices of Charles Drew University of Medicine and Science, a trusted name and a partner for health care in the community.”

Long-term community activist and Chair of the Black Health Task Force Mrs. Lillian Mobley stated: “It is wonderful when a service or program that is greatly needed by the community is provided. I am proud to see this clinic open in an area that may seem forgotten. I look forward to the opening of many more.”

Dr. Richard Baker, Dean of CDU’s College of Medicine, noted that this and future CDU clinics have been specifically designed to meet the needs of community residents, with convenient locations and extended hours.

“Patients in our community are looking for a clinic that can offer high quality of care, bilingual staff, affordability, a friendly, comfortable environment, and extended hours with access to this care after work. We have adopted these concepts in our new ‘patient-friendly’ clinics,” Baker stated.

CDU’s clinic fills a vital need in the Watts-Willowbrook community, following the closure of Martin Luther King, Jr.-Harbor Medical Center in 2007. A large number of patients in South Los Angeles are uninsured or underinsured, and have previously depended on County health care facilities. Preliminary estimates indicate that more than 16,000 patients annually will receive care at this new University-owned facility. The other University-developed clinic, located in Lynwood, is expected to open within the next six months.

The new facility opening on Friday will include electronic medical records, state-of-the-art diagnostic and testing equipment, six private examination rooms and treatment areas, and laboratory services.

Because an estimated 70% of medical students will practice in areas where they received their training, Dr. Kelly said the University’s clinics will have the added benefit of serving as local sites for clinical rotations of students from CDU’s College of Medicine and its College of Science and Health as part of their education.

“Many of our students are likely to practice in this area, so the clinics reinforce one of our primary objectives — keeping our graduates in medically underserved communities,” she added.

Close to major public transportation (Metro Bus and Blue Line services), the new clinic will be open from 10 a.m. to 10 p.m., Monday through Friday, and 10 a.m. to 8 p.m. Saturday and Sunday. All forms of medical insurance will be accepted as payment.

ABOUT CHARLES DREW UNIVERSITY OF MEDICINE AND SCIENCE (CDU)

CDU is a private nonprofit, nonsectarian, minority-serving medical and health sciences institution. Located in the Watts-Willowbrook area of South Los Angeles, CDU has graduated over 550 medical doctors, 2,500 post-graduate physicians, more than 2,000 physician assistants and hundreds of other health professionals. The only dually designated Historically Black Graduate Institution and Hispanic Serving Health Professions School in the U.S. CDU is recognized as a leader in health inequities and translational research, specifically with respect to heart disease, diabetes, cancer, mental health, and HIV/AIDS. The University is among the top 7% of National Institutes of Health (NIH)-funded institutions and rated one of the top 50 private universities in research in the U.S. Recently, the CDU/UCLA medical program was named the “best performer” in the University of California System with respect to producing outstanding underrepresented minority physicians. For more information, visit http://www.cdrewu.edu.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  Charles Drew University of Medicine and Science           Elia Esparza           (323) 563-5822           [email protected]            Parsons Communications           Craig Parsons           (310) 472-7632           (310) 200-4310 

ValiMed(TM) Reduces Drug Diversion in Hospitals Quickly and Inexpensively

CDEX Inc. (OTCBB:CEXI): An article published in the August issue of the Association of Perioperative Registered Nurses (AORN) Journal documents the benefits of CDEX’s Enhanced Photoemission Spectroscopy Technology in reducing narcotics diversion in the healthcare community. AORN J 88 (August 2008) 249-252. (C) AORN, Inc, 2008. http://www.aornjournal.org/article/S0001-2092(08)00258-5/abstract. The AORN Journal publication conclusion is similar to an earlier American Journal of Health-System Pharmacists peer-reviewed article detailing an 18-month independent study of the ValiMed(TM) Medication Validation System. Am J Health-Syst Pharm — Vol 65, pp 49-54, Jan 1, 2008.

“Drug diversion is an ongoing problem in health care settings,” said Dr. Kevin B. Sharer, MD, MBA, CPE and author of the AORN Journal article. “Records of the flow of controlled substances are kept by various accounting systems, but these systems can be inaccurate because the returned medications rarely are tested to verify that they have not been diluted or replaced. For example, fentanyl is a potent narcotic that is administered frequently in hospitals for the relief of pain as an adjunct to anesthesia in surgical procedures. It is diverted primarily from operating rooms through product substitution or outright theft, resulting in the potential under dosing of patients and falsifying of records,” continued Dr. Sharer. “The ValiMed System technology provides a quick and relatively inexpensive solution to this problem.”

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures such as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

About CDEX

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technologies. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technologies are being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets — Medication Safety and Security. The ValiMed System is providing life-saving validation of high-risk medications in healthcare facilities and pharmacies. The ID2 Meth Scanner(TM) is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France. For more information, visit www.CDEXInc.com and www.valimed.com or contact Pascal Pouligny ([email protected]) at 520-745-5172.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,””plans,””may,””anticipates,””believes,””should,””intends,””estimates,” and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

San Diego’s Original Biotech Company Celebrates 30th Anniversary With Reunion

SAN DIEGO, Sept. 9 /PRNewswire/ — The Hybritech Reunion Committee today announced the 30th Anniversary Reunion for Hybritech employees will take place on Saturday, September 13th, 2008 at the headquarters of AMN Healthcare in San Diego.

In September 1978 Hybritech, San Diego’s “Granddaddy” biotech company, began operations in temporary trailers located in the parking lot of the La Jolla Cancer Research Foundation (now the renowned Burnham Institute). The company quickly produced the world’s first commercially manufactured monoclonal antibody product, and soon thereafter, a series of diagnostic kits for allergy, pregnancy, anemia and certain forms of cancer. The company was also instrumental in the earliest investigations of in vivo and therapeutic applications of monoclonal antibodies for the diagnosis and treatment of cancer.

By 1985, Hybritech had developed its “Prostate Specific Antigen (PSA)” product, the first monoclonal antibody test for prostate cancer. The blood test soon became the standard method for physicians to diagnose and monitor prostate cancer patients, the second biggest cancer killer among American men.

In 1986, the pharmaceutical company, Eli Lilly paid $450 million in cash and warrants to buy Hybritech — at that point the largest M&A in San Diego history. The company’s early success — and the visibility it created among its founders and employees — spurred other academic scientists and entrepreneurs to form dozens of additional life sciences companies in San Diego.

Hybritech’s original founders and employees have gone on to found more than 175 of the several hundred life science companies now located in San Diego county — and comprising the San Diego life sciences “technology cluster”.

“This event is a milestone celebration of all the tremendous things that came from the genesis of this small company 30 years ago. Who would have foreseen how significant the impact of one company could be on our community’s economy and its reputation as a leading area of biotech research and scientific development? I am very proud to have led this brilliant, dedicated and innovative group of individuals,” said Ted Greene, chief executive of Hybritech until the Lilly acquisition.

“There are several hundred Hybritech alumni who continue to live and work here in San Diego who plan to attend the reunion. We also have former employees planning to attend who currently live across the United States and in Europe — and who are returning to San Diego for the event. These Hybritech alumni rank among the earliest founders of San Diego’s now vibrant biotech and life sciences ‘technology cluster’. Many people, even former employees, are surprised to learn that the Hybritech success has become a point of study among academic and governmental investigators who want to understand how ‘technology clusters’ are successfully created and sustained,” said Cole Owen, a member of the Hybritech Reunion Committee.

The Hybritech 30th Anniversary Reunion (for former Hybritech employees only) will be held at the AMN Healthcare facility in San Diego, on Saturday, September 13, 2008, beginning at 3 PM. The host for the Reunion is AMN’s President and CEO, Susan Nowakowski, herself a Hybritech alumnus.

Further registration information is available online at http://www.hybritech.org/ for former Hybritech employees and media.

The Hybritech Reunion is a non profit corporation dedicated to preserving the legacy of Hybritech.

Hybritech Reunion Committee

CONTACT: Guy Iannuzzi of Mentus Life Science, +1-858-455-5500,[email protected], for Hybritech Reunion Committee

Web site: http://www.hybritech.org/

Akorn Wins Approval for Lyophilized Product

Akorn, a manufacturer and marketer of diagnostic and therapeutic pharmaceuticals in specialty areas, has announced that the FDA has granted supplemental new drug application approval for IC-Green for injection, USP.

Akorn said that this approval is the company’s first lyophilized product approval for manufacture in its Decatur, Illinois production facility.

Akorn has invested approximately $23 million in a new liquid and lyophilized injectable manufacturing fill line at its Decatur, Illinois production facility.

Arthur Przybyl, Akorn’s president and CEO, said: “We intend to commercialize our lyophilization manufacturing capabilities by developing an internal abbreviated new drug application injectable product line and by expanding our contract pharmaceutical manufacturing business segment to include lyophilized injectable products.”

CompuMed Signs Agreement With ANY LAB TEST NOW(R) to Provide ECG Systems and Services Nationwide

CompuMed, Inc. (OTCBB:CMPD) (www.compumed.net), a medical informatics company serving the healthcare community with telemedicine applications and diagnostic software solutions, today announced that it has signed a new and exclusive agreement with ANY LAB TEST NOW(R), a franchise direct-access lab testing facility with more than 70 locations, and will provide remote electrocardiogram (ECG) interpretation systems and services at selected facilities nationwide.

“We’re delighted to team with ANY LAB TEST NOW to help the company expand its unique model for providing direct-to-consumer laboratory services to a wide range of customers,” said CompuMed CEO Maurizio Vecchione.

“We are thrilled about this partnership because not only do both companies benefit, but more importantly, consumers benefit by having access to professional ECG services conveniently and affordably,” said Chief Operating Officer Clarissa Windham.

CompuMed’s traditional core business is providing remote ECG interpretation terminals and related services to medical facilities that may not have access to physicians trained and qualified to interpret ECG results. Traditional customers for the Company’s CardioGram system include correctional facilities, ambulatory surgery centers, occupational health clinics and physicians’ offices. Its systems reduce healthcare costs substantially by providing remote cardiac screening at the point of care. Another key advantage is an optional feature that automatically sends ECG results to a trained cardiologist for an over-read when the results are abnormal.

About ANY LAB TEST NOW(R)

Founded in 1992, ANY LAB TEST NOW(R) is a franchise laboratory testing company with more than 70 facilities throughout the United States. It offers thousands of standard laboratory tests direct-to-consumers and employers in a professional, convenient and cost-effective manner. Lab tests include general health and wellness, paternity, pregnancy, HIV/STD, drug and many more. At ANY LAB TEST NOW(R), consumers and employers don’t need insurance or an appointment, and results are typically given within 24-48 hours. Visit www.anylabtestnow.com.

About CompuMed

CompuMed, Inc. (CMPD.OB) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The Company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed’s core products, the OsteoGram(R) and CardioGram(TM), are cleared by the FDA and reimbursable by Medicare. The OsteoGram is a non-invasive diagnostic system that has been proven by many clinical studies to provide effective and accurate bone density measurement for screening osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within minutes of receipt and has the additional capability of automatically providing an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed on-line at www.compumed.net.

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company’s plans, objectives, expectations and intentions are based largely on management’s expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

Pri-Med Institute Receives ACCME Re-Accreditation and NC-CME Certifications

Pri-Med Institute’s continued leadership and professionalism in CME is underscored today by the announcement of two industry recognitions–ACCME re-accreditation and NC-CME certifications. Earned independently, but supportive of Pri-Med Institute’s mission and ongoing commitment to provide world-class, clinically relevant educational content that is professional, fair-balanced, evidence-based, and scientifically rigorous.

Pri-Med Institute (PMI), the accreditation unit of Pri-Med, was recognized by the Accreditation Council for Continuing Medical Education (ACCME) to be in compliance in all areas, and received exemplary compliance in two critical areas: PMI Mission Statement, including its purpose, content areas, and the expected results of the program, and Needs Assessment. There were no areas of deficiencies or concerns identified. ACCME accreditation is a mark of quality continuing medical education (CME) activities that are planned, implemented and evaluated by ACCME accredited providers in accordance with ACCME’s Essential Areas and Elements and Accreditation Policies (“Accreditation Requirements”). ACCME accreditation assures the medical community and the public that such activities provide physicians with information that can assist them in maintaining or improving their practice of medicine. Re-accreditation demonstrates Pri-Med’s continued commitment to delivering fair-balanced, clinically relevant CME solutions to meet the growing need for physician education.

“As I compare you to both academic and non-academic providers, Pri-Med is clearly doing some of the most advanced practices in CME,” says Steve Passin, President, Steve Passin and Associates, a leading CME consulting firm. “Your process of planning complex modules based on the analysis of practice gaps/needs and national standards, that translate into state-of-the-art CME content is the best we see. Likewise, you are leading the way with the resources you have invested into the measurement of educational outcomes. Pri-Med has moved into a process of sequential learning that is a model for others throughout the nation.”

Pri-Med Institute received additional recognition from the National Commission for Certification of CME Professionals (NC-CME) with two of its CME professionals receiving the first-of-its-kind, CME Certification. Marissa Seligman, PharmD, Chief Clinical, Regulatory Affairs and Compliance Officer, Senior Vice President, and Kristin Fludder, Senior Accreditation Manager, both passed the inaugural CME certification exam. The NC-CME is a nonprofit organization founded in 2006 by a group of CME professionals whose goal was to establish an independent certification program. The program includes a credentialing exam for those who are employed in the field of CME. The exam was administered for the first time in May is designed to measure the competence of CME professionals who are responsible for developing CME activities, essential for re-licensure of more than 700,000 physicians.

“CME in the US is going through tremendous change. We have new and challenging responsibilities and accountabilities,” says Dr. Seligman. “Through the next four years of our accreditation period, we are charged with conducting education that specifically and measurably meets the updated accreditation criteria, whereby education is linked to clinical care gaps and identified educational need and that is designed to produce education that results in change in physician competence, performance and/or patient outcomes. Pri-Med will continue to be laser-focused on achieving these new accreditation criteria and devote our efforts to lead the industry in delivering independent, credible, fair-balanced, objective, and scientifically rigorous information to advance their clinical practice.”

Re-accreditation and certification from leading industry organizations supports Pri-Med’s ongoing commitment to delivering high-quality CME. The ACCME re-accreditation will benefit physicians in their knowing that they are earning course credit from a reputable professional organization whereby their learnings can then be carried into their daily practice to improve patient care. The NC-CME certification program will benefit the public health by offering stakeholders a way to verify the knowledge and skills of CME staff. The examination allows employers to monitor and document their ability to be compliant with national guidelines developed by groups such as the ACCME, the Food and Drug Administration (FDA), and the Health and Human Services Office of the Inspector General (HHS OIG). Together, the two recognitions accentuate Pri-Med Institute’s commitment to providing clinically relevant educational activities for clinicians that will advance healthcare practice and the outcomes of care for patients.

For more information about ACCME, visit www.accme.org or NC-CME, visit www.nccme.org.

About Pri-Med Institute

Clinical Education Division of M|C Communications

Pri-Med Institute is structured to provide continuing medical education programs to physicians that will advance healthcare practice and patient outcomes. Established in 2001, Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) with exemplarily status in three essential elements. Pri-Med Institute is committed to providing relevant, evidence based education and educational intervention strategies that are innovative in design and motivate physicians to adopt appropriate, up-to-date clinical practices. For more information about Pri-Med Institute, visit www.pri-medinstitute.org.

About Pri-Med

Pri-Med is a global provider of innovative, cutting-edge clinical education that is designed to meet the individual learning needs of specialists and primary care practitioners. Pri-Med’s CME/CE is developed through extensive collaboration with leading professional associations, academic institutions, hospitals, technology companies and over 1,500 prominent faculty. Today, 350,000 health care professionals globally trust Pri-Med as their source to stay better informed and educated. Pri-Med Institute, the accreditation division, is accredited by the Accreditation Council for Continuing Medical Education (ACCME). For more information about Pri-Med, visit www.pri-med.com.

Supermodel Beverly Johnson Speaks Out to End Silence About Uterine Fibroids

ROCKLAND, Mass., Sept. 9 /PRNewswire/ — Supermodel Beverly Johnson is on a mission to get women to Ask 4 questions and Tell 4 or more others about a health condition faced by up to 75 percent of all women in the U.S.(1): uterine fibroids. Although uterine fibroids are common, many women remain uninformed about this condition, and a majority wait up to a year before finding treatment, often despite pain, heavy bleeding and weight gain. Beverly did, and now she is sharing her story to ensure that other women not only avoid silent suffering, but actively seek suitable treatment options now. Women can read Beverly’s personal story and learn more about uterine fibroids and their treatment at http://www.ask4tell4.com/.

“It is my personal mission to help ensure that women are informed about uterine fibroids and feel empowered, if they think they have fibroids or are diagnosed with them, to talk with their healthcare providers about their treatment options,” said Beverly Johnson. “When I was diagnosed with uterine fibroids, I didn’t know a lot about the condition, and as a result I suffered for a long time, both physically and emotionally. My hope is that women will not be embarrassed to talk about uterine fibroids or afraid to discuss treatment options with their doctors.”

Lack of information about uterine fibroids and treatment options can have serious consequences for a woman’s health and quality of life. According to a national survey*, less than half of the women surveyed could identify non-surgical and uterine sparing options for fibroids. Left untreated, fibroids can cause heavy bleeding, pelvic pain, enlargement of the abdomen, and can lead to reproductive problems.

“Many women silently accept symptoms of uterine fibroids as an unfortunate fact of life, or the result of aging. Others hesitate to discuss their condition because they fear that major surgery is their only treatment option. It is not,” said Linda Bradley, M.D., Chair of the OB/GYN Section of the National Medical Association and Vice Chair of Obstetrics, Gynecology, and Women’s Health Institute at the Cleveland Clinic. “Women who have uterine fibroid tumors should know that many treatments are available that can ease their pain and symptoms. While hysterectomy has been the standard surgical treatment for many years, technology has advanced and a number of clinically-proven, non-surgical and uterine-sparing procedures are widely available.”

Beverly’s Story

Beverly developed uterine fibroids in her 30s, and for years faced symptoms including heavy bleeding, abdominal pain, fatigue and emotional stress. After attempting to manage her symptoms with diet and acupuncture, she consulted with two doctors; both recommended she get a hysterectomy. Unfortunately, Beverly didn’t fully understand what a hysterectomy entailed, and she suffered severe complications from the surgery. It took several years of recovery and hormone replacement therapy for her to get her body and life back in balance.

Beverly hopes her willingness to share her story will encourage women to learn about the variety of uterine fibroid treatment options available today, so they can play a more active role in talking with their doctors to select the treatment that best suits their condition and lifestyle.

Ask4Tell4.com

Beverly’s new Web site, Ask4Tell4.com, highlights the four questions she thinks all women should ask themselves and their healthcare provider about uterine fibroids, whether they currently have the condition or not. The site also includes the answers to these questions and information about a variety of treatment options that will help them have a more informed discussion with their doctor. Additionally, women can join Beverly’s cause by sharing the information with four or more of their friends or family members through an instant email message sent from the Web site.

The Ask4Tell4 campaign is sponsored by BioSphere Medical, Inc. BioSphere is a pioneer in commercializing minimally invasive therapeutic applications based on proprietary bioengineered microsphere technology. BioSphere’s principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE.

   * Survey cited was also sponsored by BioSphere and conducted by Caravan     Research Corporation.  The survey was conducted via telephone to 1,000     women during July 2007.    (1) Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM.  High       cumulative incidence of uterine leiomyoma in black and white women:       ultrasound evidence.  Am J Obstet Gynecol 2003;188:100-7  

Ask4Tell4.com

CONTACT: Alyson Cavalere of Fleishman-Hillard, Inc., +1-617-692-0510,[email protected], for Ask4Tell4.com; or Sandi Duxbury ofBioSphere Medical, Inc., +1-781-681-7951, [email protected]

Web site: http://www.ask4tell4.com/

AAHE and HealthTeacher Partner to Create First National Health Education Awards Program

The American Association for Health Education (AAHE) and HealthTeacher today is announcing a partnership to create, promote and bestow national K-12 health education awards. The Blue Apple Health Education Awards will recognize up to 12 U.S. schools for their commitment and creativity in teaching students about the power of practicing a healthy lifestyle.

“We are excited to launch an awards program that extols those schools that serve as models of excellence in health education,” said Katherine Wilbur, Past President of AAHE. “Our goal is to bring much deserved recognition to schools promoting healthy behavior for all students and inspire more schools to adopt a comprehensive health education curriculum.”

“HealthTeacher is excited to be partnering with AAHE to create a national recognition program for schools that demonstrate a strong commitment to teaching quality health education,” said Scott McQuigg, CEO of HealthTeacher. “Exemplary health education in schools demonstrates commitment by administrators and teachers to help children and adolescents develop a healthy approach to life. The Blue Apple Health Education Awards Program will serve to recognize this type of leadership.”

The Blue Apple Health Education Awards are designed to capture how schools empower teachers and administrators to teach and promote health education, utilize best practices in the classroom and coordinate with other aspects of school health. Schools receiving the inaugural Blue Apple Health Education Award will be honored at an award reception and luncheon during AAHE’s annual national convention with the American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) to be held in Tampa, Fla., in April 2009. Recipients will receive a host of benefits associated with the award including:

— Recognition award and flag denoting their school as a Blue Apple recipient

— AAHPERD/AAHE convention registration and travel stipend

— Inclusion in national and local public relations campaign highlighting Blue Apple recipients

— Free one-year subscription to HealthTeacher, a comprehensive online health education curriculum

Applications for the Blue Apple Awards will be available beginning October 2008 and they must be received by December 12, 2008.

Schools may submit detailed profiles of their health education programs and their link to coordinated school health. The awards criteria are based on the best practices for the discipline as outlined in National Health Education Standards: Achieving Excellence and Characteristics of Effective Health Education Curricula (U.S. Centers for Disease Control and Prevention, Division of Adolescent and School Health). The AAHE School Health Education Recognition Awards Committee will review all award submissions.

More information about the Blue Apple Health Education Awards can be found by visiting www.blueappleward.org

About the American Association for Health Education (AAHE)

The American Association for Health Education serves health educators and other professionals who promote the health of all people. AAHE encourages, supports, and assists health professionals concerned with health promotion through education and other systematic strategies. For more information on AAHE, visit www.aaheinfo.org or contact Becky Smith, Executive Director, AAHE, 800.213.7193, [email protected].

About HealthTeacher

HealthTeacher is a leading provider of online health education resources for kindergarten through 12th grade used by more than 15,000 teachers nationwide. HealthTeacher provides teachers the resources, tools and background material to educate students about making healthy lifestyle choices through over 300 lesson plans that meet or exceed the National Health Education Standards and the CDC’s Core Health Topics. HealthTeacher is an operating unit of ConnectivHealth, a leading provider of digital content solutions focused advancing health and wellness. For more information regarding HealthTeacher, visit www.healthteacher.com or contact Jennifer Faught, Director of Marketing, HealthTeacher, 615-345-7662, [email protected].

The H. Lee Moffitt Cancer Center & Research Institute Receives CEO Cancer Gold Standard(TM) Accreditation

Today, the H. Lee Moffitt Cancer Center & Research Institute (Moffitt) was accredited with the CEO Cancer Gold Standard(TM) certification, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines. In doing so, Moffitt joins with twenty-one other organizations that have demonstrated exemplary effort to prevent cancer in the workplace and in their leadership in the overall fight against cancer.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with the American Cancer Society, NCI-designated comprehensive cancer centers and leading corporate health professionals.

“The commitment of Moffitt and other NCI-designated cancer centers to patient care and cutting edge cancer research is well documented and the accolades are well deserved,” said Weldon. “This CEO Cancer Gold Standard certification further acknowledges that under the leadership of the Honorable H. Lee Moffitt and CEO, Dr. William C. Dalton, their commitment to the health and well-being of their employees is also unparalleled.”

The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.

The most recent President’s Cancer Panel report, “Promoting Healthy Lifestyles: Policy, Program, and Personal Recommendations for Reducing Cancer Risk,” identified the CEO Cancer Gold Standard(TM) as an initiative that is helping reverse negative, unhealthy lifestyle trends and creating hope in the fight against cancer for America’s workers and their families.

Joining Moffitt in this workplace-based effort to eliminate cancer as a public health threat are: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota and Valeant Pharmaceuticals.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of America’s Best Hospitals for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to “do something bold and venturesome about cancer within your own corporate families.” The CEOs responded with the CEO Cancer Gold Standard encouraging its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please visit www.CancerGoldStandard.org.

(Due to the length of the URL in the following contact information, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the extra space if one exists.)

Aptium Oncology Launches Multi-Institutional GI Consortium to Advance Research and Treatment Protocols

Aptium Oncology, Inc. today announced the launch of Aptium Oncology GI Cancer Consortium (AGICC), consisting of eight member institutions. Each AGICC institution has demonstrated expertise in the multidisciplinary and translational approach to gastrointestinal (GI) malignancies. The goal of the Consortium is to speed the process of finding and efficiently testing active new compounds for patients with gastrointestinal cancers, enabling useful drugs to reach the market more quickly. The Consortium will launch with a kick-off meeting September 28 and 29, 2008 at Christiana Care Healthcare Systems in Newark, Delaware.

“A number of us at Aptium Oncology have long had strong interest in advancing the state of care for GI cancers,” says John S. Macdonald, M.D., Chief Medical Officer. “With colon, stomach and other types of GI cancers affecting millions, there is considerable opportunity for introducing new drugs in GI cancer including targeted agents that are in development but still need to be tested.” Dr. Macdonald adds that Aptium “assembled a think tank of the ‘best and brightest’ physicians from around the country” – all with experience in the biology of GI cancers – to be involved in the Consortium. “And with involvement from eight cancer centers across the country, including world leaders in GI cancer, we can get drugs evaluated and, if active and likely to be helpful to patients, to market more quickly – and with less bureaucracy.”

The new, targeted GI drugs cited by Dr. Macdonald are currently being investigated and are the result of scientists’ increased understanding of the molecular events that take place within a cell to make it cancerous. The ability to potentially target those actual molecular events represents a significant step in cancer care, and is vastly preferable to cytotoxic drugs that kill large numbers of cancer cells, but also kill normal tissue, which can typically lead to severe side effects during treatment.

AGICC is an innovative model that brings investigators together to test drugs as they come along, in contrast to pharmaceutical company-driven studies that typically are created to test a specific drug. “There are about 160,000 new colon cancer patients a year,” says Dr. Macdonald. “In addition, only about fifty percent of all colon cancer patients survive five years. If we look at the patients whose cancer has metastasized, the five-year survival rate is only 10-15 percent. These patients with a very a poor prognosis are the group we want to target, in order to improve their survival rates and quality of life. And if we’re successful, the Consortium can serve as an important model for speeding time to market for drugs targeting other cancers. The Consortium underscores Aptium Oncology’s commitment to innovative research on behalf of all patients with cancer.”

Accordingly, a key goal of the Consortium is to design a new process for clinical trials that is faster, more efficient and less bureaucratic, allowing institutions to more rapidly take new drugs into test protocols, ultimately identifying those that are most effective.

“There currently are a number of compounds for treating GI cancers of the colon, rectum, liver, stomach, pancreas and esophagus,” says Lawrence Leichman, M.D., F.A.C.P., Director of the Consortium. Dr. Leichman, National Program Director of GI Malignancies, Aptium Oncology, and medical oncologist at the Comprehensive Cancer Center at Desert Regional Medical Center in Palm Springs, adds, “However, while our drug choices are more varied and effective, none of the compounds on the market for GI cancers are as effective over the long term as we would like. We have already made great advances in understanding the molecular biology of many GI cancers. The Consortium will help us take advantage of that knowledge and advance the research needed to get the new drugs on the radar screen and get these new treatments on the market – and to our patients – sooner.”

AGICC, funded by Aptium Oncology, a leader in developing hospital-based outpatient cancer centers, builds upon the complementary strengths of a select group of cancer centers chosen for their demonstrated excellence and expertise in the clinical and translational aspects of GI cancers, as well as their track records as clinical research investigators. Each of the eight institutions selected for the Consortium is funded for two years via a support grant to be used in expanding and supplementing their ongoing clinical/translational gastrointestinal cancer programs. Aptium Oncology’s funding of this effort is a clear indication of the company’s clear and longstanding commitment to provide newer and better cancer treatments to the patients that need them.

The ambitious undertaking includes five university cancer center programs and three large private groups, each possessing excellent GI cancer specialists. They include Heinz-Josef Lenz, M.D., Scientific Director, USC/Norris Cancer Genetics Unit, Associate Director, USC/Norris Gastrointestinal Oncology Program, University of Southern California; Jordan D. Berlin, M.D., Clinical Director GI Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University; Wells A. Messersmith, M.D., Associate Professor, University of Colorado Cancer Center; Bert H. O’Neil, M.D., Associate Professor, Clinical Research, University of North Carolina Lineberger Comprehensive Cancer Center; Howard Hochster, M.D., Professor, Department of Medicine, NYU Langone Medical Center; Steven J. Cohen, M.D., Associate Medical Director, Fox Chase Cancer Center Partners; Philip J. Gold, M.D., Swedish Cancer Institute, Seattle, Washington; and Bruce M. Boman, M.D., Ph.D., Director for Cancer Genetics and Stem Cell Biology for Christiana Care’s Helen F. Graham Cancer Center in Newark, Delaware.

In addition to the AGICC investigators, the Advisory Committee for AGICC includes four Aptium corporate team members: Dr. Leichman, Director; Dr. Macdonald; Dr. Gail Leichman., Research Director, Comprehensive Cancer Center at Desert Regional Medical Center; and Marti McKinley, BSN, MBA, Vice President of Clinical Research Programs.

The GI Consortium plans to enroll its first patients in January of 2009. Please contact Dr. Leichman at [email protected] or Marti McKinley at [email protected] for information about the Consortium.

About Aptium Oncology

Aptium Oncology has 25 years of experience managing outpatient oncology services at leading medical institutions throughout the United States. Aptium Oncology is a pioneer in designing, building and managing comprehensive cancer centers, with a steadfast vision to transform cancer care environments by bringing every necessary service to one central place. The intent of this single place is to help patients achieve longer, better lives. Aptium Oncology’s corporate headquarters are located in Los Angeles, Calif. For more information, visit www.aptiumoncology.com.

Affitech Appoints Dr. Keith McCullagh As Chairman

OSLO, Norway, September 9 /PRNewswire/ — Affitech AS, the Norwegian antibody therapeutics company, today announced that it has appointed Dr Keith McCullagh as non-executive Chairman of its Board of Directors. The Company’s previous chairman, Oyvin Broymer, will remain as a member of the Board. Mr Broymer welcomed Dr McCullagh’s appointment and said:

“I am delighted that Keith McCullagh has agreed to take over from me as Affitech’s new chairman. He has an outstanding entrepreneurial track record in the biopharmaceutical industry, most recently at Santaris Pharma in Denmark, where as CE0 he has played a major role in establishing the company as a leader in the RNA medicines field. Affitech’s antibody technology is in a different area of the biopharmaceuticals market, but I am confident that Affitech will benefit from his leadership and guidance. I wish him every success.”

Accepting the appointment, Keith McCullagh commented:

“Affitech has significant potential in the field of human monoclonal antibody therapeutics. Both its cell-based and target antigen screening technology is at the forefront of the industry and I look forward to assisting the Company’s management, board and shareholders to build the resources and competencies required to develop innovative potential new products. I look forward to Affitech achieving several competitive commercial goals in the coming years.”

Affitech intends to focus its future development on building a pipeline of proprietary therapeutic antibody product candidates, through both in-house research and development and alliances with other companies.

Affitech CEO, Dr Martin Welschof, commented:

“I thank Oyvin Broymer, who took over the chairmanship of Affitech in 2002 at a time of major strategic change and has skillfully guided us to our current position. I look forward to working closely with Keith McCullagh, whose experience in building successful biotech companies will be of great value as we enter the next phase of Affitech’s growth and development.”

Affitech also announced that Thomas von Rueden has retired as a director, having completed his term of office.

   Notes to Editors:   About Affitech  

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company’s current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies – (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a “reverse-screening” approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company’s proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Roche, Peregrine, Omeros, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Further information at http://www.affitech.com/.

About Keith McCullagh

Keith McCullagh, PhD, BVSc, MRCVS, is an experienced bioscience entrepreneur, having founded and built three previous companies in the life science industry. Most recently, from October 2003 to June 2008, he was CEO of Santaris Pharma, a Danish biopharmaceutical company. From 2000 to 2003 he was executive chairman of OnMedica Group plc, a European pharmaceutical e-detailing business and since 2000 has been non-executive chairman of Pharmacy 2U Ltd, the UK’s leading mail order warehouse pharmacy. From 1986 to 1998 he was chief executive of British Biotech plc, a company he built into one of Europe’s leading biopharmaceutical businesses. Prior to founding British Biotech, Keith was UK Research Director for G.D.Searle & Co, Inc, an international pharmaceutical business now part of Pfizer.

Keith also helped foster the development of the bioscience industry in Europe through the establishment of the UK BioIndustry Association, where he was inaugural chairman, and the formation of EuropaBio, where he served as a member of the first Board. Keith qualified in veterinary medicine from the University of Bristol and has a PhD in pathology from the University of Cambridge.

   Contacts for Affitech    Affitech (Norway):   Dr. Martin Welschof   Chief Executive Officer   +47-22-95-87-58   [email protected]    Affitech (USA):   Dr. Rathin C. Das President   +1-925-935-9803   [email protected]  

Affitech AS

CONTACT: Contacts for Affitech: Affitech (Norway): Dr. Martin Welschof,Chief Executive Officer, +47-22-95-87-58, [email protected]; Affitech(USA): Dr. Rathin C. Das President, +1-925-935-9803, [email protected];Media Enquiries: Richard Hayhurst, Hayhurst Media, +44-7711-821527,[email protected]

Pharmacodynamics & Toxicological Profile of PartySmart, a Herbal Preparation for Alcohol Hangover in Wistar Rats

By Venkataranganna, M V Gopumadhavan, S; Sundaram, R; Peer, Ghouse; Mitra, S K

Background & objectives: PartySmart is a herbal preparation intended for the management of alcohol hangover and other related toxic effects in clinical situation. The present study was designed to investigate the pharmacodynamics and oral toxicity of PartySmart, a herbal formulation in rats. Methods: Effect of PartySmart on blood acetaldehyde and alcohol levels was evaluated at doses of 125, 250 and 500 mg/kg b.wt. in rats. Acute toxicity study was conducted with PartySmart at a limit test dose of 2000 mg/kg b.wt., p.o. In repeated dose 90 day study, PartySmart was administered at doses of 500 and 1000 mg/kg b.wt. once-a-day, orally throughout the study period.

Results: PartySmart dose-dependently decreased blood ethanol and acetaldehyde levels as compared to control. PartySmart at a dose of 500 mg/kg b.wt. significantly reduced the area under curve (AUC) of ethanol and acetaldehyde levels. It increased the hepatic alcohol dehydrogenase (ADH) at 500 mg/kg b.wt. and aldehyde dehydrogenase (ALDH) activities at doses of 250 and 500 mg/kg b.w. significantly. Acute toxicity study showed no clinical signs and pre-terminal deaths. The LD^sub 50^ of PartySmart was found to be greater than 2000 mg/kg b.wt. No significant differences in PartySmart-treated groups were observed on body weight, food intake, haematological and clinical chemistry, and organ weight ratios as compared to control group in the repeated dose study. Histopathological examination of all target organs showed no evidence of lesions attributing to drug toxicity.

Interpretation & conclusions: PartySmart enhanced acetaldehyde metabolism by increasing ADH and ALDH activity without any side effects. These findings indicate that PartySmart may exert beneficial role in the management of alcohol hangover without any toxicity.

Key words Acetaldehyde – ADH – alcohol – ALDH – PartySmart – toxicity

Alcohol hangover is a common condition that causes substantial impairment to affected individuals1. Hangover is characterized by the constellation of unpleasant physical and mental symptoms that occur after heavy alcohol drinking. Alcohol gets metabolized to an intermediate product, acetaldehyde, by the enzyme alcohol dehydrogenase (ADH), and then acetaldehyde is converted to acetate by a second enzyme aldehyde dehydrogenase (ALDH)2. Acetaldehyde at higher concentrations causes toxic effects, such as rapid pulse, sweating, skin flushing, nausea, and vomiting. In most people, ALDH metabolizes acetaldehyde quickly and efficiently, so that this intermediate metabolite does not accumulate in high concentrations. Accumulation of acetaldehyde leads to the development of physical symptoms of hangover, which include fatigue, headache, increased sensitivity to light and sound, redness of the eyes, muscle aches, and thirst3.

Many treatments are described to prevent hangover, shorten its duration, and reduce the severity of its symptoms, including innumerable folk remedies and recommendations. PartySmart is one such herbal preparation known to have beneficial effect in preventing alcohol-induced hangover. Previous studies have demonstrated that treatment with PartySmart before alcohol ingestion was associated with rapid elimination of alcohol and acetaldehyde4- 6. PartySmart is a polyherbal formulation containing extracts of Phoenix dactylifera, Cichorium intybus, Andrographis paniculata, Vitis vinifera, Phyllanthus amarus and Emblica officinalis.

These plants have been known to contain a wide array of antioxidants and studies have shown dosedependent inhibition of superoxide and hydroxyl radicals, Fe^sup 2+^/ascorbate system- induced lipid peroxidation and protein oxidation7-11. Earlier investigations with these plants have shown that they are effective in ameliorating ethanol-induced gastric ulceration and elevation of histamine and gastrin concentrations12-15. Many of the individual ingredients of the formulation were earlier investigated for their protective effect against different models of experimental hepatotoxicity16. All these constituents have protective effect against diverse hepatotoxic agents such as ethanol, CCl^sub 4^, antitubercular agents, thioacetamide, etc.l2,17,20.Oligomeric proanthocyanidins, active principles of Vitis vinifera, have been known to regulate ethanol metabolism and prevent toxic effects21. We therefore undertook this study to evaluate pharmacodynamics and toxicological profile of oral administration of PartySmart in rats.

Material & Methods

Animals: Laboratory bred Wistar rats of either sex were used for the experiments. The animals were housed and acclimatized to a constant temperature of 22 +- 3[degrees]C with relative humidity 50- 70 per cent, and were exposed to 12 h day and night cycle. Pelleted rat feed (M/s. Amrut Feed, Pranav Agro Industries Ltd., Sangli, India) and water (passed through activated charcoal filter and exposed to ultra violet rays in Aquaguard on line water filter cum purifier manufactured by Eureka Forbes Ltd., Mumbai, India) was provided ad libitum. The study protocol was approved by the Institutional Animal Ethics Committee (IAEC) and the animals used for this study were maintained in accordance with the guidelines recommended by the Committee for the Purpose of Control and Supervision of Experiments in Animals (CPCSEA), Ministry of Environment and Forest (Animal Welfare Division), Government of India.

Chemicals: All chemicals of analytical grade manufactured by Rankem Laboratories, Delhi were used for the study.

Preparation of PartySmart: PartySmart contains dried aqueous extracts of Phoenix dactylifera (fruit : 188 mg), Cichorium intybus (seeds : 188 mg), Andrographis paniculata (aerial part : 188 mg), Vitis vinifera (fruit : 188 mg), Phyllanthus amarus (aerial part : 124 mg), and Emblica officinalis (fruit : 124 mg). The constituents of plant material were procured from M/s. Abhirami Botanical Corporation, Tuticorin, Tamil Nadu, India and identified by Dr R. Kannan, Botanist, R&D Centre, The Himalaya Drug Company, Bangalore and voucher specimens were preserved at the R&D Centre. Such two or more batches of preparations from raw materials of different origin were standardized by fingerprint analysis for characterization using high performance thin layer chromatography (HPTLC).

One gram of PartySmart was extracted by refluxing on a water bath with 15 ml of dichloromethane. Extract was filtered and concentrated to 2 ml; 10 [mu]l of concentrate was spotted on pre-coated silica gel plate. Plate was developed using dichloromethane : methanol (97:3). Developed plate was scanned using densitometer at 254 nm. HPTLC fingerprint of PartySmart is shown in the Figure.

Blood alcohol and acetaldehyde levels: Thirty two male rats weighing between 250-275 g were divided into 4 groups of 8 each. Rats of group 1 received 10 ml/kg b.wt. of vehicle (water) and served as control. Rats of groups 2, 3 and 4 received PartySmart treatment at doses of 125, 250 and 500 mg/kg body weight (b.wt.), p.o., respectively as an aqueous suspension. One hour after respective treatments, all the animals received alcohol at a dose of 5 ml/kg b.wt. The blood samples were collected from the retroorbital plexus at 1/2, 1, 2 and 4 h of post alcohol administration, into heparinized tubes and immediately stored at 28[degrees]C for further analysis.

Estimation of alcohol and acetaldehyde levels: About 0.5 ml of whole blood was added to 1 ml of 0.01 per cent isopropyl alcohol (in 10% perchloric acid) in a head space glass vial and mixed well. The vial was then placed in the headspace analyzer22,23.

Shimadzu gas Chromatograph model GC 14B (Japan) was used for the estimation of blood alcohol and acetaldehyde levels. The Porapak Q, 2 meters x 1/ 8 inch column was used with nitrogen as carrier gas at a flow rate of 30 ml per minute. Temperature conditions of oven, injector and detector were 160, 220 and 250[degrees]C respectively. Headspace analyzer (HSA-1 Mayura Analytical Pvt. Ltd., Bangalore, India) temperature was 90[degrees]C with equilibration time of 30 min and 10 min of run time. About 1 ml of vapour was injected through the headspace analyzer automatically to the column and the chromatogram was recorded using data station (Class-GCIO).

Hepatic alcohol dehydrogenase and acetaldehyde dehydrogenase enzyme activities: Twenty four male rats weighing between 250-275 g were divided into 3 groups of 8 each. Rats of group 1 received 10 ml/ kg b.wt. of vehicle (water) and served as control. Rats of groups 2 and 3 received PartySmart at doses of 250 and 500 mg/ kg b.wt., p.o., respectively as an aqueous suspension. One hour after respective treatments, all the animals were sacrificed using anesthetic ether and liver was excised and used for the estimation of ADH and ALDH.

Liver homogenates (10% concentration) was prepared in phosphate buffer (0.1 M) and mitochondrial and cytosol fractions were prepared by centrifugation (Remi Instruments, Mumbai) at 2000 and 10000 g respectively24.

Alcohol dehydrogenase activity was assayed using the method of Keung24. Aldehyde dehydrogenase activity was estimated using the method of Lindahl and Evces25. The specific activity was expressed as mU/mg protein. Protein was measured by the method of Lo wry et al26.

Acute toxicity: The laboratory bred rats of Wistar strain weighing between 170-200 g and approximately 1.52.0 months old were used in this study. They were allowed to get acclimatized to standard laboratory diet and constant room temperature of 22 +- 3[degrees]C. Following overnight fasting, animals were weighed and PartySmart was administered in a single dose by gavage using a gastric intubation tube. PartySmart powder was administered as an oral aqueous suspension in the dose of 2000 mg/kg b.wt.27 Limit test at a dose of 2000 mg/kg, b.wt. was carried out with 6 female rats (3 animals per step). The treatment was initiated with the first set of female rats at the dose of 2000 mg/kg b.wt. There were no toxic signs and pre-terminal death. Depending on the fixed time interval (after 24 h) outcome, the 3 additional animals were treated with test substance at a dose of 2000 mg/kg b.wt. On day 15, all the animals were subjected for gross necropsy and pathological observations, if any.

Repeated dose 90 day oral toxicity28: Inbred male and female rats of Wistar strain weighing between 180-210 g and approximately 8 wk old were used in this study and were allowed to get acclimatized to the standard laboratory conditions for a period of one week prior to the commencement of the study. The animals were maintained in an air- conditioned room at a temperature of 22 +- 3[degrees]C and 50-70 per cent relative humidity with 12 h light and dark cycles. The rats were fed commercial pellet diet and had free access to water.

Sixty rats were divided into 3 groups of 20 rats each in a randomized manner with equal number of males and females in each group. Group 1 received 10 ml/kg b.wt. of vehicle (water, p.o.) and served as control. Groups 2 and 3 received PartySmart treatment at doses of 500 and 1000 mg/kg b.wt., p.o., respectively for 90 days. The drug was administered in the form of an aqueous suspension.

All experimental animals were observed every day for general signs and symptoms of toxicity. Body weight and food intake of all the animals were recorded prior to the commencement of the study and once every week thereafter throughout the study period. The blood samples were collected from the retro-orbital plexus before autopsy for the evaluation of haematological parameters [Hb, packed cell volume (PCV), RBC count, WBC count, and differential leucocyte count]. Serum was subjected for the estimation of clinical chemistry parameters [hepatic function test: aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total protein and albumin; renal function test: blood urea nitrogen and creatinine; lipid profile: cholesterol and triglycerides, and other parameters: fasting blood sugar and chloride] using auto analyzer kits (Diagnostic System, GmbH, Germany).

On day 91, all the animals were sacrificed after an overnight fast using anesthetic ether. Target organs such as liver, kidneys, adrenals, spleen, heart, brain, pituitary, testes/ovaries, and uterus were collected and weighed. Other organs such as stomach, thymus, lymph nodes, oesophagus, epididymis, prostate, thyroid, parathyroid, femur, and skin were also collected. All the organs were fixed in 10 per cent neutral buffered formalin. Tissues were processed, sectioned and stained with haematoxylin and eosin (H&E) for routine histopathological examination.

Statistical analysis: The values expressed as mean +- SEM and were analyzed statistically using Oneway ANOVA followed by Dunnet’s Multiple Comparison test using GraphPad Prism software package (Version 4.01, GraphPad Software, Inc. USA) to find out the level of significance. P

Results

Kinetic profile of alcohol and acetaldehyde: Pretreatment with PartySmart reduced blood alcohol levels in a dose-dependent fashion at different time points as compared to control. Although a trend in decreased levels of blood alcohol concentration was observed at different time intervals, it was found to be insignificant. But the area under curve (AUC) at higher doses showed a significant decrease as compared to control. The total AUC of alcohol was 175.09 +- 3.06 in the control group and 168.16 +- 7.19, 160.51 +- 5.21 and 150.26 +- 8.67 in the PartySmart treated groups at doses of 125, 250 and 500 mg/kg b.wt. respectively. AUC of alcohol was reduced significantly (P

PartySmart treatment resulted in dose-dependent decrease in blood acetaldehyde levels but significant reduction was seen at 500 mg/kg dose. PartySmart treatment at doses of 250 and 500 mg/kg b.wt., significantly reduced the AUC of acetaldehyde levels (183.04 +- 6.47 and 174.74 +- 8.86) as compared to control (203.95 +- 4.43) (Table I).

Hepatic ADH and ALDH activity: Total hepatic ADH activity was significantly increased only at a dose of 500 mg/kg b.wt. as compared to control and no significant differences were observed between the control and PartySmart treatment (250 mg/kg b.wt.) though an increasing trend was observed in the enzyme activity. The hepatic ALDH activity was increased significantly after administration of PartySmart at the dose levels 250 and 500 mg/kg b.wt. as compared to control (Table I).

Acute toxicity: No mortality was observed following PartySmart treatment at a limit test dose of 2000 mg/kg b.wt. There were no toxic signs and pre-terminal deaths. No gross pathological findings were observed in any of the rats. There were no observable gross abnormalities that could be attributed to drug toxicity at the time of autopsy. The limit test was completed after testing in a total of 6 animals at a dose of 2000 mg/kg b.wt. The LD50 was found to be greater than 2000 mg/kg b.wt. by oral route.

Repeated dose 90-day oral toxicity: No clinical signs and pre- terminal deaths were observed. Body weights of male and female rats in the PartySmart-treated groups were comparable with the control group. No change in food intake was observed. Haematological and biochemical parameters were within normal range in all the drug- treated groups (Tables II and III). No gross abnormalities attributing to the drug toxicity was noticed in any of the treated groups. There was no significant difference in the organ weight profile of the animals in the treated groups as compared to control (Table IV). Histopathological examination of all target organs showed no evidence of lesions attributing to drug toxicity. Based on the results of the repeated dose 90day oral toxicity, the no observed adverse effect level (NOAEL) of PartySmart was 1000 mg/kg b.wt.

Discussion

The symptoms of alcohol-induced hangover have been attributed to several reasons. The primary attributing factors include direct physiological effects of alcohol and the physiological effects of compounds produced as a result of alcohol metabolism. It is well established that accumulation of acetaldehyde, the intermediate metabolite of alcohol metabolism play a pivotal role in the development of hangover. In the present study, we showed that PartySmart significantly reduced the blood ethanol and acetaldehyde levels as compared to controls. The observed effect was more prominent with respect to acetaldehyde elimination rather than alcohol elimination rates.

This effect might be due to the increased metabolism of alcohol by ADH enzyme, which is present in highest concentration in the liver. Alcohol, which does not undergo hepatic metabolism, enters the systemic circulation and the “blood alcohol cycle”.

Aldehyde dehydrogenase, an enzyme responsible for the metabolism of acetaldehyde is NAD^sup +^ dependent enzyme and thought to represent main pathway of acetaldehyde oxidation in the liver24,29. In our study, we have used acetaldehyde as a substrate for estimation of NAD^sup +^ dependent ALDH in liver mitochondria and cytosol. It is known that rat liver contains other enzyme systems, which are also capable of oxidizing acetaldehyde and are responsible for the acetaldehyde oxidation in the liver mitochondria due to their low affinity for the substrate. Studies with PartySmart revealed a significant, dose-dependent increase in the hepatic ADH and ALDH activities. Increased clearance of blood ethanol and acetaldehyde by PartySmart could be due to increased metabolism through enhanced ADH and ALDH activities. These observations clearly indicated that PartySmart hastened the metabolism of ethanol and acetaldehyde, thereby alleviating the toxic effects following alcohol ingestion.

Acute oral toxicity with PartySmart revealed that the LD^sub 50^ was greater than 2000 mg/kg b.wt. Repeated dose 90-day oral toxicity with PartySmart revealed no adverse effect on the parameters evaluated, thereby indicating that PartySmart is devoid of adverse effects with the doses employed.

In conclusion, PartySmart enhanced the ethanol and acetaldehyde metabolism by increasing the levels of hepatic ADH and ALDH in alcohol-intoxicated animals. It is also found to be safe and devoid of adverse effects as revealed by toxicity studies. These findings will be beneficial for the future studies on the management of alcohol hangover.

Conflict of interest

Authors hereby declare that there is no conflict of interest.

References

1. Marks V. Clinical pathology of alcohol. J Clin Pathol 1983; 36 : 365-78.

2. Wiese J, McPherson S, Odden MC, Shlipak MG. Effect of Opuntia ficus indica on symptoms of the alcohol hangover. Arch Intern Med 2004; 164 : 1334-40.

3. Swift R, Davidson D. Alcohol hangover: mechanisms and mediators. Alcohol Health Res World 1998; 22 : 54-60.

4. Wiese JG, Shlipak MG, Browner WS. The alcohol hangover. Ann Intern Med 2000; 132 : 897-902.

5. Prabhakar B, Venkataramanappa PV. A study of PartySharp in prevention of hangover and in elimination of acetaldehyde. Antiseptic 2001; 98 : 206-9.

6. Prabhakar B, Kolhapure SA. Evaluation of efficacy and safety of “PartySmart” in preventing alcohol-induced hangover. Med Update 2004; 11 : 55-60.

7. Trivedi NP, Rawal UM. Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice. Indian J Exp Biol 2001; 39 : 41-6. 8. Papetti A, Daglia M, Gazzani G. Anti- and pro-oxidant activity of water soluble compounds in Cichorium intybus var. silvestre (Treviso red chicory). J Pharm Biomed Anal 2002; 30 : 939-45.

9. Kamdem RE, Sang S, Ho CT. Mechanism of the superoxide scavenging activity of neoandrographolide – a natural product from Andrographis paniculata Nees. J Agri Food Chem 2002; 50 : 4662-5.

10. Lu Y, Zhao WZ, Chang Z, Chen WX, Li L. Procyanidins from grape seeds protect against phorbol ester-induced oxidative cellular and genotoxic damage. Acta Pharmacol Sin 2004; 25 : 1083-9.

11. Hong YJ, Tomas-Barberan FA, Kader AA, Mitchell AE. The flavonoid glycosides and procyanidin composition of Deglet Noor Dates (Phoenix dactylifera). J Agri Food Chem 2006; 54 : 2405-11.

12 . Pramy othin P, Samosorn P, Poungshompoo S , Chaichantipyuth C. The protective effects of Phyllanthus emblica Linn, extract on ethanol-induced rat hepatic injury. J Ethnopharmacol 2006; 707 : 361- 4.

13 . Al-Rehaily AJ, Al-Howiriny TA, Al-Sohaibani MO, RafatuUah S. Gastroprotective effects of ‘Amla’ Emblica officinalis on in vivo test models in rats. Phytomedicine 2002; 9 : 515-22.

14. Raphael KR, Kuttan R. Inhibition of experimental gastric lesion and inflammation by Phyllanthus amarus extract. J Ethnopharmacol 2003; 87 : 193-7.

15. Al-Qarawi AA, Abdel-Rahman H, Ali BH, Mousa HM, ElMougy SA. The ameliorative effect of dates (Phoenix dactylifera L.) on ethanol- induced gastric ulcer in rats. J Ethnopharmacol 2005; 98 : 313-7.

16. Sultana S, Ahmed S, Sharma S, Jahangir T Emblica officinalis reverses thioacetamide-induced oxidative stress and early promotional events of primary hepatocarcinogenesis. J Pharm Pharmacol 2004; 56 : 1573-9.

17. Visen PK, Shukla B, Patnaik GK, Dhawan BN. Andrographolide protects rat hepatocytes against paracetamol-induced damage. J Ethnopharmacol 1993; 40 : 131-6.

18. Sultana S, Ahmad S, Khan N, Jahangir T. Effect of Emblica officinalis (Gaertn) on CCl^sub 4^-induced hepatic toxicity and DNA synthesis in Wistar rats. Indian J Exp Biol 2005; 43 : 430-6.

19. Tasduq SA, Kaisar P, Gupta DK, Kapahi BK, Maheshwari HS, Jyotsna S, et al. Protective effect of a 50 per cent hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity. Phytother Res 2005; 19 : 193-7.

20. Ahmed B, Al-Howiriny TA, Siddiqui AB. Antihepatotoxic activity of seeds of Cichorium intybus. J Ethnopharmacol 2003; 87 : 337-40.

21 . Kushnerova NF, Sprygin VG, Rakhmanin, IuA. Regulation of the metabolism of ethyl alcohol in the body with oligomeric proanthocyanidins as a preventive measure against its toxic effect. Gig Sanit 2003; 5 : 58-61.

22. Mendenhall CL, McGeen J, Green ES. Simple, rapid and sensitive method for the simultaneous quantitation of ethanol and acetaldehyde in biological materials using head space gas chromatography. J Chromatogr 1983; 790 : 725-36.

23. Steenaart NA, Clarke DW, Brien JF. Gas-liquid chromatographic analysis of ethanol and acetaldehyde in blood with minimal artifactual acetaldehyde formation. J Pharmacol Methods 1985; 14 : 199-212.

24. Keung WM. Biochemical studies of a new class of alcohol dehydrogenase inhibitors from Radix puerariae. Alcohol Clin Exp Res 1993; 17 : 1254-60.

25. Lindahl R, Evces S. Comparative subcellular distribution of aldehyde dehydrogenase in rat, mouse and rabbit liver. Biochem Pharmacol 1984; 33 : 3383-9.

26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement by folin phenol reagent. J Biol Chem 1951 ; 193 : 265- 72.

27 . OECD guidelines for testing of chemicals, ‘Acute oral toxicityacute toxic class method, Guideline No. 423, 2001, OECD Publications Service, France, 2001. p. 1-14.

28. OECD guidelines for testing of chemicals, ‘Repeated dose 90day oral toxicity study in rodents’, Guideline No. 408, OECD Publications Service, France, 1998. p. 1-10.

29. Hasumura Y, Teschke R, Lieber CS. Characteristics of acetaldehyde oxidation in rat liver mitochondria. J Biol Chem 1976; 257 : 4908-13.

M.V Venkataranganna, S. Gopumadhavan, R. Sundaram, Ghouse Peer & S. K. Mitra

R&D Center, The Himalaya Drug Company, Bangalore, India

Received March 6, 2007

Reprint requests: Dr S. K. Mitra, Executive Director, R&D Center, The Himalaya Drug Company

Makali, Bangalore 562 123, India

e-mail: [email protected]

Copyright Indian Council of Medical Research May 2008

(c) 2008 Indian Journal of Medical Research. Provided by ProQuest LLC. All rights Reserved.

From Teaching to Learning

By Saulnier, Bruce M Landry, Jeffrey P; Longenecker, Herbert E Jr; Wagner, Teresa A

ABSTRACT This paper makes the case for movement from a teacher- centered educational paradigm to a learner-centered paradigm by employing a template-based approach consistent with the intent of the Capability Maturity Model Integration (CMMI) (2002, 2004) attempt to bring quality standards to the systems and software development industry. The paradigm shift from the Teaching Paradigm to the Learning Paradigm is discussed and comparisons of the essential features of the two paradigms are explained. The effect of the paradigm shift on the task of assessment is posited and Weimer’s guidelines for developing learner-centered assessments are enumerated and discussed. A twelve-step template-based approach to developing learner-centered teaching and assessment strategies is then proposed and discussed (Wagner et al., 2008). It is concluded that this approach to the construction of educational activities provides for greater student learning and a more authentic student assessment. It is also concluded that the approach is important for education of IS students (Landry et al., 2008).

Keywords: Learner-Centered Teaching and Learning, Educational Paradigm, Capability Maturity Model Integration, Learner-Centered Assessment.

1. FROM TEACHING TO LEARNTNG

Over the last two decades a paradigm shift has been taking place in American higher education.

The traditional, still dominant paradigm is the Instruction/ Teaching Paradigm. In this paradigm a college is viewed as an institution that exists to provide instruction. Under it, colleges have created structures to provide for the activity of teaching, an activity conceived primarily as delivering 50-minute to 75-minue lectures; i.e., the mission of a college is to deliver instruction.

As a discipline some now recognize that our dominant paradigm mistakes a means for an end. It takes the means or method – called `instruction’ or “teaching” – and makes it the college’s end or purpose. To say that the purpose of colleges is to provide instruction is like saying that the business of Chevrolet is to operate assembly lines. Some now see that the mission of our higher education system is not instruction but rather that of producing learning with every student by whatever means work best. This paradigm is usually referred to as the Learning Paradigm.

2. COMPARISON OF TEACHER-CENTERED AND LEARNER-CENTERED PARADIGMS

When comparing alternative paradigms, we must take great care in making the comparison. A paradigm is like the rules of a game: one of the functions of the rules is to define the playing field and the domain of possibilities on that field. But a new paradigm may specify a game played on a larger or smaller field with a larger or smaller domain of legitimate possibilities. Indeed, the Learning Paradigm expands the playing field and the domain of possibilities, and it radically changes various aspects of the game.

In the Instruction Paradigm, a specific delivery methodology, the lecture, determines the boundary of what colleges can do, whereas in the Learning Paradigm, student learning and success set the boundary. Not all elements of the new paradigm are contrary to corresponding elements of the old; the new includes many elements of the old within its larger domain of possibilities. For example, the Learning Paradigm does not prohibit lecturing. Rather, lecturing becomes one of many possible instructional alternatives, all of which are evaluated on the basis of their ability to promote appropriate learning.

In the Instruction Paradigm, the mission of the college is to provide instruction, to teach. The method and the product are one and the same. The means is the end. In the Learning Paradigm, the mission of the college is to produce learning. The method and the product are separate. The end governs the means.

In the Learning Paradigm a college’s purpose is not to transfer knowledge but to create environments and experiences that bring students to discover and construct knowledge for themselves, to make students members of communities of learners that make discoveries and solve problems. The college aims, in fact, to create a series of ever more powerful learning environments. The Learning Paradigm does not limit institutions to a single means for empowering students to learn; within its framework, effective learning technologies are continually identified, developed, tested, implemented, and assessed against one another. The aim in the Learning Paradigm is not so much to improve the quality of instruction – although that is not irrelevant – as it is to improve continuously the quality of learning for students both individually and in the aggregate.

The Learning Paradigm shifts what the institution takes responsibility for: from quality instruction (lecturing, talking) to student learning. Students, the co-producers of learning, can and must take responsibility for their own learning. Hence, responsibility is a win-win game wherein two agents take responsibility for the same outcome even though neither is in complete control of all the variables. When two agents take such responsibility, the resulting synergy often produces powerful results.

By shifting the intended institutional outcome from teaching to learning, the Learning Paradigm makes possible a continuous improvement in productivity. Whereas under the Instruction Paradigm a primary institutional purpose was to optimize faculty well-being and success – including recognition for research and scholarship – in the Learning Paradigm a primary drive is to produce learning outcomes more efficiently. The philosophy of an Instruction Paradigm college reflects the belief that it cannot increase learning outputs without more resources, but a Learning Paradigm college expects to do so continuously. A Learning Paradigm college is concerned with learning productivity, not teaching productivity.

In the Instruction Paradigm knowledge, by definition, consists of chunks of information dispensed or delivered by an instructor. The chief agent in the process is the teacher who delivers knowledge; students are viewed as passive vessels, ingesting knowledge for recall on tests. Hence, any expert can teach. Partly because the teacher knows which chunks of knowledge are most important, the teacher controls the learning activities. Learning is presumed to be cumulative because it amounts to ingesting more and more chunks. A degree is awarded when a student has received a specified amount of instruction.

The Learning Paradigm frames learning holistically, recognizing that the chief agent in the process is the learner. Thus, students must be active discoverers and constructors of their own knowledge. In the Learning Paradigm, knowledge consists of frameworks or wholes that are created or constructed by the learner. Knowledge is not seen as cumulative and linear but as a nesting and interacting of frameworks, each building on its predecessor. Learning is revealed when those frameworks are used to understand and act. Seeing the whole of something – the forest rather than the trees – gives meaning to its elements, and that whole becomes more than a sum of component parts. Wholes and frameworks can come in a moment – a flash of insight – often after much hard work with the pieces, as when one suddenly knows how to ride a bicycle.

In the Learning Paradigm, learning environments and activities are learner-centered and learner-controlled. They may even be “teacher-less.” While teachers will have designed the learning experiences and environments students use – often through teamwork with each other and other staff – they need not necessarily be present for or participate in every structured learning activity.

In the Instruction Paradigm, faculties are conceived primarily as disciplinary experts who impart knowledge by lecturing. They are the essential feature of the “instructional delivery system.” The Learning Paradigm, on the other hand, conceives of faculty as primarily the designers of learning environments; they study and apply best methods for producing learning and student success.

If the Instruction Paradigm faculty member is an actor a sage on a stage – then the Learning Paradigm faculty member is more like a facilitator; that is, more like coach interacting with a team. If the model in the Instruction Paradigm is that of delivering a lecture, then the model in the Learning Paradigm is that of designing and then playing a team game. A coach not only instructs football players, for example, but also designs football practices and the game plan; he participates in the game itself by sending in plays and making other decisions. The new faculty role goes a step further, however, in that faculty not only design game plans but also create new and better “games,” ones that generate more and better learning.

3. HOW THE SHIFT TO A LEARNER-CENTERED PARADIGM AFFECTS ASSESSMENT

The Learning Paradigm necessarily incorporates the perspectives of the assessment movement. While this movement has been under way for at least two decades, under the dominant Instruction Paradigm it has not penetrated very deeply into normal organizational practice, although more and more colleges across the country are now feeling pressured by accrediting agencies to systematically assess student learning outcomes. The reason for this prior lack of outcomes knowledge is profoundly simple: under the Instruction Paradigm, student outcomes are simply irrelevant to the successful functioning and funding of a college. Our faculty evaluation systems, for example, evaluate the performance of faculty in teaching terms, not learning terms. An instructor is typically evaluated by his peers or dean on the basis of whether his lectures are organized, whether he covers the appropriate material, whether he shows interest in and understanding of his subject matter, whether he is prepared for class, and whether he respects her/his students’ questions and comments. All these factors evaluate the instructor’s performance in teaching terms. They do not raise the issue of whether students are learning, let alone demand evidence of learning or provide for its reward. In the Instruction Paradigm, teaching is judged on its own terms; in the Learning Paradigm, the power of an environment or approach is judged in terms of its impact on learning. If learning occurs, then the environment has power. If students learn more in environment A than in environment B, then A is more powerful than B. To know this in the Learning Paradigm we would assess student learning routinely and constantly.

The following list serves to summarize the major differences between the Teaching Paradigm and the Learning Paradigm:

* In the Teaching Paradigm, the professor’s role is to be primary information giver and primary evaluator, whereas in the Learning Paradigm the professor’s role it to coach and facilitate. Professor and students evaluate learning together;

* In the Instruction Paradigm, teaching and assessing are separate but related activities, whereas in the Learning Paradigm teaching and assessing are intertwined through formative and summative assessments;

* In the Instruction Paradigm assessment is used to monitor learning, whereas in the Learning Paradigm assessment is used to promote learning and diagnose learning mistakes;

* In the Instruction Paradigm emphasis is on right answers, whereas in the Learning Paradigm emphasis is on generating better questions and learning from mistakes;

* In the Instruction Paradigm desired learning is only assessed directly through the use of objectively scored tests, where in the Learning Paradigm the desired learning is assessed directly/ authentically through papers, projects, performances, portfolios, and the like depending on the fit between the activity (test, paper, performance) and the outcome;

* In the Instruction Paradigm the student culture is competitive and individualistic, whereas in the Learning Paradigm the student culture is cooperative, collaborative, and supportive.

4. GUIDELINES FOR DEVELOPING ASSESSMENT TASKS THAT PROMOTE LEARNING

In developing activities to promote student learning we should be governed by the design principle that the student successfully completing the task will, in the process of completing it, demonstrate their success in learning the task. Maryellen Weimer (2000) has identified key elements that we should consider when designing student learning tasks.

4.1 Focus Students on the Learning Process

Ensure that students know and describe the desired outcome of the learning process. Discuss how the learning process is designed to assist the students to achieve the desired outcome by being mindful of being certain to avoid passive processes known to be relatively ineffective. Discuss how learning activities lead to the desired outcome. Make students mindful of what they are doing, question why they are doing it, and expose them to alternatives (potentially more effective approaches). Challenge them to explore their approaches and presenting alternatives at times when you have their attention.

4.2 Reduce the Stress/Anxiety of Learning Experiences

Experiences that prepare students for what is to come help them manage stress. With exam reviews use authentic, bonafide test questions, not ones that would never appear on an exam. Building student confidence in their ability helps to make the assessment itself more authentic. The goal here is to provide for optimal student learning, not categorizing students according to their results on the assessment. With papers, it means access to samples that illustrate appropriate topics and levels of treatment. Anxiety falls when the stakes are lower. Does it matter how long or how many tries it takes if students ultimately learn the content? Sometimes, perhaps, it does, but not always. The goal is to reduce and better manage the kinds of stress that inhibits and prevents learning. Opportunities to redo or try again are effective tools in the pedagogical repertoire of the learner-centered teacher.

4.3 Do Not Use Evaluation to Accomplish Hidden Agendas

Avoid using evaluation to demonstrate the rigor and complexity of the content. This de-motivates students and encourages them to see success in terms of ability, not effort. Rigor and standards belong in courses. They challenge students and result in more learning, but there is a point of diminishing returns. Evaluation events can be used to measure application and critical thinking skills, but they promote these skills more effectively if students have the opportunity to work on them in class or on homework first.

4.4 Incorporate More Formative Feedback Mechanisms

Grades are summative feedback, highly judgmental, and comprehensive in their conclusions. And they often get in the way of learning. It is usually best to separate the two. Feedback should be directed toward the performance and should use language that describes more than it evaluates.

4.5 Provide Learning Approaches and Assessments that Meets the Criteria of Exemplary Assessment Tasks

Huba and Freed (2000) provide criteria of an exemplary assessment task. At the conclusion of each learning session (class or activity) it is advisable to consider how the session was conducted with respect to their criteria. According to Huba and Freed, exemplary learning tasks are considered to be:

* Valid – yields useful information to guide learning;

* Coherent – is structured so that activities lead to desired performance or product;

* Authentic – addresses ill-defined problems/issues that are either enduring or emerging;

* Rigorous – requires use of declarative, procedural, and meta- cognitive knowledge;

* Engaging – provokes student interest and persistence;

* Challenging – provokes, as well as evaluates, student learning;

* Respectful – allows students to reveal their uniqueness as learners;

* Responsive – provides feedback to students leading to performance improvement;

* Retention – leads to a high percentage of cognitive retention for most students;

* Reasonable – efficient use of class and homework, as well as instructor time commitments; and

* Resources – adequate resources are planned and provided in a timely manner.

5. USING ASSESSMENT TO MAKE OUR CLASSROOMS MORE LEARNER-CENTERED

Wagner et al. (2008) presents a demonstration of a template approach for development of documents that incorporate the principles discussed above for the development of LearnerCentered achievement of outcomes. The specific example presented shows a very successful approach we use involving building teams, which we then use as a teaching method to enhance significantly the quality of learning outcomes. This approach represents a profound break with previous methods and is essential in for achieving success for programs of information systems. Landry (2008) reviews the importance for IS faculty to embrace this new approach.

A template approach was chosen consistent with the intent of the Capability Maturity Model Integration (CMMI) (2002, 2004) attempt to bring quality standards to the systems and software development industry. The template presents a very explicit manner for implementing templates for other learning outcomes and for assessing their performance with an eye towards improvement based on measurement. In principle, this describes a CMMI level 5 reusable approach. Each step of the template consists of instruction for completing the step as well as an example of what the template user might create as a final document. When the new template is completed, the instructions may be retained or deleted. The two assessment instruments presented in Wagner et al. (2008) provide mechanisms to gain student feedback on the educational approach in a manner consistent with the above specified concepts. An additional assessment structure is provided for the instructor to pre- and post- assess the template, and to develop recommendations for maintenance. This loop closing behavior is characteristic of CMMI level 5, and allows for continuous improvement to take place. Landry et al. (2008) suggests that the improvement process can be facilitated through a community of practice type involvement, as does Longenecker (2007).

The recommended template consists of 12 steps as follows:

* Context of the Method (including goal definition);

* Mapping the Goals of the Method to National Models;

* Interaction with Other Learning Outcomes;

* Rationale for this Learning Outcome;

* Strategy for Achieving this Learning Outcome;

* Assessment Concepts/Methods;

* Exam Objectives for this Learning Outcome;

* Supporting Materials Required for the Method;

* Pilot Study Observations;

* References;

* Planning Summary for Deployment of the Method; and

* Performance Review.

6. CONCLUSIONS

What are colleges and universities for? Like many such questions, this one is often ignored even though it is so very important. And it is most likely to be ignored by those of us who work in colleges and universities. We are in the schema of teaching… we do it how it has always been done. The places where we work are so familiar to us, the schedules and rules so constant, the routines so natural that we can easily assume that they have always been done that way. We can so easily focus on delivering what we consider to be a sound curriculum that we ignore whether or not our students are learning. Indeed, we can become a bit myopic about our environment simply because we have been there for so long. We cease to notice what our environment implies about the purposes and goals of our institutions, and how these features affect the lives our both us and our students. Indeed, the things we see everyday are the things that we see not at all. The fact that we do not notice the structures of our organizations does not mean that we like them. In fact, most colleges are beset by an underlying dissatisfaction, a sense that things are not quite right. But why are things not quite right? And what is the cause of the problems? The real root of our most persistent problems may be the invisible enemy, the one we don’t see because we see it every day: the teaching-centered organizational paradigm governing our institutions.

Too many of us spend too much time focusing on what we teach and not enough time on how we teach. In fact, teaching is not the real issue here – the real issue is student learning. The template we propose herein moves the teaching, learning and assessment cycle from the traditional teacher-centered paradigm to a more learner- centered focus. The example we present, while focusing on the concept of building successful work teams, is easily transferable to any number of student learning objectives.

Authentic assessment is any type of assessment that requires students to demonstrate skills and competencies that realistically represent problems and situations likely to be encountered in their daily work life. Employing our proposed template moves the assessment of our students to a much more authentic mode. Our students are now required to produce ideas, to integrate knowledge, and to complete tasks that have real-world applications. Moreover, our students are required to analyze their own growth relative to the rubrics they generate as part of the reflective process.

So, what are our colleges and universities for? In fact, we have many stakeholders. These include our students, alumni, faculty, and the industries which employ our students. By moving from a teaching- centered to a learner-centered educational paradigm we have positively addressed the concerns of all of our stakeholders, and in doing so produced graduates of our programs much better prepared to fulfill the workplace requirements of the 21st century. As IS faculty we must embrace and support this profound change for the improvement of our students and for the improvement of our or any profession.

7. REFERENCES

Angelo, T. & Cross, P. (1993), Classroom Assessment Techniques: A Handbook for College Teachers. San Francisco: Jossey-Bass.

Astin, A. (1993), Assessment for Excellence. Phoenix, AZ: Oryx Press.

Bain, K (2004), What the Best College Teachers Do. Cambridge, MA: Harvard University Press.

Barr, RB. & Tagg, J. (1995), “From Teaching to Learning: A New Paradigm for Undergraduate Education.” Change, 27, 12-15.

Braskamp, L.A., Trautyetter, L.C. & Ward, K. Putting Students First, Bolton, MA.: Anker Publishing.

Brookfield, S.D. (2006), The Skillful Teacher. San Francisco: Jossey-Bass.

Carnegie Mellon University (2004), “Welcome to the CMMI”, from http://www.sei.cmu.edu/cmmi/

CMMI (2002). “Capability Maturity Model(R) Integration (CMMISM), Version 1.1, CMMISM for Systems Engineering, Software Engineering, Integrated Product and Process Development and Supplier Sourcing, (CMMI-SE/SW/IPPD/SS, V1.1), Staged Representation” CMU/SEI-2002-TR- 012; ESC-TR-2002-012.

CMMI Product Team (2002), Capability Maturity Model(R) Integration (CMMISM), Version 1.1″, Carnegie Mellon University.

Fink, L. D. (2003), Creating Significant Learning Experiences. San Francisco: Jossey-Bass.

Grunert, J. (2000). The Course Syllabus: A LearningCentered Approach. Bolton, MA: Anchor Publishing.

Huba, M.E. & Freed, J. (2000), Learner-Centered Assessment on College Campuses: Shifting the Focus from Teaching to Learning. Needham Heights, MA: Allyn & Bacon.

Landry, J.P., Saulnier, B.M., Wagner, T.A., & Longenecker, H.E. (2008), “Why is the Learner-Centered Paradigm so Profoundly important for Information Systems Education?”. Journal of Information Systems Education.

McGlynn, A.P. (2001), Successful Beginnings for College Teaching. Madison, WI: Atwood Publishing Company.

O’Banion, T. (1997), A Learning College for the 21st Century. Phoenix, AZ: ACE/Oryx Press.

Richlin, L. (2006), Blueprint for Learning: Constructing College Courses to Facilitate, Assess, and Document Learning. Sterling, VA: Stylus Publishing.

Svinicki, M. (2004), Learning and Motivation in the Postsecondary Classroom. San Francisco: Jossey-Bass.

Tagg, J. (2003), The Learning Paradigm College. Bolton, MA: Anker Publishing.

Wagner, T.A., Longenecker, H.E., Landry, J.P., & Saulnier, B.M. (2008), “A Methodology to Assist Faculty in Developing Successful Approaches for Achieving Learner Centered Information Systems Curriculum Outcomes: Team Based Methods”. Journal of Information Systems Education.

Weimer, M.G. (2002), Learner-Centered Teaching: Five Key Changes to Practice. San Francisco: Jossey-Bass.

Bruce M. Saulnier

Department of Information Systems Management

Quinnipiac University

Hamden, CT 06410

Jeffrey P. Landry

Herbert E. Longenecker, Jr.

School of Computer and Information Sciences

University of South Alabama

Mobile, AL 36688

Teresa A. Wagner

Department of Management

Farmer School of Business

Miami University

Oxford, OH 45056

AUTHOR BIOGRAPHIES

Bruce M. Saulnier is Professor of Information Systems Management in the School of Business at Quinnipiac University. A past- president and Distinguish Fellow of the International Society for Exploring Teaching and Learning (ISETL), he has been a featured speaker at numerous conferences focusing on the Scholarship of Teaching and Learning (SoTL). A past recipient of the Quinnipiac University Outstanding Faculty Member award and the 2007 recipient of the Information Systems Education Conference (ISECON) Best Paper Award, he was honored as the 2003 Connecticut Professor of the Year by the Carnegie Foundation for the Advancement of Teaching.

Jeffrey P. Landry is Associate Professor of Computer and Information Sciences in the School of Computer and Information Sciences at the University of South Alabama. He serves as a Center for Computing Education Research (CCER) Contributor, is an ABET IDEAL Scholar, and is the information systems assessment and self- study leader for the information systems program at South Alabama. He has co-organized two national workshops on information systems curriculum and assessment for the CCER, and has published at various information systems education journals and conferences.

Herbert E. (Bart) Longenecker, Jr. is Professor of Information Systems in the School of Computer and Information Sciences of the University of South Alabama. He teaches mainly advanced graduate classes using team- based project oriented learning. He is Director for the ICCP Education Foundation Center for Computing Education Research which produces a nationally normed assessment exam for IS programs based on IS2002. He is the co-chair for the national Model Curriculum for Information Systems of the AITP, AIS, and ACM organizations for IS’90, ’95, ’97, and 2002. He is the distinguished “Educator of the Year” for the AITP. He received the “2007 DAMA Education Award for Outstanding Research Contribution in the area of IRM/DRM”.

Teresa A. Wagner is Visiting Assistant Professor of Management in the Farmer School of Business at Miami University in Oxford, Ohio. Her doctorate is in Industrial Organizational Psychology from Virginia Tech. She has worked on projects associated with ABET accreditation and NSF grants and has been an invited speaker for meetings of the Society for Human Resource Management. Teresa is the 2008 Associated Student Government Outstanding Professor of the Year for Miami University.

Copyright EDSIG Summer 2008

(c) 2008 Journal of Information Systems Education. Provided by ProQuest LLC. All rights Reserved.

‘I Get Severe Night Sweats – and No One Knows Why’

By Dr Fred Kavalier

Casebook

I’ve been suffering for the past two or three years with severe night sweats. I am a 42-year-old man who is relatively healthy. My GP has sent me for an X-ray (to rule out TB, I think) which did not show anything abnormal. The GP is at a loss to provide me with any advice. This doesn’t happen every night, although it does seem to be increasing in frequency.

There are certain symptoms that ring alarm bells for doctors, and night sweats is one of them. I am reassured by the fact that you seem to be healthy even though you have had these sweats for two or three years. TB is one possible cause, and it’s good to know that your chest X-ray is normal. But not all types of TB show up on a chest X-ray.

Your doctor also needs to think about blood diseases, such as lymphoma or leukaemia, and unusual infections. Hormonal abnormalities, including an overactive thyroid and rare hormone- secreting tumours, also need to be considered. Another common cause of night sweats is too much alcohol. Talk to your GP about having more tests.

CHICKENPOX DURING PREGNANCY

I am 24 weeks pregnant and I’m worried about chickenpox, as my three-year-old son has been exposed to it at his nursery. Is there any chance that the baby will be infected or damaged by chickenpox?

Chickenpox can cause problems to babies in the womb, but these problems are relatively uncommon. The first important question is whether you have had chickenpox yourself. If you have had chickenpox, then there is nothing to worry about, because you will be immune and this immunity will protect the baby in the womb.

If you are not sure whether or not you have had chickenpox, you should have a blood test to see if you are immune. You should know the results within a couple of days. If a pregnant woman who is not immune catches chickenpox during the first 20 weeks of pregnancy, there is a small risk (about two in 100) of the baby having fetal varicella syndrome. This can cause limb deformities, brain damage and damage to the eyes and skin of the baby.

Between 20 and 36 weeks of pregnancy, chickenpox in the mother will not harm the baby. Chickenpox in the last four weeks of pregnancy can infect the baby in the womb, and this can sometimes be severe and even life-threatening.

HYDROGENATED OIL

I am trying to find a calcium/vitamin D3 supplement which does not contain hydrogenated oil. The information is not provided in direction leaflets. My GP suggests asking a pharmacist, but I get no clear answer. Are pharmaceutical companies obliged to declare whether an oil listed in ingredients is hydrogenated? How can I find a suitable product?

Pharmaceutical companies (and food supplement and vitamin manufacturers) use a variety of “non-medicinal ingredients” when they manufacture drugs. There are strict European regulations about what ingredients can be used. Companies are required to include all the ingredients (including the inactive ones) in the labelling of the drug. However, these regulations only apply to medicines.

At least four different oils are used in medicine manufacture: arachis oil (peanut oil), soya oil, castor oil and sesame oil. When soya oil is hydrogenated, the label should say “hydrogenated soya oil”. When unhydrogenated soya oil is used, the label should say “soya oil”.

Unfortunately, there is at least one product (Calcichew-D3) with hydrogenated soya oil that simply says “vegetable fat” on the label. You can look up a list of additional ingredients on the website of the electronic Medicines Compendium (emc.medicines.org.uk). Now I have a question for you: why are you so concerned about swallowing tiny amounts of hydrogenated soya oil?

[email protected]

Readers write

VS, a dentist, gives some information on the lights that dentists use:

You said that dentists use UV light. We most certainly do not! The light we use is of a short wavelength, but absolutely not UV. We shield the rays with amber plastic simply due to the intensity of the light.

Please send your questions and suggestions to A Question of Health, ‘The Independent’, Independent House, 191 Marsh Wall, London E14 9RS; fax 020-7005 2182 or e-mail to [email protected]. Dr Kavalier regrets that he is unable to respond personally to questions.

(c) 2008 Independent, The; London (UK). Provided by ProQuest LLC. All rights Reserved.

Upcoming Model Hunt Looks for Teen Girls — Winner to Get $500 Spree, Possible Magazine Feature

By Barbara Bradley

A teen model search set for Saturday in Collierville will give one outstanding girl a $500 back-to-school shopping spree at Macy’s, as well as a chance to be featured in a national teen magazine.

Macy’s and Justine, the teen magazine published in Memphis, invite girls ages 13 to 19 to try out from 2 to 4 p.m. in Macy’s junior department at Avenue Carriage Crossing.

Similar events have been held in four other cities. The winners of each search will get the shopping spree and will appear in Justine. A grand prize winner will be chosen from among them to appear in a fashion or beauty feature in Justine photographed by New York photographer Rick Day.

To enter, girls can get an application at the junior department at Macy’s at Avenue Carriage Crossing or download an entry form and rules from justinemagazine.com (http://www.justinemagazine.com) .

Even girls who don’t win the contest will get to walk a runway and show their stage presence before an editor from Justine, which, just between us, uses a lot of young girls from this area on their pages. Girls will be allowed to line up as early as 1 p.m.

Also on hand will be Monica Hudson, Macy’s spokeswoman and manager of Macy’s Teen Board. Teen Board members will help with the event. Hudson also plans to have them present a short fall fashion show prior to the tryouts.

Justine publisher and editorial director Jana Pettey, recently back from a search in Indianapolis, said she has been impressed by the quality of the applicants.

“There were girls who had their college and postgraduate schools all mapped out,” she said. One 13-year-old spoke four languages. “It’s refreshing to see teens who can speak on their feet and have the self-confidence to be a part of this,” she said.

Political wives show style

Michelle Obama continues to display confidence in her own sense of style.

The wool dress in blue-state blue she wore to speak at the Democratic National Convention in Denver last week fit well and the abbreviated sleeves, which hid her toned arms, gave her a softer look. Designed by Maria Pinto, a Chicago native, it offered a wide V- neck that drew attention to her shoulders helping balance her figure.

Brooches often ride awkwardly on a woman’s shoulder. But her big turquoise and silver pin, reportedly from her jewelry box, that was placed at the point of her neckline looked as if the dress were designed around it.

Obama set her own direction again wearing a print dress designed by Thakoon Panichgul, a young New York designer, on the night her husband accepted his presidential nomination. The multiple ornaments fastened around the neckline was an unusual touch, but it worked.

We plan to take a look at the fashion choices of Cindy McCain, the wife of Republican Sen. John McCain, in the next column.

Shorts ride up popularity polls

An article from The New York Times says shorts have made inroads as office wear this summer. But get this – the leggy look is being sported by men.

Designers are pushing more calf exposure, and young men who enjoy shorts as stylish streetwear are seeing fewer reasons not to walk them into the office. Even some fashion-forward men here have accepted capri pants (an acquaintance of mine calls them “man preez”) as a substitute for casual pants.

A Salt Lake City, Utah, ad agency tried out a no-long-trousers policy this summer when temperatures neared 100 for a long stretch, reported the Times. But men were expected to dress appropriately when meeting with clients.

So what about it? Are nice-looking walking shorts acceptable in Memphis offices ? Tell us what you think.

Fashion editor Barbara Bradley can be reached at 529-2370 or [email protected].

Originally published by Barbara Bradley .

(c) 2008 Commercial Appeal, The. Provided by ProQuest LLC. All rights Reserved.

Tylenol — or Acetaminophen — Can Be Harmful If Patients Take More Than 4 Grams Daily

By MICHELLE KOMARA

By MICHELLE KOMARA

Special to The Daily Record

Tylenol, also known as acetaminophen, is a drug we often turn to when we have any type of ache or pain. Acetaminophen, however, is not as harmless a drug we imagine it to be.

The maximum daily dose of acetaminophen is 4 grams or 4,000 milligrams. Many people accidentally overdose on acetaminophen because they exceed that daily limit and do not realize it.

One of the reasons why it is so easy to accidentally overdose on acetaminophen is because it is found in many prescriptions and over- the-counter drug products the consumer may not be aware of.

It can be found in prescription pain medications such as Vicodin, Percocet, Darvocet, Ultracet and Tylenol with codeine. If a patient takes the maximum daily dose allowance of their pain medication the patient should not take any more acetaminophen.

Many patients, while on these pain medications, will take acetaminophen containing products such as Tylenol PM to help them go to sleep, not realizing they are in fact overdosing on acetaminophen.

When consumers try to alleviate each symptom, as opposed to just letting one product help all symptoms, that is when the overdose most likely occurs. Some over-the-counter products consumers may be surprised to find contain acetaminophen are many cold products — Actifed Plus, Benadryl Cold and Nighttime, Drixoral Plus, all Excedrin products, Nyquil Nighttime Cold, Percogesic, Sinutab, all TheraFlu products and all Tylenol products.

Consumers need to be more aware of the amount of acetaminophen they are taking by adding up their daily dosage to ensure they do not exceed 4 grams.

Tylenol overdose can cause liver damage after only a couple days of taking more than the maximum dose. Patients who are taking acetaminophen and drinking alcohol can have an increased chance of having liver damage. While taking acetaminophen, consumers should be cautioned to limit alcohol intake.

Symptoms of acetaminophen overdose are abdominal pain, upset stomach, nausea, vomiting, diarrhea, appetite loss, irritability, coma, convulsions, sweating and jaundice.

If the overdose goes untreated, severe liver damage can occur.

Although Tylenol is a commonly used drug that can be safe if used properly, it is not a harmless drug. The amount taken daily should be monitored closely. Consumers should be counseled to never exceed more than 4 grams in one 24-hour period.

Michelle Komara is a pharmacist from Ohio Northern University. Buehler Food Markets, which provides this column, has relationships with five schools of pharmacy.

Originally published by By MICHELLE KOMARA Special to The Daily Record.

(c) 2008 Daily Record, The Wooster, OH. Provided by ProQuest LLC. All rights Reserved.

AAMC on Pace for Another Record Year for Births

By SHANTEE WOODARDS Staff Writer

The region is experiencing a baby boom and Anne Arundel Medical Center is on the receiving end.

The hospital delivered a record 5,603 babies last year and it is on track to surpass that milestone with an estimated 5,770 babies expected to be delivered there by the end of the year. The quick pace makes AAMC the second-largest birth site in the state, according to hospital officials.

It also puts the hospital on par with a record 4.32 million births nationally in 2007.

Hospital officials said they believe the birth rate continues to grow because patients are coming to AAMC from outside the county to have their babies. New parents have come from Prince George’s and Calvert counties, as well as the Eastern Shore, they said.

“July and August are usually our biggest time (for births),” said Maura Callahan, the hospital’s executive director of women’s and children’s services. “One day we’ll be slammed and the next day it’ll be quiet. This is the happiest place in the hospital.”

AAMC’s birthing numbers in 2007 are roughly a 6 percent increase from their totals in 2006. This summer, the staff even had a period where six sets of twins and one set of triplets were born within a week. There was also a period in July when 14 babies were delivered in a span of three hours.

To accommodate the swell in the number of babies, the hospital continues to recruit doctors through physician groups and coordinates non-emergency staff with scheduled Cesarean sections. Last year, AAMC added an OBGYN hospitalist program, which is a staff of five doctors who are available around-the-clock to help patients when the patient’s primary care physician is unavailable.

Hospital officials also attributed the hospital’s popularity to its advanced neonatal intensive care unit, which cares for 10 to 15 percent of the babies delivered there. For many expectant mothers, the unit is a deciding factor in where they will have their baby, officials said in a release.

“Our NICU is across the hall from where these babies are born, not miles away at a separate facility,” said Dr. Joseph Morris, an AAMC obstetrical hospitalist, in a prepared statement. “New mothers want that security in the same building.”

Officials said keeping mother and baby close to each other is important even with normal births.

“Our parents love having the babies with them,” said Pat Mlynarski, the hospital’s clinical director of labor and delivery. “We’ve got a great staff that steps up to the plate and we do what we need to do.”

After a normal delivery, new mothers and their infants are taken to a room that offers a sleeper sofa for the dads and a fetal- monitoring unit for the baby.

Next year Baltimore Washington Medical Center in Glen Burnie also gets into the baby business. Doctors there delivered infants up until 1967, when it ended because of low interest from patients and a lack of beds.

The hospital’s labor-and-delivery unit and mother-baby unit is expected to be ready by the fall of next year. {Corrections:} {Status:}

REGIONAL BABY BOOM FOLLOWS NATIONAL TREND

(c) 2008 Capital (Annapolis). Provided by ProQuest LLC. All rights Reserved.

CSA Medical, Inc., Is Set to Put the Freeze on Thoracic Disease

BALTIMORE, Sept. 8 /PRNewswire/ — A new medtech spin-off from CSA Medical, Inc., is about to give cancer patients and their caregivers a reason to breathe more easily. Literally.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080721/NEM114LOGO )

In July, Reset Medical, Inc., secured $8.6 million in investments and is now poised to distribute CSA Medical, Inc.’s endoscopic cryospray ablation (CSA) tool for use worldwide in the treatment of cancers and other diseases of the chest, lungs, and airway. Additional products, customized for various thoracic diseases, are now under development.

CSA Medical’s CryoSpray Ablation(TM) System, which has been cleared by the FDA, is a safe, simple, and effective treatment that delivers a low-pressure, non-contact spray of liquid nitrogen using a standard endoscope for destroying unwanted tissues. The CSA System has been successful in treating esophageal cancer and Barrett’s esophagus, a pre-cancerous disease caused by chronic acid reflux, in nearly 50 major U.S. healthcare institutions and comprehensive cancer centers.

William Krimsky, MD, an interventional pulmonologist and intensivist at Franklin Square Hospital in Baltimore, first had the vision to use the CSA technology for airway and thoracic diseases. In 2006 he contacted company CEO Timothy Askew to see if he would consider using the device to fight malignancies in the lungs and chest.

“You could build an entire practice around this device,” says Dr. Krimsky, who now serves on the Scientific Advisory Board for Reset Medical.

Although skeptical of the idea at first, Askew says he eventually decided to “take a step out of my comfort zone.” He authorized $200,000 to fund animal tests, and initiated a company-sponsored human clinical trial with Dr. Krimsky at Franklin Square to demonstrate safety and tissue response when using the CSA system in the airway.

“This is a unique device, serving a huge global market, from patients with lung cancer to severe asthma, pleural disease, etc.,” says Dr. Krimsky. “Patients have few good alternatives for treatment, and none as clinically affordable, safe, effective, and tolerable.”

According to national healthcare statistics, more people die of lung cancer than any other type of cancer. In addition, the technology shows great promise for other chest and airway diseases. As a result, company officials estimate that the treatment market for Reset Medical is substantial. Not surprising, convincing the existing investors to participate in another round of funding was not terribly difficult. In fact, more than half of CSA Medical’s 66 stockholders contributed.

“When investors saw the size of the markets and the level of unmet medical need, matched with the potential of this breakthrough technology, it became a very competitive environment for participation,” says Steve Schaefer, CFO and Board Member. “We capped the Series A round at $8.6 million and did not permit participation from venture firms.”

Out of the proceeds from the financing, Reset Medical was able to purchase a license and certain assets from CSA Medical. Reset is using the remaining capital to advance the science of cryotherapy through further clinical studies in the airway and chest and to further product development. The Company has begun selectively distributing the CSA System to thoracic surgeons and critical-care pulmonologists who are cooperating in this advanced research and treating patients in great need.

There are three new clinical trials underway to investigate the technology as a treatment for a range of ailments, including malignant and benign obstructive airway disease and pleural disease. Other studies being planned will include chronic bronchitis, emphysema, and asthma.

About CSA Medical, Inc.

CSA Medical, Inc is the manufacturer of the CryoSpray Ablation(TM) System. The CSA System utilizes a patented technology that regulates and transports a low-pressure cryogen through the CSA Catheter, an open-tipped catheter that is easily passed through a standard endoscope. This rapid delivery system of repetitive freeze-thaw cycles has been shown to be a safe and effective treatment for destroying unwanted tissues.

About Reset Medical

Reset Medical, Inc., is committed to bringing the proven science of cryotherapy to endoscopic treatments in the chest and airways. The CSA System allows therapeutic endoscopists to have the ability to quickly and easily ablate unwanted tissue. The CSA System utilizes a patented, FDA-cleared technology that regulates and transports a low-pressure cryogen through an endoscope. Reset Medical, privately held and headquartered in Baltimore, Maryland, is the exclusive worldwide distributor of CSA Medical, Inc.’s product line for the thoracic marketplace.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080721/NEM114LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

CSA Medical, Inc.

CONTACT: Richard Hughen of CSA Medical, Inc., [email protected]

Web site: http://www.csamedical.com/

Universal Health Services, Inc. Announces Sale of Acute Care Hospital and Addition of Two Behavioral Health Hospitals

KING OF PRUSSIA, Pa., Sept. 8 /PRNewswire-FirstCall/ — Universal Health Services, Inc. announced today that it has signed a definitive agreement to sell Central Montgomery Medical Center, a 125 bed acute care hospital located in Lansdale, Pennsylvania to Abington Memorial Hospital. The sale is subject to customary regulatory approvals and we expect the closing to occur later this fall.

UHS also announced that it completed the acquisition of SummitRidge Hospital located in Lawrenceville, Georgia. SummitRidge is a behavioral health hospital with 76 beds, consisting of 26 adolescent beds and 50 adult beds and also provides hospitalization and outpatient programs for adolescents, adults and gero-psychiatric patients. In addition UHS announced that it has completed the renovation of the 120-bed Central Florida Behavioral Hospital and expects to receive licensure and open for business before the end of the month. Both of these hospitals complement existing facilities in the Atlanta and Orlando markets and will provide an opportunity to offer new programs and services in each market.

Universal Health Services, Inc. is one of the nation’s largest hospital companies, operating acute care and behavioral health hospitals and ambulatory centers nationwide and in Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust . For additional information on the Company, visit our web site: http://www.uhsinc.com/.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors in our Form 10-K for the year ended December 31, 2007 and in Item 2- Forward-Looking Statements and Risk Factors in our Form 10-Q for the quarterly period ended June 30, 2008), may cause results to differ materially from those anticipated in the forward-looking statements. Many of the factors that will determine our future results are beyond our capability to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof. We undertake no obligation to revise or update any forward- looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Universal Health Services, Inc.

CONTACT: Steve Filton, Chief Financial Officer, +1-610-768-3300

Web site: http://www.uhsinc.com/

Company News On-Call: http://www.prnewswire.com/comp/916225.html

APIPA and Flagstaff Medical Center Sign Contract to Provide Services to Arizona CRS Beneficiaries

Arizona Physicians IPA (APIPA) and Flagstaff Medical Center today announced an agreement that will provide beneficiaries of Arizona’s Children’s Rehabilitative Services program (CRS) with access to the medical center and its affiliated facilities and physicians.

Bill Hagan, CEO of APIPA, which was awarded a contract by the State to manage the CRS program beginning next October 1, said, “We are pleased that CRS beneficiaries and their families across northern Arizona will continue to have access to the services provided by Flagstaff Medical Center. APIPA and the Medical Center are committed to high quality health care and comprehensive services to the vulnerable population served by the CRS program.”

Mr. Hagan noted that the agreement was the last piece in assembling the network of providers who had cared for CRS beneficiaries under the previous system, and assures that all of them will receive care without interruption.

Joanne Parkes, director of Flagstaff Medical Center’s Children’s Health Center, said, “Flagstaff Medical Center has been caring for Northern Arizona children with special needs for more than 20 years. It was important to us to be able to continue serving these children and their families, and we’re pleased that we now will be able to do so.”

Joan Agostinelli, Administrator of the CRS program, said, “We are pleased that CRS members will continue to be able to receive care from the doctors that they have come to know through Flagstaff Medical Center. ADHS looks forward to working with both APIPA and Flagstaff Medical Center in continually improving the system of care for children and youth with special health care needs.”

About APIPA

APIPA, a unit of AmeriChoice, a UnitedHealth Group company, has served the needs of medically underserved Arizonans since 1982, including beneficiaries of the State’s AHCCCS program and other government sponsored program such as Medicare Advantage Special Needs Plans, developmentally disabled, premium share and Medicaid in the Public Schools. APIPA currently serves nearly 280,000 AHCCCS members, many with unique or complex health conditions. In addition, it has 14,200 Medicare Special Needs Plans members and more than 9,600 Developmentally Disabled (DD) individuals through its contract with the Arizona Department of Economic Security/Division of Developmentally Disabled.

About Flagstaff Medical Center

Flagstaff Medical Center is Northern Arizona’s only regional referral center, caring for more than 85,000 patients each year. Since 1936, FMC, a member of Northern Arizona Healthcare, has provided high-quality healthcare services to the residents and visitors of Northern Arizona. With more than 200 physicians and approximately 2,000 employees, FMC provides comprehensive, state-of-the-art healthcare including cardiovascular surgery, weight-loss surgery, pediatric intensive care and cancer care.

About Children’s Rehabilitative Services

The Children’s Rehabilitative Services program (CRS) is administered by the Arizona Department of Health Services, Office for Children with Special Health Care Needs (OCSHCN). The mission of CRS is to improve the quality of life for children and youths up to age 21 with special health care needs by providing family-centered medical treatment, rehabilitation, and related support services.

Renowned Dentists to Present Latest on Dental Innovations

   SACRAMENTO, Calif., Sept. 8 /PRNewswire/    WHEN:      Thursday, Sept 11, 2008 to Sunday, Sept 14, 2008    WHERE:     Moscone South Convention Center              747 Howard Street              San Francisco, CA 94103               and               Marriott Hotel San Francisco              55 4th Street              San Francisco, CA 94103    CONTACTS:  Doug Elmets  (916) 206-8662              Kim Nickols  (916) 704-8965    WHAT:      Approximately 15,000 dentists and dental professionals are              expected to attend the 2008 Fall Scientific Session of the              California Dental Association, which will feature presentations              by the industry's leading dental professionals.               More than 100 workshops and lectures are planned for the four              days, allowing dentists from across the United States the              opportunity to see the latest methods and techniques in oral              health treatments. Also, more than 400 exhibitors will be on              hand to demonstrate the latest technology, products and              services.               Speakers and topics that will be addressed include:               Fighting Dental Disease -- Drugs, Bugs and Dental Products              Dr. Peter Jacobsen, PhD, DDS              This seminar will review the management of herpes, aphthous              ulcers, bacterial disease and fungal infections; all conditions              that dentists treat every day. Which over-the-counter drugs              work the best and how should they be used will also be covered.              Friday, September 12, 2008              10:00 a.m. - 12:30 p.m.              Moscone South, Room 106               Overcoming the CSI Effect: Redefining Dentistry's Role in the              Forensic Arena              Col. Theresa S. Gonzalez, DMD, MS, MSS              This lecture will explore dentistry's role in the              identification of human remains, which is generally a              prerequisite for estate planning, payment of life insurance and              prosecution of homicide cases.  It will also cover the forensic              dentists' role in mass disasters.              Friday, September 12, 2008              9:30 a.m. - 12:00 pm and repeats 2:00 - 4:30 p.m.              Moscone South -- 101               Oral Cancer: Get it early, Get it all!              Carrie L. Magnuson, DDS              Learn the most up-to-date facts on oral cancer, the current              state of the disease and the importance of early detection.              Friday, September 12, 2008              12:00 - 1:00 p.m.              Moscone South -- 305/307               Ergonomics: a Fitness Prescription              Miss Fitness Universe Kary Odiatu              Uche Odiatue, BA, DMD              Whether you are a dentist or a business manager, increasing              your physical conditioning will enhance everything that you do.              Reclaim energy and vitality with the latest research on              breathing, posture and performance. Immerse yourself and enjoy              relaxation and breathing techniques guaranteed to diminish the              effects of stress.              Saturday, September 13, 2008              10:00 a.m. - 12:30 p.m.              Marriott -- Salon 9               Fighting Early Childhood Cavities: How the Tooth Fairy Can Help              Jennifer H. Holtzman, DDS              Lori C. Daby, RDH              Deborah Adair              Early childhood cavities are the most prevalent and preventable              chronic childhood disease in California. Learn various              techniques to educate children and parents on the importance of              oral health and healthy eating habits.              Saturday, September 13, 2008              2:00 -4:00 p.m.              Marriott -- Salon 14-15               Recognizing Cultural Differences in the Patient Population              Charles J. Alexander, PhD              Learn how dentists break down barriers and access disparities              to embrace cultural differences, communicate and provide              culturally responsive treatment to various ethnic groups.              Saturday, September 13, 2008              2:30 -4:30 p.m.              InterContinental Hotel -- Twin Peaks Room    

The California Dental Association is the non-profit organization representing organized dentistry in California. Founded in 1870, CDA is the largest and most high profile constituent of the American Dental Association. CDA contributes to the dental health of consumers in California through various comprehensive programs aimed at improving dental health. CDA’s membership consists of more than 24,000 dentists.

California Dental Association

CONTACT: Doug Elmets, +1-916-206-8662, or Kim Nickols, +1-916-704-8965,both for California Dental Association